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This study has investigated three caspase-dependent apoptotic pathways using HL60 
and Jurkat cells as haematopoietic models. The three apoptotic pathways studied were 
the Fas death receptor pathway, the mitochondrial-mediated apoptosis pathway and the 
endoplasmic reticulum (ER)-stress induced apoptosis pathway. These pathways were 
induced in the cells via pathway-specific drug treatment.  
  
The first part of the study involved obtaining and testing for markers specific to each 
pathway (after pathway-specific drug treatment). HL60 cells were treated with 
Brefeldin A (BFA), to induce the ER-stress induced apoptotic pathway, and hydrogen 
peroxide (H2O2), to induce the mitochondrial-mediated apoptotic pathway. Jurkat cells 
were treated with FLAG-tagged FasL and ANTI-FLAG® antibody to induce the death 
receptor pathway. The assays used to analyse the pathway-specific markers were 
optimised to ensure that each technique was sensitive and reproducible. In addition, the 
drug concentrations required to induce a low (5-15%) and high (20-50%) percentage of 
early apoptosis were established for each pathway. In the final part of this study, these 
drug concentrations were used to induce apoptosis in the cells, which were subsequently 
tested for all the pathway-specific markers.   
 
It was found that the flow cytometry assays were sensitive to detect changes within the 
cells. Both Annexin V-FITC (AV)-propidium iodide (PI) labelling and MitoCaptureTM 
assays could be used to determine the apoptotic status (early or late) of the cells. There 
was evidence of changes in mitochondrial transmembrane potential (MTP) for all three 
drug treatments. Therefore it was concluded that the mitochondrial-mediated apoptotic 
pathway was activated, to some extent, in all three pathways. The western blot assays 
were not as sensitive as desired, since a large amount of protein and volume of cells 
were required. In addition, it was not quantitatively reproducible in all instances. The 
caspase assays were sensitive and appeared to be reproducible, however, the assay 
seemed to be sensitive to sample reagents like H2O2, which affected readings. The 
caspases appeared to be specifically activated for each pathway and caspase activity was 












The results suggested that the Fas death receptor and ER-stress induced apoptosis 
pathways interact, to some extent, with the mitochondrial-mediated apoptosis pathway. 
Hence, the mitochondria seem to play central roles in amplifying and transmitting the 













































1.1 General Introduction 
 
Apoptosis is a strictly controlled, natural form of programmed cell death. It is an 
important regulatory process, which allows multicellular organisms to tightly control 
and maintain cell numbers and tissue size and to safeguard against dysfunctional and 
defective cells (Greenberg, 1998).  
 
Apoptosis signalling pathways exist in inactive states in viable cells and are activated in 
response to apoptotic stimuli. Various amplification steps and positive feedback loops 
within the apoptosis signalling pathways ensure that a cell either completely commits to 
apoptosis or totally refrains from it (Hengartner, 2000). Apoptosis can be initiated by 
external stimuli such as ligation of cell surface receptors, cytokines, cytotoxic drugs, 
lack of survival signals, growth factor withdrawal and developmental death signals 
(Fig. 1). In addition, various internal signals such as DNA damage, the formation of 
reactive oxygen species (ROS) and defects in protein production can also initiate 
apoptosis (Fig. 1). Survival signals like growth factors, nutrients, and hormones 
continuously inhibit apoptosis by enhancing the activity and/or expression of anti-
apoptotic regulatory molecules. In so doing it represses the activity of pro-apoptotic 
























Apoptotic cells share morphological features, which include cell shrinkage and 
deformation, loss of contact to neighbouring or supportive structures, chromatin 
condensation and cell membrane blebbing or budding (Kerr et al., 1972). These changes 
occur as a result of proteolysis, by proteolytic enzymes known as caspases. Caspase 
activity affects the integrity of cellular organelles and the cytoplasm and induces DNA 
cleavage into oligonucleosomal pieces by nucleases (Zhang et al., 2005). In the final 
stages the cell ruptures and is compacted into membrane-bound apoptotic bodies, which 
contain cytoplasm, organelles and condensed chromatin. These apoptotic bodies are 
subsequently removed by macrophages without eliciting an inflammatory response. 
These features are in contrast to cells that undergo necrotic cell death, which is usually 
 
Fig. 1. Various apoptosis pathways within a nerve cell. The figure shows a schematic representation 
of the death receptor, mitochondrial-mediated and ER-stress induced apoptotic pathways, with the 











caused by mechanical injury to the cells. Depending on the severity of damage suffered, 
the cell membrane either bursts upon impact or, after injury, the cell swells and 
eventually its membrane ruptures. Therefore necrotic cell death causes the 
uncontrollable leakage of cell contents into the extracellular environment. This, in turn, 
leads to the damage of neighbouring cells and an inflammatory response in the affected 
tissue (Gewies, 2003).   
 
Defective apoptotic signalling, which either causes disproportionate cell proliferation or 
apoptosis, plays an important role in the pathogenesis of several diseases, including the 
myelodysplastic syndromes (MDS) (Hellström-Lindberg, 2005). MDS are a set of pre-
leukaemic myeloid clonal haemopathies, characterized by a high incidence of 
intramedullary apoptosis. This brings about the symptoms of peripheral cytopenias, 
ineffective haematopoiesis and refractory anaemia observed in these disorders (Mundle, 
2003). There are many controversies surrounding the incidence of both apoptosis and 
proliferation and the potential of clonogenic expansion in MDS (Parker et al., 2000). 
The fundamental mechanisms that cause progenitor cell abnormalities are still poorly 
characterised (Tehranchi et al., 2003). Multiple intrinsic and extrinsic factors influence 
the stem cells. These factors can cause increased apoptosis, abnormalities within the 
signalling pathways and changes in the bone marrow stroma and stromal cell cytokine 
production. How these factors contribute to bring about accelerated proliferation and 
accelerated apoptosis simultaneously still remains unclear (Liesveld et al., 2004). 
Understanding apoptosis signalling in haematopoietic cells is fundamental in 
unravelling the underlying disease mechanisms of conditions like MDS and leukaemia. 
 
The three caspase-dependent apoptosis pathways reviewed here are the death receptor 
pathway, in particular the Fas (CD95) apoptotic pathway, the endoplasmic reticulum 
(ER)-stress induced and mitochondrial-mediated apoptosis pathways (Fig. 1). The death 
receptor pathway forms part of the extrinsic apoptosis pathway, whereas the ER-stress 
induced and mitochondrial-mediated apoptosis pathways are part of the intrinsic cell 















1.2   The role of caspases in caspase-dependent apoptosis 
 
The set of cysteine proteases, known collectively as caspases, play a central role in the 
apoptosis signalling network, since they activate, execute and amplify the apoptotic 
signal (Thornberry et al., 1997). Caspases are cysteine-dependent aspartate-specific 
proteases, which specifically cleave their substrates after aspartate residues (Alnemri et 
al., 1996; Chowdhury et al., 2008).  
 
Caspase substrates are a tightly regulated set of protein targets, which are either 
activated or rendered inactive after cleavage. For example, by cleaving off a negative 
regulatory domain or inactivating a regulatory subunit on a substrate, the caspases can 
regulate the apoptosis signalling cascade (Hengartner, 2000). The caspases are 
responsible for cleaving many cellular proteins. Cleavage of cytoskeletal and structural 
proteins (like fodrin and gelsolin) causes cell shrinkage and deformation, whereas 
cleavage of nuclear lamins are essential for nuclear shrinking and budding (Rao et al., 
1996; Takahashi et al., 1996). Other caspase substrates include transcription factors, 
protein kinases, proteins involved in the cell cycle and cell replication, as well as B-cell 
lymphoma-2 (Bcl-2) protein family members, like Bid (section 1.3.4) (Stroh and 
Schulze-Osthoff, 1998).  
 
Caspases are synthesized intracellularly as inactive zymogens (procaspases) that possess 
three domains: an N-terminal prodomain and one large and one small subunit, the p20 
and p10 domains, respectively (Fig. 2). The procaspases are activated by proteolytic 
cleavage between the large and small subunits, since all of the cleavage sites have 
aspartate residues, and the prodomain may or may not be removed in the process 
(Thornberry et al., 1997).  The active caspase is a hetero-tetramer consisting of two 













            
 
             
 







The caspases can be divided into two groups. A group of initiator caspases that include 
caspase-2, -4, -12, -8, and -9 and a group of executioner or effector caspases that 
include caspase-3, -6 and -7 (Thornberry et al., 1997). The initiator caspases possess 
long prodomains, containing death effector domains (DED) or caspase recruitment 
domains (CARD), whereas the executioner caspases possess short prodomains (Li, P et 
al., 1997; Liu et al., 2005). The initiator and effector caspases are activated via different 
mechanisms and so far three mechanisms of caspase activation have been elucidated 
(Fig. 2 A-C) (Hengartner, 2000).  
Fig. 2. Three mechanisms of caspase activation. Procaspases are activated by induced 
proximity (A), holoenzyme formation (B), and/or proteolytic cleavage by an upstream initiator 
caspase (C). Activated initiator caspases proteolytically cleave downstream effector procaspases 
to initiate a caspase cascade resulting in cell death. Initiator procaspases can be activated 
through recruitment by apoptosis inducing signalling complexes resulting in cross activation of 
caspases in close proximity or via holoenzyme formation like the apoptosome complex 

















Initiator procaspases can be activated through induced proximity by oligomerization, 
aided by adapter proteins, and subsequent recruitment to apoptosis inducing signalling 
complexes (such as the death-inducing signalling complex) (Budihardjo et al., 1999) 
(Fig. 2 A). The formation of holoenzyme complexes, such as the apoptosome complex, 
is another mechanism of initiator caspase activation (Fig. 2 B). These holoenzyme 
complexes recruit various molecules to facilitate in procaspase cleavage and activation 
(Rodriguez and Lazebnik, 1999; Stennicke et al., 1999). The activated initiator 
caspases, like caspase-4, -8 and -9, subsequently bring forth a downstream caspase 
cascade, by proteolytic cleavage, which leads to the activation of executioner caspases 
such as caspase-3 (Earnshaw et al., 1999).  
 
The group of executioner caspases are generally activated through proteolytic cleavage 
by an upstream initiator caspase (Fig. 2 C) via a caspase cascade, which integrates and 
amplifies the apoptotic signals (Liu et al., 2005). Executioner caspase activation occurs 
during the late stages of apoptosis and results in proteolysis. This affects the integrity of 
the cell’s organelles and cytoplasm and leads to cellular breakdown and eventual cell 
lysis (Cohen, 1997). 
 
1.3   The Fas death receptor apoptotic pathway  
 
1.3.1   The Fas ligand (FasL)  
 
FasL is a cytokine, which is primarily expressed in activated T lymphocytes and 
Natural Killer cells of the immune system (Suda et al., 1995; Oshimi et al., 1996). 
Expression of FasL during stressful conditions is dependent on activation of the 
MEKK1 and c-Jun N-terminal kinase (JNK) pathways, which results in binding of c-
Jun and ATF2 to the promoter region of the FasL gene (Faris et al., 1998).  
 
FasL is synthesized as a membrane-bound protein, sharing a well conserved 
extracellular region of approximately 150 amino acids with the other members of the 
tumor necrosis factor (TNF) family (Suda et al., 1993). Although membrane-bound 
FasL is active in initiating apoptosis, a soluble trimeric form of FasL (sFasL) can be 











at its extracellular domain (section 1.6.3) (Kayagaki et al., 1995; Tanaka et al., 1996). 
This cleavage of FasL from its membrane was found to significantly decrease its 
activity in inducing apoptosis. It was also found that membrane-bound FasL was more 
active in inducing apoptosis than its soluble form (Suda et al., 1997; Tanaka et al., 
1998). This indicates that circulating cells, which express membrane-bound FasL, can 
interact with other cells and are therefore powerful inducers of apoptosis and systemic 
tissue damage. Schneider et al. (1998) found that although sFasL was less active, it still 
maintained its capacity to bind to Fas and its cytotoxicity could be restored by addition 
of cross-linking antibodies. 
 
1.3.2   The Fas/CD95 receptor 
 
Apoptotic signalling via the death receptor pathway is mediated by activation (through 
ligation) of the death receptors, which are situated on the external cell membrane 
surface (Zhang et al., 2005). These receptors are members of the tumour necrosis factor 
receptor (TNFR) family, which includes TNFR-1, Fas/CD95, and TRAIL receptors 
DR-4 and DR-5 (Gewies, 2003). TNFR, a monocyte/macrophage-derived 
transmembrane protein, is the prototype receptor of the TNF family and was found to 
be responsible for the cytotoxicity in tumour cells (Old, 1985; Beutler and Cerami, 
1986).  
 
The death receptors are composed of cysteine rich extracellular subdomains, which 
recognize specific ligands, and a cytoplasmic death domain (Boldin et al., 1996) (Fig. 
3). Fas and TNFR1 share a homologous cytoplasmic death domain, which consists of 
approximately 80 amino acids. This death domain is essential for relaying the apoptotic 
signal (Itoh et al., 1993; Tartaglia et al., 1993). 
 
X-ray diffraction analysis has shown that the TNFα ligand, in its trimerized form, binds 
to three TNF receptor molecules (Banner et al., 1993). Upon ligation, the death receptor 
trimerizes and becomes activated (Boldin et al., 1996) (Fig. 3). Both TNFR1 and Fas 
are only activated upon oligomerization (Dhein et al., 1992; Takahashi, 1996). FasL 
shares similarities in structure to TNFα, and likewise the Fas receptor shares similarities 
in structure to TNFR. Therefore it was deduced that in the same way as TNFα activates 











the transfer of the apoptotic signal through the trimerized cytoplasmic regions of the 
Fas receptor to downstream effector molecules in the death receptor pathway (Banner et 














Some researchers have found alternative ways of activating the death receptor pathway. 
Yonehara et al. (1989) found that anti-Fas antibody exerts identical cytotoxic effects as 
TNFα. Studies have also found that cross-linking of Fas by agonistic antibodies, in Fas-
bearing cells, can induce apoptosis (Trauth et al., 1989; Yonehara et al., 1989; Itoh et 




Fig. 3. Caspase-8 activation at the death-inducing signalling complex (DISC). Trimerization of the 
death receptor occurs upon ligand binding, followed by the recruitment of adaptor proteins via death 
domain (DD) interactions. The adaptor proteins subsequently recruit procaspase-8 molecules through 
death effector domains (DED) to the DISC. Active caspase-8 is produced by autoproteolytic cleavage 
of procaspase-8 molecules in close proximity. The active caspase-8 consists of two small and two 
large subunits forming a hetero-tetramer. Caspase-8 induces a caspase cascade by cleaving and 










1.3.3  FADD and Caspase-8 
 
After FasL binds to the Fas receptor, the activated trimeric Fas receptor recruits the 
adapter protein FADD (Fas-associated death domain protein) (Kischkel et al., 1995; 
Barnhart et al., 2003) (Fig. 3).  
 
FADD contains a death domain at its C-terminal region and a death effector domain at 
its N-terminus (Fig. 3). Its death domain allows complex formation with the death 
domain of the activated Fas receptor. The resultant complex that is formed is known as 
the death-inducing signalling complex (DISC) (Boldin et al., 1996) (Fig. 3). Studies 
have shown that cells that are deficient in FADD or possess mutations in FADD are 
resistant to death receptor-mediated apoptosis, either by Fas, TNFR1 or DR-3. This 
infers the importance and necessity of FADD in the Fas-mediated apoptosis pathway 
(Yeh et al., 1998; Zhang et al., 1998).   
 
Caspase-8 possesses two death effector domains at its N-terminus, which interacts with 
FADD’s death effector domains and in so doing is recruited to the DISC (Martin et al., 
1998) (Fig. 3). Due to the weak intrinsic protease activity of procaspase-8, it is able to 
cleave and activate other procaspase-8 molecules upon oligomerization (Ashkenazi and 
Dixit, 1998; Yang et al., 1998). As more procaspase-8 molecules associate with the 
DISC, they oligomerize and undergo autoproteolytic cleavage and cross-activation due 
to their high local density and close proximity (Thornberry and Lazebnik, 1998). This 
mechanism used for procaspase-8 activation is called the induced proximity model, and 
requires a high concentration of procaspase molecules to be in close proximity to each 
other (Muzio et al., 1998; Salvesen et al., 1999).  
 
1.3.4   The two pathway model: Type I and Type II cells 
 
There are two Fas-mediated apoptotic pathways, which diverge after caspase-8 
activation. The two pathways exist based on the ability of the type of cell to execute 
apoptosis independently of the mitochondria (Type I cells) or in a dependent manner, 
relying on amplification of the death signal by the mitochondria (Type II cells) (Strasser 
et al., 1995; Li et al., 1998; Luo et al., 1998) (Fig. 4). Examples of Type I cells include 











cell line, H9 (Scaffidi et al., 1998; Huang et al., 1999). Examples of Type II cells 
include the T cell lines, CEM and Jurkat and the human myeloid cell line, HL60 
(Scaffidi et al., 1999). 
 
In Type I cells, the amount of caspase-8 activated at the DISC is sufficient to bring 
forth a downstream caspase cascade (Scaffidi et al., 1998) (Fig. 4). The activated 
caspase-8 molecules activates procaspase-3 and/or procaspase-7, which in turn activates 
procaspase-6 thereby transmitting the apoptotic signal to bring about cell death (Hirata 
et al., 1998). 
 
In Type II cells, however, the amount of activated caspase-8 is insufficient to elicit a 
caspase cascade. Therefore the apoptotic signal needs to be amplified via the 
mitochondria, thereby significantly delaying activation of the caspase cascade (Kuwana 
et al., 1998; Scaffidi et al., 1998). In Type II cells, the Fas death receptor pathway 
therefore converges with the mitochondrial-mediated apoptosis pathway to initiate 
apoptosis (Fig. 4). A pro-apoptotic member of the Bcl-2 family of proteins, Bid, forms 
the link between the death receptor- and mitochondrial-mediated apoptosis pathways. 
Activated caspase-8 cleaves Bid to produce its truncated form, tBid, which translocates 
to the outer mitochondrial membrane where it initiates the mitochondrial-mediated 
apoptosis pathway (as described in sections 1.5.2.2 and 1.6.1.2). Here tBid interacts 
with other pro-apoptotic members of the Bcl-2 family, Bax and Bak, to induce the 
release of pro-apoptotic factors from the mitochondria. These released molecules 
further amplify and execute the apoptotic cascade (Li et al., 1998; Luo et al., 1998). 
One of the released apoptotic molecules, cytochrome c, activates procaspase-9 in the 
apoptosome complex (described in section 1.5.3), leading to the activation of caspase-3 


















1.4   ER-stress induced apoptosis 
 
Cellular stress is defined as conditions in which the homeostatic balance is disturbed 
and cells encounter and react to abnormal states. Cells are very capable of maintaining 
homeostasis through various stress responses. Transient levels of cellular stress occur 
regularly, however, more severe stress signalling may be too challenging to overcome. 
Therefore the best option for the organism, as a whole, would be programmed cell death 
for these affected cells (Cullinan and Diehl, 2006).  
Fig. 4. The two different Fas/CD95 pathways involved in Type I and Type II cells. Type I cells are 
able to execute apoptosis independently of the mitochondria, however Type II cells rely on amplification 













Healthy proficient functioning of the ER is vital for maintaining cellular homeostasis 
and survival. The ER-stress induced apoptotic pathway forms part of the intrinsic 
apoptosis machinery (Morishima et al., 2002; Rao et al., 2002 a). The malfunctioning of 
this apoptosis pathway is implicated in the pathology and disease progression of 
numerous neurodegenerative and cardiovascular diseases (Szegezdi, et al., 2006). 
 
The ER is the site of protein synthesis and folding (Gaut and Hendershot, 1993). For 
optimum protein processing and folding, a number of factors are important, including 
ATP, calcium and an oxidizing environment to allow the formation of disulphide bonds 
(Imaizumi et al., 2001). Stress conditions that negatively affect the functioning of the 
ER, reduce its protein folding ability, which leads to the accumulation and aggregation 
of unfolded proteins inside the ER lumen (Kaufman, 2002). This, in turn, activates the 
unfolded protein response (UPR) (Lee, 1992; Forman et al., 2003). However, if the 
stress is too severe or prolonged to overcome and the UPR fails, the ER-stress induced 
apoptotic pathway is initiated and cell death ensues (Wu and Kaufman, 2006). 
 
1.4.1   The Unfolded Protein Response (UPR) 
 
The UPR is a pro-survival stress response that attempts to restore normal ER function. It 
does this by inhibiting further accumulation of misfolded proteins, initiating the 
degradation of aggregated proteins and improving the folding capacity of nascent 
proteins (Haze et al., 1999; Bertolotti et al., 2000). 
 
The UPR is initiated and mediated by three ER transmembrane receptors, which detect 
the onset of ER stress (Harding et al., 1999; Forman et al., 2003). These transmembrane 
receptors are Pancreatic eIF2 ER protein kinase (PERK), Activating transcription factor 
6 (ATF6) and Inositol-requiring enzyme 1 (IRE1). The receptors are maintained in an 
inactive state via their association with Immunoglobulin heavy chain-binding protein 
























1.4.1.1   Bip 
 
Bip, also known as glucose-regulated protein 78 (GRP78), is an ER membrane protein 
and chaperone (Haas and Wabl, 1983; Munro and Pelham, 1986). Bip and other GRPs 
are constitutively expressed in all cells and their expression is upregulated when ER 
function is disrupted (Kozutsumi et al., 1988; Chang et al., 1989; Li et al., 1994). This 
increase in Bip transcription is an attempt by the UPR to prevent the accumulation of 
cytotoxic misfolded protein aggregates in the ER. Bip molecules, that have dissociated 
from the ER receptors and/or are newly synthesized, act as protein chaperones by 
Fig. 5. Schematic representation of the UPR and initiation of ER-stress induced apoptosis pathway. 
During resting (unstressed) conditions the three ER transmembrane receptors are maintained in an inactive 
state via their association with Bip. At the onset of ER stress, Bip dissociates from the receptors resulting in 
their sequential activation and the induction of the UPR. PERK is activated first, then ATF6 and lastly IRE1 
(modified from Szegezdi, et al., 2006). 
 
















binding unfolded or misfolded proteins. Therefore Bip becomes directly involved in 
protein folding and translocation, and in so doing increases the protein folding capacity 
of the ER (Dorner et al., 1989; Flynn et al., 1991). 
 
In addition to its chaperone function, Bip also serves as a negative regulator of the three 
ER transmembrane receptors (Fig. 5). Induction of the UPR leads to the dissociation of 
Bip from the three ER stress receptors allowing for their sequential activation and 
dimerization (Fig. 5). This results in their autophosphorylation and subsequent increase 
in activity, allowing them to act on their substrates (Ma et al., 2002 a). PERK is 
activated first, followed by ATF6 and lastly IRE1 (Fig. 5). This sequence of activation 
allows time for the PERK and ATF6-mediated pathways to resolve the stress before 
IRE1 is activated (Szegezdi, et al., 2006). 
 
1.4.1.2    The three ER transmembrane receptors  
 
1.4.1.2 A)   PERK 
 
PERK dimerization and autophosphorylation occurs when Bip dissociates from it, 
generating the active form of PERK (Shi et al., 1998). Activated PERK phosphorylates 
the eukaryotic initiation factor 2 (eIF2), which inhibits protein synthesis and translation. 
In so doing, the load of emerging proteins at the ER is decreased, thereby promoting 
cell survival (Kimball and Jefferson, 1992; Sood et al., 2000).  
 
Cell survival, during ER stress, depends on the UPR’s ability to block the accumulation 
of unfolded nascent proteins. However, a number of genes, which are involved in the 
UPR, carry specific regulatory sequences in their 5’ untranslated regions. These 
regulatory sequences enable them to bypass the PERK-mediated eIF2-dependent 
translational block, thereby allowing these proteins to be synthesized to mediate the 
UPR and stress response (discussed in section 1.6.2) (Miller and Hinnebusch, 1990; 















1.4.1.2 B)   ATF 6 
 
Upon dissociation from Bip, ATF6 translocates from the ER to the Golgi apparatus (Li 
et al., 2000) (Figs. 5 and 6). AFT6 is proteolytically cleaved and activated in the Golgi 
compartment by the site-1 and site-2 proteases (S1P and S2P) to produce ATF6DC, 
which is a transcription factor (Haze et al., 1999; Ye et al., 2000). ATF6DC translocates 
to the nucleus where it induces and regulates genes with an ER stress response element 
(ERSE) that code for proteins involved in protein folding (Figs. 5 and 6). The 
transcription factors CEBP homologous protein (CHOP) and X box-binding protein 1 
(XBP1), as well as the ER chaperones Bip, GRP94 and protein disulphide isomerase are 
among these genes that are induced. XBP1 is important in the IRE1 pathway signalling, 
as described in section 1.4.1.2 C (Yoshida et al., 2001; Okada et al., 2002). The ATF6-
mediated signalling pathway is entirely pro-survival and has not yet been linked to ER-
stress induced apoptosis but rather the prevention of ER stress (Szegezdi, et al., 2006).  
 





Fig. 6. ATF6 activation in response to ER stress. Upon induction of ER stress, Bip releases ATF6, 
which is then transported into the Golgi where cleavage by S1P and S2P follows. Cleaved and activated 
ATF6DC then translocates to the nucleus. Here it binds and activates ER-stress inducible target genes, 












1.4.1.2 C)   IRE1  
  
During resting conditions, inactive IRE1 is bound to Bip by its ER-lumenal domain 
(Bertolotti et al., 2000). Bip releases IRE1 during conditions of ER stress, thereby 
allowing for its activation. IRE1 is a type I transmembrane protein that has both anti-
apoptotic and pro-apoptotic functions. It is an enzyme that possesses a serine-threonine 
kinase domain, as well as an endoribonuclease domain, presenting it with dual activity 
(Tirasphon et al., 1998; Wang et al., 1998).  
 
As an endonuclease, IRE1 splices XBP1 mRNA, thereby rendering it competent for 
translation (Yoshida et al., 2001) (Fig. 5). The translated protein, XBP1, is an active 
transcription factor. XBP1 attaches to the promoters of numerous genes involved in ER-
induced protein degradation and retrograde transport of misfolded proteins (out of the 
ER into the cytoplasm) to counteract apoptosis (Yoshida et al., 2001; Lee et al., 2003). 
However, XBP1 also regulates genes such as P58IPK, which bind and inhibit PERK thus 
creating a negative feedback loop that lifts the PERK-mediated translational block 
(section 1.6.2) (Yan et al., 2002; van Huizen et al., 2003). This occurs several hours 
after the activation of PERK and eIF2 and represents the point of termination of the 
UPR and initiation of apoptosis. Therefore, during the initial stages of IRE1 activation it 
aids the UPR by splicing XBP1 mRNA. However, later on it becomes important for 
initiating pro-apoptotic signals by inducing genes such as P58IPK and removing the 
translational block. If the UPR was successful in counteracting ER stress, the ER will 
return to its normal functioning and the cell will survive. However, if the UPR failed 
and/or the stressful conditions persist, removal of the translational block allows for the 
synthesis of pro-apoptotic proteins leading to cell death (Yan et al., 2002).  
 
IRE1 also initiates apoptosis by recruiting and activating caspase-12 through its 
complex with Tumour-necrosis-factor receptor-associated factor 2 protein (TRAF2) 
(Yoneda et al., 2001). The IRE1-TRAF2 complex releases procaspase-12 from the ER 
membrane, thereby allowing for its cleavage and activation.  
 
The IRE1-TRAF2 complex also recruits Apoptosis-signal-regulating kinase (ASK1) 
(Fig. 5). ASK1 is a mitogen-activated protein kinase kinase kinase (MAPKs), which 











(JNK) and p38 (Nishitoh et al., 1998; Urano et al., 2000). The activated JNK pathway 
subsequently allows for the activation of pro-apoptotic factors that transmit the 
apoptotic signal to the mitochondria (section 1.6.1.2). Here the apoptotic signal is 
amplified and relayed via the mitochondrial apoptosis pathway (discussed in section 
1.5) (Leppa and Bohmann, 1999; Nishitoh et al., 2002). Activated p38 regulates pro-
apoptotic molecules, such as CHOP, through phosphorylation, thereby increasing their 
activity and enhancing the apoptotic signal (Wang et al., 1996; Harding et al., 2000 a; 
Harding et al., 2002) (Fig. 5).  
 
1.4.2   CHOP  
 
CHOP, also known as Growth arrest- and DNA-damage-inducible gene 153 
(GADD153), is involved in ER-stress induced apoptosis and serves as an important 
switch from the pro-survival to pro-death signalling pathways (Marciniak et al., 2004). 
Under normal unstressed conditions CHOP is not constitutively expressed, unlike the 
ER chaperone genes, which include Bip (Brewer et al., 1997). 
 
CHOP is a pro-apoptotic basic leucine zipper-containing transcription factor that is 
induced with the commencement of the ER-stress induced apoptosis pathway (Ron and 
Habener, 1992; McCullough et al., 2001). CHOP is involved in all three arms of the 
UPR, namely the PERK, ATF6 and IRE1 signalling pathways (Carlson et al., 1993; 
Wang et al., 1996; Ma et al., 2002 b) (Fig. 5). In addition to controlling levels of CHOP 
transcription and translation, the UPR is also involved in its post-translational 
modification and activation (Fig. 5). Activation of CHOP mediates and enhances 
apoptosis by inducing gene expression of apoptotic molecules and inhibiting the 
expression of the anti-apoptotic Bcl-2 gene (discussed in section 1.6.1.2) (Zinszner et 
al., 1998; Oyadomari et al., 2002).  
 
1.4.3   Caspase-4/12  
 
Initiation of the ER-stress induced apoptotic pathway also leads to the specific 
activation of caspase-4. In humans ER stress is mediated by caspase-4, however, in 
rodents caspase-12 takes on this role (Nakagawa et al., 2000; Hitomi et al., 2004). 











interrupts this gene, in addition to a loss of caspase function caused by amino acid 
substitution in the critical site (Fischer et al, 2002). Therefore human caspase-12 does 
not mediate ER-stress induced
 
 apoptosis. Studies have found that human caspase-4 
could functionally substitute the function of murine caspase-12 in human systems 
(Nakagawa et al., 2000). Human colon cDNA libraries were screened using the murine 
caspase-12 gene as probe and it was found that caspase-4 is the homologous gene to 
murine caspase-12 (Hitomi et al., 2004).  
Caspase-4 is predominantly localized to the ER membrane in its inactive form. This 
allows it to sense ER stress signals and changes in ER homeostasis, making it a central 
player in the ER-stress induced apoptotic pathway. Hitomi et al. (2004) also showed 
that caspase-4 is also found on the mitochondrial outer membrane. Bcl-2, which was 
found to completely inhibit the downstream mitochondrial apoptotic signal, did not 
inhibit ER-stress induced cleavage and activation of caspase-4. It was therefore 
concluded that mainly caspase-4 localized to the ER is activated upon ER-stress 
induced apoptosis and not mitochondrial caspase-4
 
 (Hitomi et al., 2004). 
Karki et al. (2007) found that caspase-4 activation requires both oligomerization and 
proteolytic cleavage for activation. It was found that caspase-12, in murine systems, 
could be activated by calcium-activated cysteine endopeptidases (proteases similar to 
caspases) called calpains (Nakagawa and Yuan, 2000). Other studies have shown that 
caspase-7 activates caspase-12 after prolonged ER stress (Rao et al., 2001). Yoneda et 
al. (2001) found that caspase-12 activation is mediated by TRAF2 and regulated by 
IRE1. Studies have also found that caspase-12 activates caspase-9 in a cytochrome c-
independent (Morishima et al., 2002) and Apaf-1-independent (Rao et al., 2002 a) 
manner, thereby bypassing the apoptosome pathway (section 1.5.3).  
 
The exact mechanism of caspase-4 activation, the function of mitochondrial-localized 
caspase-4 and the group of caspases linked or activated upon ER-stress induced 
 
apoptosis are, however, still not fully elucidated (Yoneda et al., 2001; Rao et al., 2002 













1.5   Mitochondrial-mediated apoptosis 
 
The mitochondria are responsible for cellular metabolism and producing most of the 
cellular ATP. In cells that are undergoing apoptosis, the mitochondria function as 
central executioners and/or regulators. The mitochondrial-mediated apoptosis pathway 
can amplify and intercede in the extrinsic and intrinsic apoptotic pathways. In addition, 
it can also initiate and propagate death signals that originate within the cell. DNA 
damage, radiation, chemotherapy, oxidative stress, nutritional deprivation and cytotoxic 
drugs are all stimuli that induce the mitochondrial-mediated apoptotic pathway 
(Skommer et al., 2007).  
 
1.5.1   The structure of the mitochondria 
 
Mitochondria possess double membranes, which form two compartments, namely the 
intermembrane space and the matrix (Fig. 7). The intermembrane space exists between 
the inner and outer mitochondrial membranes, whereas the matrix is the space enclosed 
by the inner mitochondrial membrane (Fig. 7). The matrix contains powerful pro-
apoptotic molecules. Under physiological circumstances these molecules are used in the 
processes of oxidative phosphorylation, whereby energy from food molecules are 
converted into usable forms of chemical energy (Solomon et al., 1999).  
 
The outer mitochondrial membrane is quite permeable and contains many aqueous 
channels, which allow small molecules to pass through it. These aqueous channels are 
made up of the transport protein called Voltage dependant anion channel (VDAC) (also 
called porin) (Beutner et al., 1998). The inner mitochondrial membrane is selectively 
permeable and folded into numerous cristae (Solomon et al., 1999). The cristae contain 
the transport proteins necessary for oxidative phosphorylation, including Adenine 
nucleotide transporter (ANT), which controls the exchange of ADP and ATP across the 























1.5.2  Mitochondrial membrane depolarisation and outer membrane 
permeabilization 
 
The mechanisms responsible for mitochondrial membrane depolarisation and outer 
membrane permeabilization include the opening of the permeability transition pore and 
the interaction of pro-apoptotic members of the Bcl-2 family (also discussed in section 
1.6.1) (Crompton, 1999; Harris and Thompson, 2000). 
  
1.5.2.1   The permeability transition pores 
  
A permeability transition pore, also known as a mitochondrial megachannel or multiple 
conductance channel, is made up of a complex of proteins situated at contact sites 
Fig. 7. Drawing and transmission electron microscopy (TEM) of a mitochondrion. The 
drawing shows the different compartments and membranes of the mitochondrion. The 
double membranes, matrix and cristae can also be seen in the TEM (drawing by D.W. 











between the inner and outer mitochondrial membranes (Bernardi, 1996; Lohret et al., 
1996). A permeability transition pore consists of several proteins, which include 
VDAC, ANT, cyclophilin D (CypD), and peripheral benzodiazepine receptor (PBR) 
(Beutner et al., 1998; Bauer et al., 1999) (Fig. 8). Due to their location, the permeability 
transition pores form important sites of metabolic coordination between the 
mitochondrial matrix, intermembrane space and the cytoplasm (Fig. 8). They function 
as regulators of the matrix’s pH and volume, as well as intracellular calcium 
concentration. This allows it to act as voltage and redox-gated channels, with different 
levels of conductance (Zoratti and Szabò, 1995; Ichas et al., 1997; Marzo et al., 1998).  
 
Following apoptosis-inducing stress conditions, the mitochondrial inner transmembrane 
potential is disrupted (Bras et al., 2005). This change in inner mitochondrial membrane 
potential causes permeability transition pores to open. As a result, due to an influx of 
water molecules, the matrix and outer mitochondrial membrane expands. This 
distension causes depolarisation of the outer membrane, which also becomes more 
permeable (Kantrow and Piantadosi, 1997; Petit et al., 1998). The increased 
permeability of the outer mitochondrial membrane results in further osmotic swelling of 
the mitochondrion and eventual rupture of the outer membrane. When the 
mitochondrion ruptures, it releases pro-apoptotic proteins, which were sequestered in 
the matrix and intermembrane space, into the cytoplasm (Loeffler and Kroemer, 2000). 
As a result, the synthesis of ATP stops, levels of ROS increase and redox molecules, 
such as NADH, NADPH and glutathione, are oxidized. A positive feedback loop is 
produced as ROS oxidizes the cell’s lipids, proteins and nucleic acids. This further 
enhances the death signal and reinforces the cell’s fate towards apoptosis (Kroemer et 
al., 1997; Marchetti et al., 1997; Ricci et al., 2003). Studies have shown that 
pharmacological inhibition of the permeability transition pores safeguards the cell 
























1.5.2.2  Involvement of the Bcl-2 family proteins in outer mitochondrial membrane 
permeabilization 
 
The Bcl-2 family of proteins directly affect mitochondrial homeostasis and play a 
crucial role in regulating the mitochondrial mediated apoptotic pathway (as discussed in 
section 1.6.1) (Antonsson et al., 1997; Kuwana et al., 2002). The Bcl-2 proteins can 
form channels in the mitochondria, or facilitate channel formation by interacting with 
other family members or mitochondrial proteins. In so doing, the Bcl-2 proteins 
increase the outer mitochondrial membrane’s permeability, which leads to its eventual 
rupture (Crompton, 1999; Harris and Thompson, 2000). 
 
Fig. 8. The different mechanisms involved in mitochondrial outer membrane permeabilization. It 
is proposed that release of the pro-apoptotic mitochondrial factors can result from either permeability 
transition pore opening (A) or mitochondrial permeabilization due to the interaction of pro-apoptotic 
members of the Bcl-2 family (such as Bax) with VDAC and/or ANT (B). Another mechanism proposes 
that the release of pro-apoptotic proteins depends on the balance between the pro- and anti-apoptotic 











Central pro-apoptotic members of the Bcl-2 family are truncated Bid, Bax and Bak, as 
they can directly interact with outer mitochondrial membrane proteins (Shimizu et al., 
1999; Wei et al., 2001). As mentioned in section 1.3.4, Bid provides a link between the 
death receptor and mitochondrial-mediated apoptosis pathways. Activated, truncated 
Bid relocates to the mitochondria where it is required to activate the pro-apoptotic 
function of Bax and Bak (Li et al., 1998; Luo et al., 1998) (Fig. 8). Oligomerised Bax 
and Bak molecules initiate or contribute to the permeability of the outer membrane by 
forming channels themselves or by interacting with other mitochondrial proteins, like 
VDAC and ANT (of the permeability transition pores) (Fig. 8). A number of Bcl-2 
family members can bind to VDAC, causing it to undergo conformational change and 
in so doing, regulate its channel activity. These Bcl-2 proteins therefore modulate 
mitochondrial homeostasis by regulating channel activity, in addition to producing 
pores to increase outer mitochondrial membrane permeability (Shimizu et al., 1999; 
Wei et al., 2001) (Fig. 8). 
 
1.5.3   The apoptosome pathway 
 
The powerful mixture of pro-apoptotic proteins that are released from a mitochondrion 
(when it ruptures) include cytochrome c, Apoptosis-inducing factor (AIF), 
Smac/DIABLO, several procaspases such as procaspase-2, -3 and -9, Omi/HtrA2 and 
the endonuclease endoG (Susin et al., 1999; Li et al., 2001; Verhagen et al., 2002). 
Upon release, these proteins ensure that the apoptosis cascade rapidly progresses to the 
end. The release of cytochrome c into the cytosol is a key event in mitochondrial-
mediated apoptosis (Liu et al., 1996). 
 
Cytochrome c is situated between the outer and inner mitochondrial membrane. It is 
strongly linked with complex IV of the respiratory chain and functions mainly to 
mediate the electron transport between complex III and IV (Skommer et al., 2007). In 
the cytoplasm, the released cytochrome c oligomerises with Apoptotic protease 
activating factor-1 (Apaf-1) and ATP to form the apoptosome complex (Li, P et al., 
















The apoptosome is a cytosolic apoptosis signalling protein complex. To form the 
apoptosome complex, cytochrome c requires dATP to bind to monomeric Apaf-1 (Fig. 
9). The cytochrome c-Apaf-1 complex undergoes a conformational change and 
oligomerizes to form a wheel-like structure with 7-fold symmetry (Fig. 9). Apaf-1 
contains a caspase recruitment domain, which binds procaspase-9, and it also possesses 
multiple WD-40 repeats that allows for self-oligomerization and auto-activation of 
caspase-9 (Zou et al., 1997; Cain et al., 2000) (Fig. 9). The apoptosome complex is seen 
as the true active form of caspase-9, forming a caspase-9 holoenzyme. Cytochrome c 
and Apaf-1 are therefore not just activators of caspase-9 but are essential regulatory 
subunits of this holoenzyme (Rodriguez and Lazebnik, 1999). Activated caspase-9 in 
turn activates downstream effector caspases like caspase-3, relaying and amplifying the 
caspase cascade towards cell death (Slee et al., 1999; Acehan et al., 2002).  
 
1.6   Regulation of the apoptosis signalling pathways 
 
The apoptotic pathways have various regulatory molecules and mechanisms in place to 
prevent healthy cells from apoptosing under normal unstressed conditions. 
 
1.6.1   The Bcl-2 family of proteins regulate all three apoptotic pathways 
Bcl-2 was identified by Vaux et al. (1988) as an oncogene, which inhibits apoptosis 







Fig. 9. Formation and activation of the apoptosome complex. Mitochondrial release of 
cytochrome c leads to the formation of the apoptosome complex and subsequent activation of 











presence of highly conserved sequence motifs, which were identified as Bcl-2 
homology domains. These proteins are grouped together as the “Bcl-2 family of 
proteins” and are divided into two groups, namely the pro-apoptotic and anti-apoptotic 
members. Some anti-apoptotic members are Bcl-2, Bcl-XL, Bcl-w, A1 and Mcl-1. Two 
subgroups of pro-apoptotic members exist, namely the Bax-subfamily, which include 
the proteins Bax, Bak and Bok, and the BH3-only protein subgroup, which include Bid, 
Bim, Bik, and Bad (Gross et al., 1999; Cory and Adams, 2002; Willis and Adams, 
2005). 
The highly conserved Bcl-2 homology domains are vital for homo-complex and hetero-
complex formation between pro- and anti-apoptotic family members (Muchmore et al., 
1996; Borner, 2003). This enables the Bcl-2 proteins to interact with each other and 
neutralize the effect of each one on the other. Therefore, cells with more pro-apoptotic 
proteins will apoptose, whereas cells with more anti-apoptotic members will survive or 
are resistant to apoptosis (Rosse et al., 1998; Harris and Thompson, 2000). 
1.6.1.1   Regulation of the Fas death receptor pathway via Bcl-2 proteins 
Fas-induced apoptosis that occurs via the mitochondria in Type II cells can be inhibited 
by Bcl-2 (Strasser et al., 1995). Overexpression of anti-apoptotic members of the Bcl-2 
family, Bcl-2 and Bcl-xL, were found to block mitochondrial apoptotic activity in both 
Type I and II cells. However, caspase-8 and -3 activity was only blocked in Type II 
cells, followed by inhibition of apoptosis (Scaffidi et al., 1998). The death receptor 
pathway, in Type II cells, can therefore be regulated by events that control the 
mitochondrial apoptosis response (section 1.2.5). 
 
1.6.1.2 Regulation of the ER-stress induced and mitochondrial-mediated apoptotic 
pathways via Bcl-2 proteins 
 
The ER-stress induced apoptosis pathway is regulated by CHOP, JNK and the Bcl-2 
family of proteins, which also regulates the mitochondrial-mediated apoptotic pathway. 
In this way the apoptotic signal is passed on from the ER to the mitochondria 
 
(Boya et 





































In resting conditions, the pro-apoptotic proteins Bax and Bak are kept in an inactive 
state by their association with Bcl-2 on the mitochondrial and ER membranes 
(Krajewski et al., 1993; Zong et al., 2003) (Fig. 10). When stressful conditions in the 
ER develop, it leads to the activation of the JNK pathway and induction of CHOP, both 
of which remove the anti-apoptotic effect of Bcl-2 (McCullough et al., 2001; Bassik et 
al., 2004) (Fig. 10)
 
.  
The phosphorylation of Bcl-2 by JNK, at the ER, abolishes the anti-apoptotic effect of 
Bcl-2. This allows for the activation of pro-apoptotic factors, Bax and Bak, which relays 
Fig. 10. Regulation of the ER-stress induced and mitochondrial-mediated apoptosis pathways. In 
unstressed conditions, the pro-apoptotic Bax and Bak are kept inactive by their association with Bcl-2 
on the mitochondrial and ER membranes. By binding to cytoskeletal dynein, the pro-apoptotic member, 
Bim, is kept inactive. Stressful conditions in the ER cause the activation of JNK and induction of 
CHOP, both of which remove the anti-apoptotic effect of Bcl-2. JNK phosphorylates Bcl-2 and CHOP 
blocks its expression. JNK also activates Bim by phosphorylation, leading to its release from the 
cytoskeleton. Through the activation of Bax and Bak the unresolved stress results in the transmission of 
the apoptotic signal from the ER to the mitochondria where death signal is amplified. Subsequently 
caspases are activated both on the ER membrane (caspase-4/12) and through the apoptosome (caspase-
9) (modified from Szegezdi, et al., 2006). 
 
 











the apoptotic signal to the mitochondria where it is amplified (Hacki et al., 2000) (Fig. 
10). CHOP blocks the expression of Bcl-2 and in so doing reduces the amount of Bcl-2 
protein able to prevent apoptosis (McCullough et al., 2001) (Fig. 10). Consequently 
caspases are activated both on the ER membrane (caspase-4/12) and through the 
apoptosome (caspase-9), although this mechanism is still unclear 
 
(Nakagawa et al., 
2000; Hitomi et al., 2004) (Fig. 10). 
JNK also regulates BH3-only members through phosphorylation, thereby increasing 
their pro-apoptotic potential. The pro-apoptotic member, Bim (BH3), is kept inactive by 
its association with the cytoskeletal protein dynein (Fig. 10). JNK phosphorylates and 
activates Bim, leading to its release from the cytoskeleton. Activated Bim translocates 
to the mitochondria were it acts as a pro-apoptotic protein on the outer mitochondrial 
membrane (Lei and Davis, 2003; Morishima et al, 2004) (Fig. 10)
 
.  
1.6.2  General regulation of the ER-stress induced apoptotic pathway  
 
The ER transmembrane receptors, IRE1 and PERK (sections 1.4.1.2 A and 1.4.1.2 C), 
are also regulated during ER stress. Regulatory proteins such as c-Jun N-terminal 
inhibitory kinase (JIK) and Jun activation domain-binding protein 1 (JAB1), interacts 
with IRE1, thereby controlling its function (Urano et al., 2000; Yoneda et al., 2001). 
During resting conditions JAB1 associates with IRE1 and the interaction is increased 
upon mild ER stress. However, severe ER stress causes JAB1 to dissociate from IRE1, 
which can then be activated. JIK can also bind to TRAF2, and in that way regulate the 
recruitment of TRAF2 by IRE1, as well as the activation of the MAPK pathway (section 
1.4.1.2 C). More research into the regulatory activities of JIK and JAB1, and how 
exactly they provide the switch between pro-survival and pro-apoptotic signalling via 
IRE1, is still required (Oono et al., 2004). 
 
Activating transcription factor 4 (ATF4) is one of the proteins that are able to bypass the 
eIF2-dependent translational block (PERK pathway) (section 1.4.1.2 A). ATF4 induces 
genes involved in the stress response, amino-acid metabolism, redox reactions, and 
protein secretion to promote cell survival and to restore ER homeostasis (Harding et al., 
2003). However, ATF4 also induces pro-apoptotic genes such as the transcription factor 











PERK is inhibited by P58IPK, thereby releasing the PERK-mediated translational block 
(section 1.4.1.2 A) (Yan et al., 2002; van Huizen et al., 2003). The translational block is 
also lifted when the protein phosphatase 1 (PP1)-interacting protein, GADD34, 
mediates the dephosphorylation of eIF2 by PP1 (Connor et al., 2001; Brush et al., 
2003). GADD34 expression is associated with apoptosis induced by a variety of signals 
and its overexpression can induce or augment apoptotic cell death (Adler et al., 1999). 
The release of the translational block acts as a positive feedback loop, creating more 
unfolded proteins and also allows for the synthesis of pro-apoptotic proteins, which 
drives the cell towards apoptosis (Novoa et al., 2001; Ma and Hendershot, 2003).  
 
1.6.3   General regulation of Fas-mediated apoptosis 
 
The shedding of membrane-bound FasL and formation of sFasL is one way in which the 
death receptor pathway is regulated. Soluble FasL, which has decreased activity, retains 
its binding affinity to the Fas receptors and can thereby act as a competitive inhibitor 
(Suda et al., 1997; Schneider et al., 1998; Tanaka et al., 1998). Decoy receptors, which 
are part of the TNF family, have also been discovered (Nagata, 1999). One such decoy 
receptor, DcR3, is secreted from cells and can bind FasL with almost the same affinity 
as Fas, even though these two receptors do not share similar primary structures. It was 
found that the DcR3 gene is amplified in more than 50% of colon and lung carcinomas, 
which express high levels of DcR3 mRNA. Since FasL would bind the decoy receptors, 
this could explain why these defective cells, having an increased expression of DcR3, 
cannot die via Fas-mediated apoptosis (Pitti et al., 1999).  
 
There are also regulatory and/or inhibitory steps involved once the Fas receptors have 
been activated and start recruitment of FADD and formation of the DISC. Once the 
DISC is assembled for caspase-8 activation, the degenerate caspase homologues, 
FADD-like interleukin-1 β-converting enzyme inhibitory proteins (FLIPs), can be 
recruited by FADD instead of caspase-8 molecules. FLIPs therefore act as decoys by 
binding to FADD and in so doing prevents caspase-8 activation (Irmler et al., 1997; Shu 












1.6.4   Regulation of the caspase cascade by the Inhibitors of apoptosis proteins 
(IAPs) 
 
The apoptosis pathway is also regulated once the caspase cascade is initiated. The 
Inhibitor of apoptosis proteins (IAPs), are powerful inhibitors of caspases. The IAPs are 
a family of anti-apoptotic proteins that are essential for their interaction with caspases. 
IAPs regulate caspase activity by acting as caspase substrates and can therefore directly 
inhibit caspase function and regulate the caspase cascade (Miller, 1999; Uren et al., 
1999). 
 
Human IAP homologues that have been identified are NAIP, c-IAP1, c-IAP2, XIAP and 
survivin (Deveraux et al., 1997; Takahashi et al., 1998). XIAP, c-IAP1 and c-IAP2 also 
contain a greatly conserved domain with E3 ubiquitination activity at their C-terminal 
ends. Proteins that interact with IAPs are therefore targeted for ubiquitination and 
degradation by the proteasome (Huang et al., 2000; Yang et al., 2000; Huang et al., 
2001). 
An important negative regulator of IAP activity is the protein Second mitochondria-
derived activator of caspases (Smac), which is also known as Direct IAP-binding 
protein with low pI (DIABLO). Smac/DIABLO is one of the pro-apoptotic factors 
released from the mitochondria during apoptosis. It possesses a conserved tetrapeptide 
motif, which enables it to bind to IAPs. In so doing, it displaces bound caspases, thereby 
neutralising the inhibitory effect of IAPs on caspase activation (Du et al., 2000; 

















1.7  Aim and objectives of the investigation 
 
The aim of this investigation was to study and monitor three caspase-dependent 
apoptotic pathways (death receptor, mitochondrial-mediated and ER-stress induced
 
) in 
a defined haematopoietic cell population (HL60 cells).  
The objectives were as follows: 
 
• To establish appropriate drug concentrations and exposure times required to induce 
different levels (low and high) of early apoptosis in the cells. 
 
• To find pathway-specific markers for each pathway during the initial (Bip and 
FADD), intermediate (changes in mitochondrial transmembrane potential) and later 
(CHOP, cytochrome c release and caspase activation) stages of apoptosis.  
 
• To optimise the assays and techniques required to detect these pathway-specific 
markers. 
 
• To determine if the techniques are sensitive and reproducible and if the cell models 
are reliable. 
 
• To determine if each marker is specific to its pathway or if there is cross talk 























MATERIALS AND METHODS 
 
 
2.2   Cell culture  
 
2.1.1   Cell lines and culture conditions 
 
The promyleocytic leukaemic HL60 (passage number 2; 01/11/1985), as well as the 
Jurkat (passage number unknown; gift from Division of Clinical Immunology at UCT) 
cell lines, were cultured in accordance with American Type Culture Collection (ATCC) 
protocol (ATCC: Cell Biology Collection, 2007). The HL60 cells were maintained at 
approximately 105-106 viable cells per ml in suspension in Iscoves Modified Dulbecco 
Medium (IMDM) (GibcoTM, Invitrogen), which was supplemented with 20% (v/v) heat 
inactivated Foetal bovine serum (FBS) (GibcoTM, Invitrogen). The Jurkat cell line was 
maintained at approximately 105-106 viable cells per ml in suspension in Roswell 
Memorial Park Institute (RPMI 1640) culture medium (GibcoTM, Invitrogen), which 
was supplemented with 10% (v/v) FBS (GibcoTM, Invitrogen). All cells were cultured in 
the absence of antibiotics. The cells were sustained at 37°C in a humidified 
(approximately 80-90% relative humidity) atmosphere with 5% carbon dioxide (CO2).  
 
2.1.2   Quantification of cells 
 
2.1.2 A)   Determination of cell viability 
 
Cell viability was determined via Trypan blue (0.4% (w/v) Trypan blue in 1x PBS) 
staining and cell counting using a light microscope (Zeiss, West Germany) at 10x 
magnification. A drop of cell suspension, from the same sample of cells to be counted 
(section 2.1.2 B), was placed on a microscope slide. A drop of Trypan blue was placed 
on top of the cells and covered with a cover slip. Cell viability was expressed as 












2.1.2 B)   Determination of cell number 
 
The cell number was determined using an automated cell counter, Coulter Counter® 
model ZF (Beckman Coulter, Florida USA). The Coulter Counter® settings were: 
amplification at ½, threshold at 60 units and aperture current at 1 mA. The average cell 
number calculated by the Coulter Counter® was multiplied by the %viability of the 
cells (section 2.1.2 A) to reflect the number of viable cells in the culture. 
 
2.1.3   Culture initiation and maintenance  
 
The cells (HL60 or Jurkat) were thawed and washed with pre-warmed (37°C) medium 
(IMDM and 20% (v/v) FBS), to remove the dimethylsulphoxide (DMSO) 
cryopreservant (Doyle et al., 1998). The cells were collected by centrifugation (MSE, 
UK) at 1500 revolutions per minute (RPM) for 10 min at room temperature. The 
supernatant was removed and the pellet resuspended in 2 ml fresh pre-warmed medium. 
The cell number and viability was determined as described in section 2.1.2.  
 
Cells were plated at 105-106 cells per ml in 100mm x 20mm tissue culture dishes 
(Corning® Inc.). The growth medium was changed every 2-3 days to prevent depletion 
of nutrients and medium constituents. To maintain approximately 106 cells per ml of 
medium, the cells were collected through centrifugation (1500 RPM for 10 min at room 
temperature), the medium removed, and the pellet resuspended in fresh pre-warmed 
medium. The cell counts and viabilities were determined (as described in section 2.1.2) 
and the cells were plated at 105-106 cells per ml in 100mm x 20mm tissue culture dishes 
(Corning® Inc.).  
 
2.1.4   Storage of cells 
 
The cells were cryopreserved for future use in freezing solution (for HL60 cells: 70% 
(v/v) IMDM, 10% (v/v) DMSO, 20% (v/v) FBS and for Jurkat cells: 80% (v/v) IMDM, 
10% (v/v) DMSO, 10% (v/v) FBS) according to Doyle et al. (1998) with some 
modifications. The freezing solution was kept on ice before addition to the cells. Cells 
were collected through centrifugation (1500 RPM for 10 min at room temperature), the 










viabilities were determined as described in section 2.1.2. The cells were then diluted 
with medium so that the final concentration of cells, after addition of the freezing 
solution, would be approximately 106 to 107 cells per ml. The freezing solution was 
added to the cell suspensions in a ratio of 1:1. Cells were frozen at -20°C over night 
(O/N) then placed at -80°C for short-term storage (at passage number 5 or 7 for HL60).  
 
2.1.5   Drug treatment of cells over different exposure times (initial optimisation 
experiments) 
 
The HL60 cells (passage number 14-16) were treated with Brefeldin A (BFA) (0.5 
µg/ml - 30 µg/ml) for 6, 24 and 48 hrs to induce the ER-stress induced apoptotic 
pathway (Guillemain and Exton, 1997; Li et al., 2006). The HL60 cells (passage 
number 8-34) were treated with hydrogen peroxide (H2O2) (0.005 mM - 1.5 mM) for 6, 
15 and 24 hrs to induce the mitochondrial-mediated apoptotic pathway (Hosokawa et 
al., 2005). FLAG-tagged FasL with ANTI-FLAG® M2 antibody (Sigma®-Aldrich, 
2008) was used to induce the death receptor pathway via Fas receptor for both HL60 
(passage number 35-37) (0.5 - 500 ng/ml FLAG-tagged FasL, 4 and 24 hrs) (Li, W. et 
al., 2006; Sigma®-Aldrich, 2008) and Jurkat (0.04 ng/ml - 5 ng/ml FLAG- tagged FasL 
for 4 hrs) (Huang et al., 1999; Sigma®-Aldrich, 2008) cells in the presence of 0.25 
μg/ml or 0.5 μg/ml ANTI-FLAG® M2 antibody. The FLAG-tag (FLAG octapeptide: N-
DYKDDDDK-C) is a polypeptide protein tag, which can be attached to a recombinant 
expressed protein to facilitate, for example, recognition by an antibody. For drug 
treatment, the drugs (BFA, H2O2, FasL) were always added with fresh medium (with 
FBS) to the cells. 
 
2.1.6   Drug treatment of cells for analysis of all three apoptosis pathways (final 
experiments) 
 
HL60 cells (passage number 11-19) (106 viable cells per ml, approximately 15-20 ml 
volume) were treated with BFA (5 µg/ml or 30 µg/ml) for 24 hours to induce the ER-
stress induced apoptosis pathway (Guillemain and Exton, 1997). HL60 cells (passage 
number 16-20) (106 viable cells per ml, approximately 15-20 ml volume) were also 











apoptotic pathway (Hosokawa et al., 2005) (as determined in section 3.1.1.3). Jurkat 
cells (106 viable cells per ml, approximately 15-20 ml volume) were treated with 
FLAG-tagged FasL (0.2 ng/ml or 0.4 ng/ml) for 4 hrs, in the presence of 0.25 μg/ml 
ANTI-FLAG® M2 antibody, to induce the Fas-mediated death receptor pathway 
(Huang et al., 1999; Sigma Aldrich, 2008) (as determined in section 3.1.1.3 D). The 
drugs (BFA, H2O2, FasL) were added to the cells with fresh medium (with FBS) each 
time. These drug-treated cells were used for the final experiments of section 3.2 
 
2.2   Annexin V (AV) and Propidium Iodide (PI) labelling and flow cytometry 
 
The percentage of apoptosing cells, after induction, was determined with Annexin V- 
fluorescein isothiocyanate (AV-FITC) and propidium iodide (PI) labelling using flow 
cytometry. 
 
2.2.1   AV/PI labelling procedure 
 
Following drug treatment, the cells were collected by centrifugation (Beckman GS-15R, 
Beckman Coulter, USA) (1500 RPM for 10 min at room temperature) and labelled with 
AV and PI according to the manufacturer’s recommendations (Annexin V-FITC 
Apoptosis detection kit, Beckman Coulter). The cell pellets were washed once with ice-
cold 1x PBS (Oxoid Dulbecco A Tablets, Typical formula: 140 mM NaCl, 2.7 mM 
KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4) (pH 7.2), to remove culture medium and/or 
drug and centrifuged for 10 min, at 1500 RPM and 4°C. Following the removal of the 
PBS wash, the cells were resuspended in ice-cold 1x Binding buffer to 5x105 - 5x106 
cells per 500 µl. From each cell suspension, 100 µl (of the 500 µl sample) was 
transferred to a new microcentrifuge tube and placed on ice. AV-FITC solution (1 µl of 
a 0.025 µg/µl stock solution) and PI solution (5 µl of a 0.25 µg/µl stock solution) were 
added to each tube, and mixed gently. The samples were subsequently incubated on ice, 
in the dark, for 15 min to allow for cell labelling. After the incubation period, 400 µl of 
1x Binding buffer was added to each sample and the samples transferred to flow 













2.2.2   AV/PI flow cytometry analysis protocol 
 
A flow cytometry protocol was first established using HL60 cells (passage number 16) 
treated with 10 µg/ml BFA for 24 hrs (Guillemain and Exton, 1997; Li et al., 2006). 
The cells were either labelled with AV or PI, or both, to allow for colour compensation 
of the small signal overlap between the two fluorochromes, AV (detected in the FL1 
channel) and PI (detected in the FL4 channel). The experimental controls included: 
untreated cells (negative control), unlabelled cells (to test for auto-fluorescence) and 
cells treated with drug solvent (DMSO) only (to determine if it had an effect on 
fluorescence of the cells). All samples were prepared and analysed in triplicate. 
 
The flow cytometry protocol was set up by adjusting the voltages of the FL1 (AV-
FITC) and FL4 (PI) channels to obtain clear positive or negative peaks in each channel 
using the untreated and/or drug-treated cells. The protocol was set up so that there was a 
clear increase in fluorescence (positive peak) detected in the FL1 (AV-FITC) and FL4 
(PI) channels for the drug-treated cells. Colour-compensation was also performed to 
obtain distinct cell populations in the colour-coded density plots (PI vs. AV plots). The 
resultant flow cytometer protocol, used to analyse both cell lines, incorporated the 
cytometer settings shown in Table 1.  
 
Table 1: Flow cytometer settings for the AV and PI labelling protocol 
 FS SS FL1 FL2 FL3 FL4 FL5 AUX 
Voltage 189 663 318 337 402 295 530 300 
Gain 2.0 5.0 1.0 1.0 1.0 1.0 1.0 1.0 
 FS SS FL1 FL2 FL3 FL4 FL5 AUX 
Discriminator 100 OFF OFF OFF OFF OFF OFF OFF 
 FL1 FL2 FL3 FL4 FL5    
FL1  0 0 2.5 0    
FL2 0  0 0 0    
FL3 0 0  0 0    
FL4 0 0 0  0    














2.2.3   Flow cytometer laser alignment verification 
 
To ensure that the optical and fluidics systems were aligned for maximal detection of 
fluorescence signals, a flow cytometer laser alignment verification was performed on a 
regular basis. Beckman Coulter FLOW-CHECKTM fluorospheres were used for this 
purpose according to manufacturer’s instructions.  
 
2.3   Western blot analysis 
 
After drug treatment, levels of FADD, Bip and CHOP proteins (with β–actin as the 
invariant positive control) were determined by immunodetection. Proteins in whole cell 
extracts were immobilized on microporous polyvinylidene difluoride (PVDF) 
membrane and each specific protein was detected using the BM Chemiluminescence 
Western Blotting Kit (Mouse/Rabbit) (Roche, Germany).  
 
2.3.1   Protein Extraction 
 
HL60 cells (passage number 14-34) (106 cells per ml) were treated with 30 µg/ml BFA 
for 24 hrs to induce the ER-stress induced apoptotic pathway, after which they were 
collected via centrifugation (at 1500 RPM for 10 min at room temperature). The cell 
pellets were subsequently pooled to a density of approximately 107 cells per ml and 
washed once with ice-cold 1x PBS (pH 7.2) to remove any remaining culture medium 
and/or BFA. The cells were collected by centrifugation (Beckman GS-15R, Beckman, 
USA) at 1500 RPM for 10 min at 4°C and the PBS removed.  
 
Ice-cold radioimmunoprecipitation (RIPA) buffer (0.05 M Tris-HCl, 1 mM EDTA, 15 
mM NaCl, 1% Triton X-100, 1% NP-40, 0.1% SDS, 1x Protease inhibitors cocktail 
(Complete protease inhibitor cocktail tablets, Roche, Germany)) was added to each 
sample (approximately 100 µl of RIPA buffer to 107 cells). The samples were incubated 
on ice for 20 min to allow for complete cell lysis according to Pae et al. (2007) with 
some modifications. The samples were centrifuged (Beckman GS-15R, Beckman 











supernatant was transferred to new tubes (kept on ice). The protein lysates were stored 
in aliquots at -80°C. 
 
Protein concentration was determined using the BCATM protein assay kit (Pierce 
Biotechnology, USA) according to manufacturer’s instructions. Briefly, protein 
standards were prepared using bovine serum albumin (BSA) diluted in RIPA buffer. 
The microplate procedure for preparing the samples was followed whereby 10 µl of 
each standard and unknown sample was added to the microplate wells followed by 200 
µl of the BCATM working reagent. The contents were subsequently mixed on a plate 
shaker for 30 sec, followed by incubation at 37°C for 30 min. The plate was cooled to 
room temperature, after which the samples’ absorbances (562 nm) were measured using 
a NanoDrop® ND-1000 spectrophotometer (NanoDrop® Technologies, LLC, USA). A 
standard curve was drawn for the BCATM protein standards and the equation of the 
curve was used to determine the protein concentrations of the unknown samples from 
their absorbance values. 
 
2.3.2   Sodium dodecyl sulphate polyacrylamide gel electrophoresis of protein  
 
Protein samples were resolved by discontinuous sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) according to the method described by 
Laemmli (1970). A Hoefer electrophoresis system (Hoefer, USA) and 12.5%T/3%C 
Glycine-SDS polyacrylamide gels were used. The Glycine-SDS polyacrylamide 
separating gels (12.5% T/3% C) were prepared by mixing 12.5 ml Glycine lower gel 
buffer (pH 8.8) (0.75 M Tris, 0.007 M SDS), 12.5 ml Acrylamide stock solution (48.5% 
(w/v) Acrylamide, 1.5% (w/v) Bis-acrylamide), 60 μl TEMED, 120 μl of 10% (w/v) 
APS (prepared fresh each time) and 24.7 ml sterile dH2O (final volume of 50 ml). The 
Glycine-SDS polyacrylamide stacking gels (7.5% T/3%C) were prepared by mixing 7.5 
ml Glycine upper gel buffer (pH 8.8) (0.25 M Tris, 0.007 M SDS), 4.5 ml Acrylamide 
stock solution (48.5% (w/v) Acrylamide, 1.5% (w/v) Bis-acrylamide), 60 μl TEMED, 
120 μl of 10% (w/v) APS (prepared fresh each time) and 17.7 ml sterile dH2O (final 
volume of 30 ml). 
  
The protein samples were denatured by addition of 2x sample application buffer (SAB) 











(pH 6.8), 0.02% (w/v) Bromphenol blue) in a ratio of 1:1. The samples were incubated 
in a rapidly boiling water bath for 10 min to allow for complete protein denaturation. 
The denatured protein samples were placed on ice to cool and then loaded into the gel 
wells (1-100 µg protein). A peqGOLD prestained protein marker III (Peqlab 
Biotechnologie GmbH, Germany) was used to determine protein sizes. The samples 
were electrophoresed using 1x Running buffer (0.25 M Tris, 1.29 M Glycine, 0.035 M 
SDS) at a constant current of 20 mA until the samples reached the separating gel 
interface, after which, the current was increased to 40 mA. 
 
2.3.3   Transfer of protein onto PVDF membrane and immunodetection 
 
Following electrophoresis, the proteins were transferred onto PVDF membrane by semi-
dry electrophoretic transfer, according to the manufacturer’s recommendations (PVDF 
Western Blotting Membranes, Roche, Germany and Trans-Blot® SD Semi-Dry 
Electrophoretic Transfer Cell, Bio-Rad, USA).  
 
Briefly, the gel, extra thick filter paper (BioRad, USA) and PVDF membrane were 
incubated in Bjerrum and Schafer-Nielsen transfer buffer (48 mM Tris, 39 mM Glycine, 
20% (v/v) Methanol, 0.038% SDS) for 30 min. This was to ensure that the filter paper 
was completely soaked through and the gel and PVDF membrane were entirely 
equilibrated in transfer buffer. The transfer stack was set up according to the 
instructions in the Trans-Blot® SD Semi-Dry Electrophoretic Transfer Cell instruction 
manual. The voltage was set for 15 - 23 V and the transfer process allowed to proceed 
for 30 - 60 min. The current was maintained at approximately 80 - 234 mA throughout 
the transfer process. After the transfer was complete, the gel was stained in heated 
(90°C) Coomassie Brilliant Blue staining solution (0.025% (w/v) Coomassie Brilliant 
Blue R250, 10% (v/v) Acetic acid) for approximately 30 min. The gel was destained in 
10% (v/v) Acetic acid O/N, to check if the protein transfer was sufficient (Westermeier 
and Marouga, 2005). Due to the extreme hydrophobicity of the PVDF membrane, it was 
placed in methanol for a few seconds (before and after the transfer process) to allow it 
to wet in aqueous solutions. Afterwards the membrane was quickly rinsed twice with 












Chemiluminescence detection was performed using the BM Chemiluminescence 
Western Blotting Kit (Mouse/Rabbit) (Roche, Germany) according to the 
manufacturer’s recommendations. Briefly, after the transfer procedure, the membrane 
was incubated O/N in 1% (v/v) Blocking solution (10 ml of 10% (w/v) stock solution of 
BM Chemiluminescence Western Blotting Kit Blocking reagent in 1x TBS (50 mM 
Tris, 150 mM NaCl)), at 4°C while rotating. This was to ensure that non-specific 
binding sites were blocked, thereby preventing non-specific binding of antibody to the 
membrane. After blocking the membrane, the 1% (v/v) Blocking solution was discarded 
and the membrane incubated with primary antibody solution. 
 
The polyclonal primary antibodies used were against β-actin, Bip and FADD (human 
specific) (Cell Signaling Technology®, Inc.), as well as the monoclonal GADD153 
(CHOP) antibody (Santa Cruz Biotechnology Inc., USA). The Bip and FADD 
antibodies were diluted in a ratio of 1:500 in 0.5% (v/v) Blocking solution (5 ml of 10% 
(w/v) stock solution of BM Chemiluminescence Western Blotting Kit Blocking reagent 
in 1x TBS), whereas the β-actin antibody was diluted in a ratio of 1:1000. The 
GADD153 antibody was diluted for use at concentrations ranging from 0.4 - 8 μg/ml 
(antibody stock was supplied at 200 μg/ml) to find the optimal concentration required 
for CHOP detection. (In the final experiments (section 3.2.2), the GADD153 antibody 
was used at a concentration of 1 μg/ml.) All antibody stocks were diluted with 0.5% 
(v/v) Blocking solution for use. All primary antibodies were incubated with the 
membrane at 4°C O/N, while rotating, to allow antibody binding to the immobilized 
antigen. After incubation with primary antibody, the membrane was washed twice with 
Tris buffered saline plus Tween-20 (TBST) (0.1% (v/v) Tween 20® in 1 L TBS) for 10 
min each, followed by two 10 min washes with 0.5% (v/v) Blocking solution.  
 
The membrane was incubated in the horseradish peroxidase (POD)-conjugated 
secondary antibody (anti-mouse/rabbit IgG) solution for 30 min at room temperature 
with constant shaking (to allow binding to the primary antibody). The secondary 
antibody was used at a concentration of 40 mU/ml for β-actin, Bip and FADD and 40-
160 mU/ml for the GADD153 antibody. (In the final experiments of section 3.2.2, 160 
mU/ml secondary antibody was used for GADD153 immunodetection). Following this, 
the membrane was first rinsed with TBST and then washed four times for 15 min each 











mU/ml secondary antibody, the number of washes in TBST was increased to six times 
for 15 min each.  
 
Afterwards, the membrane was incubated in detection reagent (BM Chemiluminescence 
Western Blotting Kit starting solution B added to substrate solution A in a 1:100 ratio) 
for 60 s. The membrane was placed between two transparent plastic sheets and exposed 
to X-ray film (Fuji Super RX Medical X-ray Film, Fuji Photo Film Co., Ltd., Japan). 
The film was exposed for different time intervals (1 - 60 min) depending on the strength 
of the signal obtained. The exposed films were immediately developed using fixer and 
replenisher solutions from Axim Africa X-ray Industrial & Medical (PTY) Ltd., RSA. 
 
2.3.4   Determination of optimal protein concentration required for detection   
 
Protein was extracted (section 2.3.1) from untreated HL60 cells, separated according to 
size via SDS-PAGE (section 2.3.2) and transferred onto PVDF membrane (section 
2.3.3) (30 min transfer at 22-23 V). The optimal concentration of protein (1 - 100 µg) 
required for detection was determined by probing the membrane with β-actin antibody 
(1:1000) (section 2.3.3) after transfer. 
 
2.3.5   Stripping and reprobing of membranes 
 
After development of the X-ray film, the membrane was stripped and reprobed 
according to manufacturer’s instructions (BM Chemiluminescence Western Blotting Kit 
(Mouse/Rabbit), Roche, Germany) with some modifications. Briefly, the membrane was 
incubated in stripping solution (0.7% (v/v) β-mercaptoethanol, 2% (w/v) SDS, 0.0625 
M Tris.Cl (pH 6.7)) for 30 min at 50°C while shaking. The membrane was washed 
twice for 10 min each and twice for 5 min each with TBST at room temperature, after 
which, it was incubated O/N in 1% (v/v) Blocking solution (at 4°C while rotating). The 
membrane was subsequently reprobed with primary antibodies and exposed to film as 
described in section 2.3.3).  
 
In the final experiments of (section 3.2.2) the membrane was first probed with 











antibodies (together). The membrane was stripped a second time and reprobed with β-
actin antibody.   
 
2.5.6 Densitometric analysis 
 
Darker images of the western blots were shown in Figs. 46 A and 47 A (section 3.2.2) 
so that the lighter bands appear more visible, since the figures come out lighter when 
printed. However, only bands that fell within the linear range of exposure, and were 
neither underexposed nor overexposed, were used to obtain the densitometric data of 
section 3.2.2. The densitometric analysis was performed using UVIgeltec version 12.4 
software (UVItec Limited, UK). Results were obtained from the two western blot 
analysis performed for all drugs (BFA, H2O2 and FasL), after normalisation with β-
actin. 
 
2.6 Caspase activity assays 
 
Caspase activity was measured by fluorogenic detection of the enzymatically cleaved 
product, 7-Amino-4-methylcoumarin (AMC) (AnaSpec, Inc., USA) (Anaspec, 2007). 
AMC, a synthetic fluorogenic compound, acts as a reporter molecule for caspase 
activity after the hydrolysis of the peptide-AMC (caspase substrate) bond by the caspase 
enzyme. This cleavage releases AMC, thus resulting in an increase in fluorescence. 
 
2.4.1   Preparation of cell lysates for caspase assays 
 
Following drug treatment, cell lysates were prepared according to the method described 
by Proteus BioSciences Inc.© ZappaZyme™ Enzyme Activity Assay Protocol (2007). 
The cells were pelleted (10 min at 1500 RPM and room temperature), the supernatant 
discarded, the pellets washed with 1x PBS (10 min at room temperature and 1500 
RPM), and the wash removed. The cell pellets were resuspended in 100 µl ice-cold Cell 
lysis buffer (10 mM HEPES (pH 7.4), 0.1% CHAPS, 5 mM DTT (added fresh each 
time), 2 mM EDTA) (with or without the addition of protease inhibitor cocktail) per 107 
cells. The samples were mixed and incubated on ice for approximately 30 - 60 min for 
cell lysis to occur. The samples were vortexed every 10 - 15 min to promote cell lysis. 










and viewed to assess cell lysis. Following complete cell lysis, the samples were 
centrifuged (Beckman GS-15R, Beckman Coulter, USA) at 4°C for 30 min and at 
14000 RPM to pellet the cell debris. The supernatants were transferred to clean tubes 
and kept on ice while the protein concentration was determined.  
 
Protein concentration was determined using a QubitTM Fluorometer and the QubitTM 
assay system for proteins (Invitrogen) according to manufacturer’s instructions. The 
incubation time, to ensure that the assay samples reach the optimal fluorescence, was 15 
min at room temperature. The assay is accurate for protein concentrations from 12.5 
µg/ml - 5 mg/ml and exhibits low protein-to-protein variation. The lysates were stored 
at -80°C in aliquots to avoid freeze-thaw cycles. 
 
2.4.2   Initial caspase assay optimisations 
 
2.4.2.1   Initial caspase assay protocol 
 
The caspase activity assays were performed in black 96-well plates (NuncTM, 
ApogentTM, Denmark) and were set up as described in Table 2. The following caspase 
substrates (AnaSpec, Inc., USA) were used: Ac-D-M-Q-D-AMC for caspase-3, Ac-L-E-
V-D-AMC for caspase-4, Ac-I-E-T-D-AMC for caspase-8 and Ac-L-E-H-D-AMC for 
caspase-9 (Köhler et al., 2002; Anaspec, 2007). These caspase substrates consist of 
peptides (with the specific amino acid residues recognized and cleaved by its specific 
caspase) that are labelled with AMC. 
 

































Up to 200 µl ** 
 
1-10 µg 




* Cell lysis buffer was added in equal volume to blank wells as that of protein volume added to 
experimental wells 











All assay components were equilibrated to room temperature before use and DTT was 
added fresh to the assay buffers before addition to the well plate. The 25x Caspase 
Reaction Buffer consisted of 250 mM PIPES (pH 7.4), 2.5% CHAPS, 125 mM DTT 
and 50 mM EDTA. Once all assay components were added, the well plate was mixed on 
a shaker for 30 s and incubated at 37°C for 60 - 120 min prior to reading on the 
fluorimeter.  
 
2.4.2.2   Determination of optimal incubation time 
 
To determine the optimal incubation time required for maximal fluorescence detection 
(Relative Fluorescence Units (RFU)), caspase activity (using 50 µM caspase-3 substrate 
per reaction) was established after different incubation times. 
 
Cell lysates (1, 5 or 10 µg protein) from HL60 cells (passage number 32), treated with 
2.5 µg/ml - 30 µg/ml BFA for 24 hrs were used in caspase activity assays (as described 
in Table 2). The assay samples were incubated at 37°C for 60 min. Sample readings 
were then taken at 5 min intervals (60-85 min), with the well plate placed at 37°C in 
between readings, and the RFU determined.  
 
Caspase activity was also established after 120 min incubation at 37°C using BFA 
treated (30 µg/ml BFA; 24 hrs) HL60 cell (passage number 31-40) lysates (5 µg 
protein).  
 
2.4.2.3   Optimal caspase substrate concentration 
 
To determine the optimal caspase substrate concentration required, different 
concentrations of caspase-3 substrate (12.5 µM, 25 µM, 50 µM and 75 µM) were added 
to sample reactions (were set up as described in Table 2). Cell lysates (5 µg of protein) 
from HL60 cells (passage number 32-41), treated with 1.5 mM H2O2 for 24 hrs, were 















2.4.3   Fluorimeter settings 
 
Sample fluorescence was detected by a Cary Eclipse fluorimeter (Varian, USA) with the 
excitation wavelength set at 354 nm and emission wavelength at 442 nm. The sample 
readings were given in Relative Fluorescence Units (RFUs) and were converted to 
AMC release (µM) by the standard curve obtained from the AMC standards (section 
2.4.4). 
 
Initially, to find the optimal fluorimeter settings, the instrument gain (PMT Voltage) 
was set to either medium or high and the excitation and emission slits were both set at 
either 5, 10 or 20 nm before taking sample readings. It was found that by setting both 
the excitation and emission slits at 20 nm and changing the instrument gain (PMT 
Voltage) to high (maximum) that increased fluorescence signals for the samples were 
produced. The average reading time per sample well was set at 0.1 seconds to avoid 
longer reading times. At these settings the RFU values of the samples could clearly be 
distinguished and analysed.  
 
Initially an automatic blank setting was used for analysis, but this was found to be 
unreliable. Instead, blank readings were taken in triplicate and the average blank value 
was manually subtracted from the average value obtained for each sample, which was 
also prepared and analysed in triplicate. 
 
2.4.4   AMC standard curve 
 
For the AMC standard curve, decreasing concentrations of AMC (3.13 µM - 0.0975 
µM) (Anaspec, 2007) were prepared by serially diluting the AMC stock solution (10 
mM AMC in DMSO) with dH2O. The AMC standard wells contained the components 
















Table 3: Components of AMC standards per well  
Sample: 25x Caspase 
Reaction Buffer: 
AMC working 
solution (12.5 µM): 
dH2O: 
Blank 1x 0 µl Up to 200 µl ** 
3.13 µM AMC 1x 50 µl Up to 200 µl ** 
1.56 µM AMC 1x 25 µl Up to 200 µl ** 
0.78 µM AMC 1x 12.5 µl Up to 200 µl ** 
0.39 µM AMC 1x 6.25 µl Up to 200 µl ** 
0.195 µM AMC 1x 3.13 µl Up to 200 µl ** 
0.0975 µM AMC 1x 1.56 µl Up to 200 µl ** 
** Total volume per well was 200 µl 
 
AMC standards were prepared in triplicate for each caspase assay. The blank value was 
automatically subtracted from sample values by the fluorimeter machine. The RFU of 
the caspase assay samples were converted to AMC release (µM) using the AMC 
standard curve’s equation. 
 
2.4.5   Caspase assay for final experiments 
 
For the final experiments, caspase activity assays were performed for all three apoptotic 
pathways after drug treatment (section 2.1.6). The experiments were performed twice 
for each drug (low and high concentrations) using all four caspase substrates. This was 
done to determine which caspase(s) was activated for the specific drug 
treatment/apoptosis pathway (section 3.2.3). One protein sample per drug concentration 
(untreated, low dose and high dose) was prepared (section 2.4.1) from each experiment 
(BFA, H2O2 or FasL) for analysis. Cell lysates from HL60 cells (passage number 17-19) 
treated with BFA (30 µg/ml, 24 hrs) were used as a positive control for caspase-3 
activity in all experiments performed. All samples were prepared and analysed in 
triplicate (from one sample- either untreated, low dose or high dose). The assays were 



















































Up to 200 µl ** 
 
10 µg 
(x µl *) 
* Cell lysis buffer was added in equal volume to blank wells as that of protein volume added to 
experimental wells 
** Total volume per well (and assay) was 200 µl  
 
All assay components were equilibrated to room temperature before use and DTT was 
added fresh to the assay buffers before addition to the well plate. Once all assay 
components were added, the well plate was mixed on a shaker for 30 s and incubated at 
37°C for 60 min prior to reading on the fluorimeter. 
 
2.4.6   Statistical analysis for caspase assays 
 
A t-Test (paired two sample for means) was performed to compare caspase activity (of 
each caspase) of the low drug doses to the high drug doses, for each experiment and 
drug (BFA, H2O2 or FasL). The mean differences were considered significant when the 
p-value was less than 0.05 (level of significance was 0.05).  
 
2.7   Cytochrome c release immunohistochemistry assays 
 
2.5.1  Preparation of cells for immunohistochemistry assays 
 
The HL60 cells (untreated or treated with 1.5 mM H2O2 for 24 hrs) (passage number 
13-45) were transferred from the culture dishes to microcentrifuge tubes and centrifuged 
(Beckman GS-15R, Beckman Coulter, USA) at room temperature for 10 min at 1500 
RPM. The medium was removed and the cells washed with 1x PBS to remove culture 
medium and/or apoptosis inducing agents. The samples were centrifuged for 10 min at 











resuspended in 1x PBS to 105 - 107 cells per ml. From each sample, 100 µl cell 
suspension (104 - 106 cells) was taken and placed in a cytospin (Shandon, USA). This 
concentrated the cells in a smaller area and removed excess liquid, thereby allowing the 
specimens on the microscope slides to dry faster. Following cytospin, the slides were 
allowed to dry for approximately 10 min, after which the cells were fixed to the slides. 
 
2.5.2   Initial cytochrome c immunohistochemistry assay 
 
The first immunohistochemistry procedure was performed according to manufacturer’s 
recommendations (Santa Cruz Biotechnology, Inc., USA) with modifications. Briefly, 
the cells (104 - 106 cells per slide) were fixed with 1-3 drops of ice-cold methanol for 5 
min and air-dried. The slides were briefly washed three times in 1x PBS to remove the 
methanol. The excess liquid was removed from the slides and the specimens were 
incubated in 1-3 drops of undiluted FBS for 20 min to block non-specific binding sites. 
The slides were rinsed with 1x PBS and the excess liquid removed. The samples were 
incubated for 2 hrs at room temperature with cytochrome c (6H2)-phycoerythrin (PE) 
labelled murine monoclonal antibody (0.4 µg/ml and 4 µg/ml) (Santa Cruz 
Biotechnology, Inc., USA), which was diluted for use with FBS. The cells were not 
incubated in the dark.  
 
After incubation with the antibody, the slides were first rinsed, and then washed twice 
with 1x PBS for 5 min each on a stir plate. The excess liquid was removed from the 
slides and 1-2 drops of 1,4-Diazabicyclo-octane (DABCO) (Sigma®-Aldrich) mounting 
medium was placed over the specimen and covered with a glass coverslip. DABCO is a 
colourless antifade mounting medium, which prevents or minimizes photobleaching of 
the fluorescent dye conjugates when they are excited by UV light (required for 
visualization).   
 
2.5.3   Cytochrome c immunohistochemistry assays using different cell 
permeabilization protocols to improve antibody labelling 
 
Untreated HL60 cells (105 cells per slide) were either fixed and permeabilized using the 
IntraPrepTM kit (Immunotech, Coulter) or via methanol fixation and permeabilization, 












Briefly, the cells were fixed with either 1-3 drops of ice-cold methanol or IntraPrepTM 
fixation reagent (IntraPrepTM Kit, Immunotech, Coulter) for 5 min and air-dried. The 
slides were briefly washed three times in 1x PBS to remove the fixatives. The excess 
liquid was removed from the slides and the specimens were either incubated in 1-3 
drops of cold permeabilization buffer (0.2% Triton X-100 in 1x PBS) or IntraPrepTM 
permeabilization reagent (IntraPrepTM Kit, Immunotech, Coulter) for 15 min. The cells 
were blocked with 1-3 drops of 10% (v/v) Blocking solution (BM Chemiluminescence 
Western Blotting Kit Blocking reagent) for 20 min. The slides were rinsed with 1x PBS 
and the excess liquid removed.  
 
The cells were either incubated with cytochrome c (6H2)-PE labelled murine 
monoclonal antibody (4 µg/ml) or 1.5% (v/v) Blocking solution (unstained, to test for 
auto-fluorescence) for 2 hrs at room temperature in the dark. After the cells were 
labelled, the slides were first rinsed, and then washed twice with 1x PBS for 5 min each 
on a stir plate. The excess liquid was removed from the slides and 1-2 drops of 
VECTASHIELD® (Vector Laboratories, USA) mounting medium was placed over the 
specimen and covered with a glass coverslip. VECTASHIELD® is also an antifade 
mounting medium but, unlike DABCO, it contains a counterstain. VECTASHIELD® 
mounting medium contains 4',6-diamidino-2-phenylindole (DAPI), which is a 
fluorescent dye that specifically stains the nuclei of cells by binding double-stranded 
DNA, thereby assisting in visualizing the cells.  
 
2.5.4  Cytochrome c immunohistochemistry assay optimisation with higher 
antibody concentration 
 
Untreated and H2O2 treated (1.5 mM H2O2 for 24 hrs) HL60 cells (105 cells per slide) 
were fixed with 1-3 drops of ice-cold methanol for 5 min and air-dried. The slides were 
briefly washed three times in 1x PBS to remove the fixative. The excess liquid was 
removed from the slides and the specimens were incubated in 1-3 drops of cold 
permeabilization buffer (0.2% Triton X-100 in 1x PBS) for 15 min. The excess liquid 
was removed and the cells blocked with 1-3 drops of 10% (v/v) Blocking solution (BM 
Chemiluminescence Western Blotting Kit Blocking reagent) for 20 min. The slides 












The cells were either incubated with cytochrome c (6H2)-PE labelled antibody (8 µg/ml 
and 20 µg/ml), IgG1 (mouse)-PE conjugated monoclonal antibody (2.5 µg/ml) 
(IOTest®, Beckman Coulter) or 1.5% (v/v) Blocking solution (unstained) for 2 hrs in 
the dark at room temperature. The IOTest® IgG1 (mouse)-PE conjugated monoclonal 
antibody was used as an isotypic control to test for non-specific labelling and 
fluorescence (IOTest®, Beckman Coulter). After the cells were labelled, the slides were 
first rinsed, and then washed twice with 1x PBS for 5 min each on a stir plate. The 
excess liquid was removed from the slides and 1-2 drops of VECTASHIELD® (Vector 
Laboratories, USA) mounting medium was placed over the specimen and covered with 
a glass coverslip.  
 
2.5.5  Immunohistochemistry assays to determine cell membrane permeability 
 
Untreated and H2O2 treated (1.5 mM H2O2 for 24 hrs) HL60 cells (105 cells per slide) 
were fixed with 1-3 drops of ice-cold methanol for 5 min and air-dried. The slides were 
briefly washed three times in 1x PBS to remove the fixative. The excess liquid was 
removed from the slides and the specimens were either incubated with 1-3 drops of cold 
permeabilization buffer or 1x PBS (methanol-fixation only) for 15 min. The excess 
liquid was removed and the cells blocked with 1-3 drops of 10% (v/v) Blocking solution 
(BM Chemiluminescence Western Blotting Kit Blocking reagent) for 20 min. The slides 
were rinsed with 1x PBS and the excess liquid removed. 
 
The cells were either incubated with 20 µl of CD45-FITC murine monoclonal antibody 
(Stem-KitTM Reagents, Beckman Coulter) (diluted in 30 µl 1.5% (v/v) Blocking 
medium), 2.5 µg/µl PI (Annexin V-FITC Apoptosis detection kit, Beckman Coulter) or 
1.5% (v/v) Blocking solution (unstained). The CD45-FITC antibody and PI were 
incubated in the dark at room temperature for 20 min and 15 min, respectively. The 
cells stained with PI (Annexin V-FITC Apoptosis detection kit, Beckman Coulter) 
served as a positive control for permeabilized cell membranes. The CD45-FITC murine 
monoclonal antibody (Stem-KitTM Reagents, Beckman Coulter) was used as a positive 
control to determine cell viability, since it binds to the CD45 family of cell-surface 
markers of intact haematopoietic cells. After the cells were labelled, the slides were first 











liquid was removed from the slides and 1-2 drops of VECTASHIELD® (Vector 
Laboratories, USA) mounting medium was placed over the specimen and covered with 
a glass coverslip.  
 
2.5.6  Cleaved caspase-3 (Asp175) antibody immunohistochemistry assay to 
determine viability of assay protocol 
 
Untreated and H2O2 treated (1.5 mM H2O2 for 24 hrs) HL60 cells (105 cells per slide) 
were fixed with 1-3 drops of ice-cold methanol for 5 min and air-dried. The slides were 
briefly washed three times in 1x PBS to remove the fixative. The excess liquid was 
removed from the slides and the specimens were permeabilized with 1-3 drops of cold 
permeabilization buffer for 15 min. The excess liquid was removed and the cells 
blocked with 1-3 drops of 10% (v/v) Blocking solution (BM Chemiluminescence 
Western Blotting Kit Blocking reagent) for 20 min. The slides were rinsed with 1x PBS 
and the excess liquid removed.  
 
The cells were either incubated with cleaved caspase-3 (Asp175) polyclonal rabbit 
antibody (Alexa Fluor®488 (FITC) conjugate) (Cell Signaling Technology®, Inc.), 
IgG1 (mouse)-FITC conjugated monoclonal antibody (IOTest®, Beckman Coulter) 
(isotypic control to test for non-specific labelling) or 1.5% (v/v) Blocking solution 
(unstained). The cleaved caspase-3 antibody was diluted 1:10 for use (with 1.5% (v/v) 
Blocking solution) whereas the IgG1-FITC antibody was used at 2.5 µg/ml. The cells 
were incubated O/N in the dark at 4°C. After the cells were labelled, the slides were 
first rinsed, and then washed twice with 1x PBS for 5 min each on a stir plate. The 
excess liquid was removed from the slides and 1-2 drops of VECTASHIELD® (Vector 
Laboratories, USA) mounting medium was placed over the specimen and covered with 
a glass coverslip.  
 
2.5.7 Immunohistochemistry assays without cell permeabilization for cytochrome c 
(6H2)-PE and cleaved caspase-3-FITC antibodies 
 
Untreated and H2O2 treated (1.5 mM H2O2 for 24 hrs) HL60 cells (105 cells per slide) 
were fixed with 1-3 drops of ice-cold methanol for 5 min and air-dried. The slides were 











removed from the slides and the cells blocked with 1-3 drops of 10% (v/v) Blocking 
solution (BM Chemiluminescence Western Blotting Kit Blocking reagent) for 20 min. 
The slides were rinsed with 1x PBS and the excess liquid removed.  
 
The cells were incubated with either cytochrome c (6H2)-PE antibody (8 μg/ml), 
cleaved caspase-3-FITC antibody (1:10 dilution), IgG1-PE antibody (2.5 µg/ml), IgG1-
FITC antibody (2.5 µg/ml) or 1.5% (v/v) Blocking solution (unstained control). The 
cytochrome c (6H2)-PE and IgG1-PE antibodies (with the unstained controls) were 
incubated in the dark for 2 hrs at room temperature. The cleaved caspase-3 (Asp175) 
and IgG1-FITC antibodies (with the unstained controls) were incubated O/N in the dark 
at 4°C. After the cells were labelled, the slides were first rinsed, and then washed twice 
with 1x PBS for 5 min each on a stir plate. The excess liquid was removed from the 
slides and 1-2 drops of VECTASHIELD® (Vector Laboratories, USA) mounting 
medium was placed over the specimen and covered with a glass coverslip. 
 
2.5.8  Different immunohistochemistry assay protocol for cytochrome c release 
 
The second immunohistochemistry procedure was performed according to the method 
used by the Cardiovascular Research Unit (MRC/UCT Cape Heart Centre). Briefly, the 
cells were spun onto slides, as described in section 2.5.1, and fixed with ice-cold 
methanol for 5 min and air-dried. The slides were briefly washed three times in 1x TBS, 
pH 7.5 (50 mM Tris, 150 mM NaCl), to remove the methanol, and blocked for 20 min 
in 1-3 drops of 1% (w/v) BSA (1 g BSA in 100 ml 1x PBS), after which they were 
rinsed with 1x TBS.  
 
The cells were incubated with either cytochrome c (6H2)-PE antibody (2 or 4 µg/ml), 
IgG1 (mouse)-PE antibody (2.5 µg/ml) or 1% (w/v) BSA (unstained control) for 2 hrs at 
37°C in the dark. After incubation, the slides were first rinsed then washed twice with 
1x TBS for 5 min each on a stir plate. The excess liquid was removed from the slides 
and 1 drop of VECTASHIELD® mounting medium was placed over the specimen and 














2.5.9  Visualization of cells 
 
After covering the cells with mounting medium, the slides were viewed using a 
fluorescent Nikon Eclipse 90i microscope (Nikon, USA). The microscope was equipped 
with a colour camera (Nikon DXM 1200c) and NIS imaging software to analyse the 
specimens. The microscope had four channels, DAPI, FITC, Cy3 (PE) and DIA (triple 
band, able to visualize DAPI, FITC, and Cy3 simultaneously) that could detect specific 
fluorescence signals. The microscope was adjusted to a gamma setting of 0.45, exposure 
of 210 ms - 10 s and a gain setting of normal or high. 
 
2.6   Detection of changes in mitochondrial transmembrane potential (MTP) 
during apoptosis induction  
 
Induction of the mitochondrial-mediated apoptosis pathway causes changes in the 
membrane potential of the mitochondria (Dror, 2003; Skommer et al., 2007). The 
MitoCaptureTM apoptosis detection kit (BioVision Research Products, USA) uses a 
fluorescent-based technique that allows for the detection of changes in mitochondrial 
transmembrane potential (MTP) upon induction of apoptosis.  
 
MitoCaptureTM is a cationic dye similar to JC-1 (5,5’,6,6’-tetrachloro-1,1’,3,3’-
tetraethylbenzimidazolo-carbocyanine iodide), which changes conformation depending 
on the status of the cell it enters (Lugli et al., 2005; Chaoui et al., 2006). An interchange 
between the dye monomers (in the cytoplasm) and aggregates (inside the mitochondria) 
exist within the cell, depending on the MTP. The MTP will determine how much dye is 
taken up by the mitochondria or how much remains in the cytosol. In healthy, non-
apoptotic cells, the dye accumulates and aggregates within the mitochondria, producing 
a bright red fluorescence that is detected in the PE (Em = 488/590 ± 42 nm) channel. 
However, the MitoCaptureTM dye molecules cannot be taken up by the mitochondria in 
apoptotic cells, as a result of the changed or disrupted MTP. It therefore resides in the 
cytosol in its monomer form, which produces a green fluorescence that is detected in the 













 2.6.1   MitoCaptureTM labelling procedure 
 
The MitoCaptureTM labelling protocol was performed according to manufacturer’s 
recommendations (BioVision Research Products, USA). Briefly, after treatment the 
cells were collected at room temperature by centrifugation (Beckman GS-15R, 
Beckman, USA) for 10 min at 1500 RPM. The cell pellets were washed once with 1x 
PBS to remove culture medium and/or apoptosis inducing agents and centrifuged for 10 
min at 1500 RPM and room temperature. Cell pellets were resuspended in 
MitoCaptureTM solution (1 µl MitoCaptureTM reagent diluted in 1 ml pre-warmed 
(37°C) MitoCaptureTM Incubation buffer) to 106 cells per ml. The cells were incubated 
for 20 min at 37°C in a 5% CO2 incubator, after which they were centrifuged at room 
temperature for 10 min at 1500 RPM and the supernatant discarded. The pellets were 
resuspended in 1 ml of pre-warmed MitoCaptureTM Incubation buffer and transferred to 
flow cytometry tubes for analysis on the flow cytometer (FC 500, Beckman Coulter, 
USA).  
 
2.6.2  MitoCaptureTM flow cytometry analysis protocol 
 
Firstly, a flow cytometry protocol for detecting changes in MTP was created. HL60 
cells (passage number 33-41) were treated with 0.4 mM or 1 mM H2O2 for 24 hrs and 
labelled with MitoCaptureTM, to serve as positive controls for setting up the flow 
cytometry protocol. Untreated MitoCaptureTM-labelled HL60 cells were used as 
negative controls. Unlabelled (untreated and drug-treated) cells were used to test for 
auto-fluorescence. These controls were included to confirm that the protocol was set up 
and working correctly. All samples were prepared and analysed in triplicate. 
 
The flow cytometry protocol was set up so that the cells would either fluoresce in the 
PE (FL2) channel or FITC (FL1) channel depending on their transmembrane potential. 
The voltages of the FL1 and FL2 channels were adjusted to obtain clear positive or 
negative peaks in each channel using the untreated and/or drug-treated cells. Colour-
compensation was also performed to obtain distinct cell populations in the colour-coded 
density plots (FL2 Log vs. FL1 Log plots). The flow cytometer protocol used to analyse 











cytometer protocol, no auto-fluorescence was noted for the untreated or drug-treated 
unlabelled cells in incubation buffer only.) 
 
Table 5: MitoCaptureTM assay protocol flow cytometer settings 
 FS SS FL1 FL2 FL3 FL4 FL5 AUX 
Voltage 189 663 313 340 402 450 577 300 
Gain 2.0 5.0 1.0 1.0 1.0 1.0 1.0 1.0 
 FS SS FL1 FL2 FL3 FL4 FL5 AUX 
Discriminator 100 OFF OFF OFF OFF OFF OFF OFF 
 FL1 FL2 FL3 FL4 FL5    
FL1  80.2 0 0 0    
FL2 73.6  0 0 0    
FL3 0 0  0 0    
FL4 0 0 0  0    
FL5 0 0 0 0     
 
 
2.6.3   Fluorescent microscopy of MitoCaptureTM labelled cells 
 
MitoCaptureTM labelled cells were also visualised using a fluorescent microscope to 
verify and compare it to the flow cytometer results. A drop of MitoCaptureTM labelled 
cells were placed on a microscope slide and covered with a coverslip. The cells were 
viewed under the Nikon Eclipse 90i fluorescent microscope (Nikon, USA) using the 
DIA (triple band), FITC and Cy3 (PE) channels, at a gamma setting of 0.45, exposure of 


























3.1 Development and optimisation of assays to monitor apoptosis 
pathways in cells 
 
3.1.2 Analysis of the general apoptotic response to drug treatment 
 
After drug treatment, the percentage of cells that were committed to and undergoing 
apoptosis was determined with AV/PI labelling using flow cytometry, as described in 
section 2.2. 
 
3.1.1.1   AV and PI labelling flow cytometry analysis protocol 
 
Fig. 11 shows the typical fluorescence results obtained from AV/PI labelled cells using 
the colour-compensated protocol established in section 2.2.2 (and cytometer settings 
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Fig. 11.  Flow analysis of AV-FITC and PI labelled HL60 cells showing an increase in apoptosis after 
BFA treatment. HL60 cells were treated with 10 µg/ml BFA (24 hrs) (E,F,G,H) or untreated (A,B,C,D) 
and labelled with both AV and PI. The FS vs. SS plots for untreated (A) and drug-treated (E) cells show 
the different sizes and granularity of the cell population. The FL1-FITC histograms show the negative and 
positive peaks for AV-FITC labelling for untreated (B) and drug-treated (F) cells. The FL4 histograms 
show the negative and positive peaks for PI labelling for untreated (C) and drug-treated (G) cells. The 
colour-coded density plots (untreated (D) and drug-treated (H) cells) show the status of the apoptosing 
cells, either labelling with high PI and/or low AV (G1- mainly cellular debris containing DNA), both AV 
and PI (G2- late apoptosis), high AV and/or low PI (G4- early apoptosis) or low labelling cells (G3- viable 
cells). The different colours represent the number and density of cells in a specific area with red 
















The forward scatter (FS) setting indicates the sizes of the cells in the culture population, 
whereas the side-scatter (SS) shows the granularity of the cells (Fig. 11 A). A 
discriminator was set at 100 for the FS setting to eliminate most of the cellular debris, 
which was detected below 100 FS (Table 1).  
 
The cells, untreated and drug-treated, were either labelled with AV or PI or both to 
obtain two defined peaks by altering the voltage settings on the flow cytometer. The two 
peaks that occur in the histograms in Figs. 11 B, C, F and G represent a negative 
population, which are non-fluorescing (non-labelled) cells and a positive population, 
which represent fluorescing (labelled) cells.  
 
The colour-coded density plot of PI vs. AV shows the stages of the cells undergoing 
apoptosis (Figs. 11 D and H). This plot was used to colour-compensate the data, by 
changing the voltage settings on the flow cytometer. In so doing, the non-specific 
fluorescence that occurred due to the spectral overlap of the two fluorescent molecules, 
AV and PI, was removed. Depending on the stage of apoptosis the cells either label 
with: 
1. High PI and/or low AV - represented by area G1, indicating mainly cellular 
debris and disintegrated cells containing DNA;  
2. Both high AV and high PI - represented by area G2 and indicating late apoptosis 
with resultant cell lysis;  
3. High AV and/or low PI - represented by area G4, indicating early apoptosis (cell 
membranes are intact but have lost asymmetry);   
4. Low labelling cells - represented by area G3 and indicating viable cells. 
The different colours of the colour-coded density plot represent the density of cells in a 
specific area (G1-4) with red being the most densely populated areas and blue the least 
dense.  
 
Using this protocol, no auto-fluorescence was noted for untreated or drug-treated 
unlabelled cells and the DMSO solvent did not result in any apoptosis on its own 
(results not shown). The labelled drug-treated cells showed increased labelling with AV 
and PI as indicated by the histograms Figs. 11 F and G, compared to the untreated cells 
(Figs. 11 B and C). The colour-coded density plot for the BFA treated cells (Fig. 11 H) 











decrease in the density of area G3, compared to the untreated cells (Fig. 11 D). The 
untreated cells had the highest density in area G3. This was all indicative of an increase 
in apoptosis within the drug-treated cell population compared to that of the untreated 
cell population, as expected, and demonstrated that the protocol was set up correctly.  
 
3.1.1.2   Two populations represented by FS vs. SS plots  
 
The cells in the HL60 cultures (passage number 8) were classified via May-Grünwald-
Giemsa (MGG) staining (performed by the Haematology diagnostic laboratory, GSH) 
and identified as being a single population of predominantly undifferentiated 
promyelocytes. However, the FS vs. SS plots of drug-treated and untreated HL60 cells 
consistently showed what seemed to be two different populations of cells, with 
differences in size (FS) and granularity (SS) (Fig. 12).  
 
To establish what the two cell populations in the FS vs. SS plots represented, untreated 
cells (in 1x PBS) were compared to cells that were either freshly thawed, drug-treated or 
heat-shocked. Prior to flow analysis (FS vs. SS only), the viability of the cells was 
determined by Trypan blue staining and compared to the flow results shown in Fig. 12.  
 
The thawed cells (also resuspended in 1x PBS) showed similar cell populations to the 
untreated cells in Fig. 12 A (data not shown). The Trypan blue cell viabilities also 
























                                                                          
 








The drug-treated cells (0.1 mM H2O2 for 24 hrs) (Fig. 12 B), compared to untreated 
cells (Fig. 12 A), showed an increase in population I (green) with a decrease in H (red). 
To determine if the populations were shifting with increasing apoptosis induction, the 
drug-treated sample was heated at 50°C for 5 min and analysed (Fig. 12 C), and heated 
again at 80°C for 10 min and once again analysed (Fig. 12 D).     
 
The FS vs. SS plots for the drug-treated (Fig. 12 B) and heat-shocked cells (Figs. 12 C 
and D) show that the cell population in H (red) moved towards the population in I 
(green) as the level of apoptotic induction (heat treatment) was increased. The 
percentage viability for all the cells, as determined by AV and PI staining, 
              A: Untreated cells                                          B: 0.1 mM H2O2 (24 hrs) 
       C: Heat-shocked cells (50°C, 5 min)             D: Heat-shocked cells (80°C, 10 min) 
                SS Lin                                                                  SS Lin                                                              
FS Lin FS Lin 
FS Lin 
                SS Lin                                                                 SS Lin                                                              
FS Lin 
Fig.12. Two cell populations represented by FS vs. SS plot. HL60 cells were analysed on the 
flow cytometer to compare the FS vs. SS plots of untreated (A), drug-treated (B) and heat-
shocked (C-D) cells. The cells were treated with 0.1 mM H2O2 for 24 hrs (B) and analysed, after 
which, the sample was heated at 50°C for 5 min and analysed again (C). The sample was once 
again heated at a higher temperature, 80°C, for 10 min (D) to observe the increase in cells 











approximately corresponded with the percentage of the cells in H. The population in H 
could therefore be seen as the number of viable cells in the total cell population 
analysed, with I representing apoptotic cells. 
 
To confirm the apoptotic status of these cells, untreated and drug-treated (0.5 mM H2O2 
for 24 hrs) HL60 cells were labelled with AV and PI, analysed and the PI vs. AV plots 
gated on the areas H and I (Figs. 13 A and B).  
 
The colour-coded density plots of PI vs. AV (Fig. 13) gated on population I, for both 
drug-treated and untreated cells, showed a spread of cells predominantly in areas G1, 
G2 and G4 representing apoptotic cells. The notable increase in population I upon drug 
treatment (Fig. 13 B), as well as the increase in cells fluorescing in areas G1, G2 and 
G4, clearly demonstrated the apoptotic nature of the cell population in I. These results 
confirmed that population H contained predominantly viable cells, whereas population I 
were mostly apoptotic cells. This analysis indicated that the untreated HL60 cells 
contained approximately 5 - 10% apoptotic cells, which had to be considered in the 
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Fig. 13. The apoptotic status of the two cell populations. HL60 cells, untreated (A) and drug-treated 
(0.5 mM H2O2, 24 hrs) (B) were labelled with AV and PI and analysed on the flow cytometer to 
determine the stages of apoptosis of the two populations in areas H and I. In each case the colour-coded 
density plots were gated on either population H or I of the FS vs. SS plots to show the stages of 












3.1.1.3   Determining appropriate drug concentrations and exposure times 
required to induce low and high levels of early apoptosis  
 
The apoptotic response of the cells to drug treatment over time was determined after 
treatment with different concentrations of each specific drug. The aim was to determine 
the appropriate drug (BFA, H2O2 or FasL) concentrations to induce approximately 5 - 
15% (low %) and 20 - 50% (high %) early apoptosis, above that of the untreated cells. 
The percentage apoptosis was quantified via AV/PI labelling and flow analysis. Area 
G4, of the respective PI vs. AV colour-coded density plots, was used to determine the 
percentage of early apoptotic cells after drug treatment. By using this quadrant only, it 
would exclude any non-apoptotic and/or necrotic cells, which could directly label with 
PI and fluoresce in areas G1 and/or G2. Therefore only cells that labelled with high AV 
and low PI (area G4) were considered to be early apoptotic and taken into account for 
this analysis.  
 
3.1.1.3 A)   BFA treatment of HL60 cells to induce the ER-stress induced 
                   apoptotic pathway 
 
HL60 cells were treated with BFA (5 µg/ml - 30 µg/ml) for 24 hrs to induce the ER-
stress induced apoptotic pathway (Guillemain and Exton, 1997; Liu et al., 1997; Li et 
al., 2006). The percentage of early apoptosis (% cells in area G4 of the colour-coded 



















































Fig. 14 shows that the 24 hr BFA treatment induced a linear increase in apoptotic 
response with increasing BFA concentrations. The HL60 cells were also treated with 
BFA (0.5 µg/ml - 10 µg/ml) for 6 and 48 hrs to determine the extent of apoptosis 
induced (data not shown). However, it was found that 6 hrs exposure time was 
insufficient to produce a significant increase in apoptosis and 48 hrs was too extensive, 
thereby producing an excessive amount of apoptosis. Other studies have found that at 
least 24 hrs incubation is needed to overcome the UPR and induce apoptosis through the 
ER-stress induced apoptotic pathway (Liu et al., 1997; Rao et al., 2002 b). Therefore, it 
was decided that 24 hrs exposure to BFA was optimal. Of the different BFA 
concentrations used, it was determined from Fig. 14 that 5 µg/ml induced approximately 
5% (low level) and 30 µg/ml induced approximately 20% (high level) early apoptosis 
above that of the untreated cells. 
 
Fig. 15 shows the representative PI vs. AV colour-coded density plots that were 
obtained for the low level (5%) and high level (20%) of early apoptosis (G4) induced by 
BFA over 24 hrs, after AV/PI labelling and flow analysis.  
 
















Fig. 14. Bar graph of % early apoptosis induced vs. different BFA concentrations after 24 hrs 
exposure. The graph shows the percentage early apoptosis induced by the different BFA 
concentrations after 24 hrs exposure. The samples were either prepared and analysed in duplicate or 
triplicate. The values were corrected for background apoptosis by subtracting the average %G4 for 





















3.1.1.3 B)   H2O2 treatment of HL60 cells to induce the mitochondrial-mediated  
                   apoptosis pathway 
 
HL60 cells were treated with H2O2 (0.005 mM - 2 mM) for 6, 15 and 24 hrs to induce 
the mitochondrial-mediated apoptotic pathway (Hosokawa et al., 2005). The percentage 
of early apoptosis (% cells in G4 of PI vs. AV colour-coded density plot) induced by the 














              A: Untreated                       B: 5 µg/ml BFA                   C: 30 µg/ml BFA      







Fig. 15. PI vs. AV density plots of BFA treated HL60 cells. HL60 cells were treated with BFA 
and labelled with AV and PI and analysed via flow cytometry. The cells were treated for 24 hrs 
with (B) 5 µg/ml BFA to induce approximately 5% (low level) early apoptosis (G4) and (C) 30 
µg/ml BFA to induce approximately 20% (high level) early apoptosis (G4) above that of the 























               




Fig. 16 shows that 6 hrs exposure was not sufficient to produce a significant increase in 
apoptosis and would require higher H2O2 concentrations to produce the desired amount 
of apoptosis. At 15 hrs exposure, the results were inconclusive, since the lower H2O2 
concentrations (0.05 mM and 0.1 mM) produced higher increases in apoptosis 
compared to 6 hr and 24 hr treated cells. Furthermore, different results were obtained 
for 15 hr 0.05 mM treated cells on different occasions (data not shown). This could be 
due to differences in viability (%G3) and % early apoptosis (%G4) of the untreated cells, 
which varied between experiments. It was therefore decided that 24 hrs exposure to 
H2O2 was more appropriate. It was determined from Fig. 16 that 0.4 mM H2O2 induced 
approximately 5% (low level) and 1 mM H2O2 induced approximately 20% (high level) 
early apoptosis above that of the untreated cells. Moreover, Fig. 16 also indicated that at 
H2O2 concentrations greater than 1 mM (24 hrs), there was a decrease in the number of 
early apoptotic cells (G4), since more cells were present in areas G2 and G1 (late 
apoptosis and/or necrosis). Therefore after 24 hrs exposure to 1 mM H2O2, the 
maximum percentage of cells appeared to be early apoptotic (G4).  
Fig. 16. Bar graph of % early apoptosis induced vs. different H2O2 concentrations for 6, 15 and 
24 hours. The graph shows the percentage early apoptosis induced by the different H2O2 
concentrations after 6 hrs (yellow), 15 hrs (green) and 24 hrs (blue) exposure times. The samples were 
prepared and analysed in triplicate. The values were corrected for background apoptosis by 
subtracting the average %G4 for the untreated cells from the average %G4 for the H2O2 treated cells. 
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Fig. 17 shows the representative PI vs. AV colour-coded density plots that were 
obtained for the low level (5%) and high level (20%) of early apoptosis (G4) induced by 
H2O2 after 24 hrs, following AV/PI labelling and flow analysis.  
 
 








3.1.1.3 C)   FasL treatment of HL60 cells to induce the death receptor pathway 
 
HL60 cells were treated with 0.5 - 500 ng/ml FLAG-tagged FasL, in the presence of 
0.25 μg/ml or 0.5 μg/ml ANTI-FLAG® M2 antibody, for 4 and 24 hrs to induce the 
death receptor pathway via the Fas receptor (Li, W. et al., 2006; Sigma®-Aldrich, 
2008). The percentage of early apoptosis (% cells in area G4 of PI vs. AV colour-coded 
density plot) induced by FLAG-tagged FasL and ANTI-FLAG® M2 antibody is shown 








           A : Untreated                     B: 0.4 mM H2O2                  C: 1 mM H2O2     








Fig. 17. PI vs. AV plots of H2O2 treated HL60 cells. HL60 cells were treated with H2O2, labelled 
with AV and PI and analysed via flow cytometry. The cells were treated for 24 hrs with (B) 0.4 
mM H2O2 to induce approximately 5% (low level) early apoptosis (G4) and (C) 1 mM H2O2 to 











Table 6: Percentage of early apoptosis in HL60 cells following treatment with 












Average % early 
apoptotic cells  




 0 ** 0  2.99 (±0.01) 0  
 0.5 ** 0.25 2.81 (±0.4) -0.18 (±0.4) 
 5 ** 0.25 3.80 (±2.7) 0.81 (±2.7) 
 50 ** 0.25 4.29 (±0.2) 1.3 (±0.2) 
 0 ** 0 3.61 (±0.9) 0  
 0 ** 0.25 3.74 (±0.4) 0.13 (±0.4) 
 0 *** 0.5 4.11 0.5 
 50 *** 0.25 5.18 1.57 
 50 *** 0.5 5.47 1.86 
 200 *** 0.25 5.17 1.56 
 200 *** 0.5 4.28 0.59 
 0 * 0 1.92 (±0.4) 0  
 5 * 0.25 2.27 (±0.7) 0.35 (±0.7) 
 50 * 0.25 1.67 (±0.1) -0.25 (±0.1) 
 200 * 0.25 2.59 (±0.6) 0.67 (±0.6) 








The combination of FLAG-tagged FasL and ANTI-FLAG® M2 antibody, over 4 and 24 
hrs treatment, had very little affect on the HL60 cells as seen in Table 6. Less than 2% 
early apoptosis was induced above that of the untreated cells over the entire range 
tested.  
 
To examine the effect of higher ANTI-FLAG® M2 antibody concentrations, and to see 





Different colours represent experimental sets performed on different days 
* Values reflect the averages with standard deviation (n=3) 
** Values reflect the averages with standard deviation (n=2) 
*** n=1  
† The average % early apoptotic cells were obtained from area G4 of the respective PI vs. AV 
density plots 
‡ The values were corrected for background apoptosis by subtracting the average %G4 for the 
untreated cells from the average %G4 for the FasL treated cells (for each experimental set)   
 












antibody and different concentrations of FasL (0-200 ng/ml) over 4 hrs. The results 
(Table 6) indicated that 0.25 μg/ml antibody alone did not induce a significant amount 
of apoptosis. Furthermore, 0.5 μg/ml antibody induced only 0.5% apoptosis, above that 
of the untreated cells. It was also found that even at the higher antibody concentration 
(0.5 μg/ml) (with FLAG-tagged FasL), there was not a significant difference in early 
apoptosis induced, compared to the values obtained with 0.25 μg/ml antibody.  
 
The results in Table 6 therefore show that the FLAG-tagged FasL and ANTI-FLAG® 
M2 antibody set did not induce a significant percentage of apoptosis in HL60 cells. Due 
to this and the high expense of FasL, it was therefore decided to use a different cell line, 
which would require lower FasL concentrations to produce the required levels of 
apoptosis. The Jurkat cell line was therefore acquired to perform the FasL-death 
receptor pathway optimisation experiments.          
 
3.1.1.3 D)   FasL treatment of Jurkat cells to induce the death receptor pathway  
 
Jurkat cells were treated with FLAG-tagged FasL (0.04 ng/ml – 5 ng/ml) for 4 hrs, in 
the presence of 0.25 μg/ml ANTI-FLAG® M2 antibody, to induce the death receptor 
pathway (Huang et al., 1999; Sigma®-Aldrich, 2008). It was decided to use 4 hrs as the 
optimal incubation time, since this was the time used by the manufacturer in inducing 
apoptosis in Jurkat cells (Sigma®-Aldrich, 2008). The percentage of early apoptosis (% 
cells in area G4 of PI vs. AV colour-coded density plot) induced after treatment with 
FLAG-tagged FasL and ANTI-FLAG® M2 antibody (after 4 hrs exposure) is shown in 
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Fig. 18 shows an increase in the percentage of early apoptosis (area G4) induced in the 
FasL treated cells as the FLAG-tagged FasL concentrations were increased. It was 
determined from Fig. 18 that 0.2 ng/ml FLAG-tagged FasL together with 0.25 μg/ml 
ANTI-FLAG® M2 antibody induced approximately 15% (low level) early apoptosis, 
above that of the untreated cells. Given that 0.3 ng/ml FLAG-tagged FasL produced less 
than 20% apoptosis (G4), it was decided that 0.4 ng/ml FLAG-tagged FasL (with 0.25 
μg/ml antibody) was more appropriate, since it induced approximately 40% (high level) 
apoptosis (G4) above that of the untreated cells (Fig. 18).  
 
Fig. 19 shows the representative PI vs. AV colour-coded density plots that were 
obtained for the low level (15%) and high level (40%) of early apoptosis (G4) induced 
by FLAG-tagged FasL and 0.25 μg/ml ANTI-FLAG® M2 antibody after 4 hrs 






 FLAG-tagged FasL concentration (ng/ml) 
Fig. 18. Bar graph of % early apoptosis induced vs. different FLAG-tagged FasL concentrations 
(in the presence of ANTI-FLAG® M2 antibody) after 4 hrs exposure. Jurkat cells were exposed to 
different FLAG-tagged FasL concentrations in the presence of 0.25 μg/ml ANTI-FLAG® M2 
antibody for 4 hrs. The samples were either prepared and analysed in duplicate or triplicate. The 
values were corrected for background apoptosis by subtracting the average %G4 for the untreated cells 





































3.1.2   Western blot analysis and optimisation 
 
During the initial part of this study, the western blot assays were optimised to find the:  
• Optimal transfer conditions required for maximal protein transfer 
• Appropriate protein concentration needed for optimal detection by the antibody  
• Optimal concentration of each antibody required for detection.   
 
3.1.2.1   Optimisation of transfer conditions for western blot analysis  
 
Initial western blot analyses, using β-actin antibody as probe, determined that 20-23 V 
was the maximum voltage that could be used with the Trans-Blot® SD Semi-Dry 
Electrophoretic Transfer Cell, since it had a voltage limit of 25 V. The current was 
maintained at approximately 80-234 mA to prevent over-heating. It was also found that 
30-60 min transfer time was sufficient, depending on the size of the gel.  
 
3.1.2.2   Optimisation of Bip western blot assay  
 
To optimise the Bip western blot assay, the appropriate antibody concentration 
(required to detect Bip) was firstly determined. In previous experiments performed, it 
          A: Untreated                       B: 0.2 ng/ml FasL                C: 0.4 ng/ml FasL  







                   AV                                             AV                                            AV  
Fig. 19. PI vs. AV plots of FasL treated Jurkat cells. Jurkat cells were treated for 4 hrs with 
FLAG-tagged FasL and ANTI-FLAG® M2 antibody, labelled with AV and PI and analysed via 
flow cytometry. The cells were treated with (B) 0.2 ng/ml FLAG-tagged FasL and 0.25 μg/ml 
ANTI-FLAG® M2 antibody to induce approximately 15% apoptosis and (C) 0.4 ng/ml FLAG-
tagged FasL and 0.25 μg/ml ANTI-FLAG® M2 antibody to induce approximately 40% apoptosis 
above that of the untreated cells (A). 
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was found that Bip (5 µg protein; extracted without protease inhibitors) was not 
detected at 1:1000 diluted Bip antibody (data not shown). It was therefore decided to 
repeat the western blot analysis, using higher antibody and protein (extracted with 
protease inhibitors) concentrations. Protein was extracted from untreated and BFA 
treated (30 µg/ml BFA; 24 hrs) HL60 cells (section 2.3.1). The western blot analysis 
was performed as described in sections 2.3.2 and 2.3.3. The membrane was probed with 
1:500 diluted Bip antibody and subsequently developed (Fig. 20). 
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Fig. 20 shows that Bip (78 kDa) was detected by the increased (1:500) Bip antibody 
concentration for both untreated and BFA treated HL60 lysates and at all the protein 
concentrations used. As indicated by Fig. 20, the band intensities also increased as the 
protein concentration was increased, as expected. The higher protein concentrations (50-
100 µg) resulted in some non-specific bands directly below Bip and at approximately 20 
kDa. Fig. 20 also shows an increase in Bip protein levels after BFA treatment (lane 2), 
compared to the untreated control (lane 1), at 10 ug protein. However, the other lanes 
(3-6) were too over-exposed to observe differences between untreated and BFA treated 
protein expression levels. This western blot analysis therefore indicated that as little as 
Bip 78 kDa 
Fig. 20. Optimisation of Bip western blot assay. Protein lysates (10-100 µg) from untreated and 
BFA (30 µg/ml BFA; 24 hrs) treated HL60 cells were separated via SDS-PAGE and transferred 
onto PVDF membrane. The membrane was probed with Bip antibody (1:500) and developed. 
Lanes 1, 3 and 5 contained 10, 50, 100 µg of untreated HL60 cell protein, respectively. Lanes 2, 4 
and 6 contained 10, 50, 100 µg of BFA treated HL60 cell protein, respectively. 
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10 ug protein could be used to detect changes in Bip protein expression (section 
3.1.2.5). Moreover, the use of protease inhibitors in the RIPA buffer appeared to 
improve the detection of Bip. It was therefore decided to include protease inhibitors for 
all protein samples.  
 
3.1.2.3   Optimisation of FADD western blot analysis 
 
The western blot assay for FADD was optimised to determine the optimal FADD 
antibody concentration required for detection of the protein. Since the death receptor 
pathway drug-response (section 3.1.1.3 D) was optimised using Jurkat cells, protein 
(100 µg; extracted with protease inhibitors) from untreated Jurkat cells was used for this 
purpose. The western blot analysis was performed as described in section 2.3. Initially, 
the membrane was probed with 1:1000 diluted FADD antibody, however no signal was 
detected. Therefore, the membrane was stripped and reprobed (section 2.3.5) with 1:500 
diluted FADD antibody, which was successful (data not shown).   
 
To verify these results, the western blot assay was repeated with untreated Jurkat cell 
protein (50-100 µg; extracted with protease inhibitors). The membrane was probed with 
1:500 diluted FADD antibody and 1:1000 β–actin antibody, as a positive control, and 
subsequently developed (Fig. 21). 
 
 
              1       2        





 FADD 28 kDa 
 β-actin 45 kDa 
50 µg   100 µg     protein 
Fig. 21. FADD and β–actin western blot optimisation assay. Protein lysates (50-100 µg) from 
untreated Jurkat cells were separated via SDS-PAGE and transferred onto PVDF membrane. The 
membrane was probed with FADD (1:500) and β–actin (1:1000) antibodies and developed. Lane 













Fig. 21 shows that FADD (28 kDa) was detected by the increased (1:500) FADD 
antibody concentration at both protein concentrations (50 µg and 100 µg), however 100 
µg protein produced a more intense signal. The β-actin (45 kDa) positive control was 
detected at both protein concentrations, as expected. Since both proteins (FADD and β-
actin) were detected successfully, it indicated that the membrane could be incubated 
with both antibodies (for FADD and β-actin) simultaneously. This was important for the 
final experiments to follow (section 3.2.2), since it would minimise the stripping and re-
probing steps required (hence, minimise loss of protein from the membrane between 
stripping steps).  
 
The non-specific bands that were detected directly below β-actin (indicated on Fig. 21) 
appear to be due to the β-actin antibody, since another western blot, with β-actin only, 
produced the same bands (Fig. 22). The western blot assay was performed (as described 
in section 2.3) with protein (150 µg) extracted from untreated and BFA treated (30 
µg/ml BFA; 24 hrs) HL60 cells. The membrane was probed with 1:1000 diluted β-actin 
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Fig. 22 shows that β-actin (45 kDa) was detected for untreated and BFA treated 
samples, as expected. Fig. 22 also shows two non-specific bands, which were detected 
Non-specific bands (approx. 37 kDa) 
 β-actin 45 kDa 
     -        + 
 
Fig. 22. β–actin western blot showing non-specific bands. Protein lysates (150 µg) from 
untreated and BFA (30 µg/ml BFA; 24 hrs) treated HL60 cells were separated via SDS-PAGE and 
transferred onto PVDF membrane. The membrane was probed with β-actin antibody (1:1000) and 
developed. Lane 1 contained 150 µg of untreated HL60 cell protein. Lane 2 contained 150 µg of 











between 33 kDa and 40 kDa (at approximately 37 kDa). These non-specific bands were 
also detected in Fig. 21 (directly below β-actin), therefore confirming that these bands 
were due to the β-actin antibody and not FADD. 
 
3.1.2.4   Optimisation of CHOP western blot analysis 
 
The CHOP (GADD153) western blot assay was optimised to determine the optimal 
protein and antibody concentrations required for detection. The western blot analysis 
protocol (section 2.3.3) was also modified to improve on the results obtained. Protein 
isolated (with protease inhibitors) from untreated and BFA treated (30 µg/ml BFA for 
24 hrs) HL60 cells was resolved through SDS-PAGE (section 2.3.2) and transferred 
onto PVDF membrane (section 2.3.3) for 30-60 min at 20-23 V.  
 
For the initial experiments, 5 µg and 150 µg protein was used and the membrane was 
probed with 4 µg/ml GADD153 antibody. However, no bands were detected and a high 
background signal was present. To attempt to decrease the high background signal, 
experiments with lower protein concentrations (10 and 50 µg) were performed. The 
membranes were probed with different concentrations of GADD153 antibody (0.4 
µg/ml, 2 µg/ml or 8 µg/ml), however no signal was detected. The experiment was 
repeated but instead, 1 µg/ml GADD153 antibody was used (Fig. 23). 
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CHOP 29 kDa 
-      +      -       +                                          
   10 µg         50 µg      protein 
Fig. 23. Optimisation of CHOP western blot assay. Protein lysates (10-50 µg) from untreated 
and BFA treated (30 µg/ml BFA; 24 hrs) HL60 cells were separated via SDS-PAGE and 
transferred onto PVDF membrane. The membrane was probed with 1 µg/ml GADD153 antibody 
and developed. Lane 1: 10 µg of untreated HL60 cell protein. Lane 2: 10 µg of BFA treated HL60 












Fig. 23 shows that a very faint signal was detected for CHOP (29 kDa) at 50 µg protein 
only (lanes 3-4). Fig. 23 also shows a slight increase in CHOP protein levels after BFA 
treatment (lane 4), compared to the untreated control (lane 3). In an attempt to improve 
the signal obtained in Fig. 23, the membrane was stripped and reprobed with higher 
GADD153 antibody concentration (8 µg/ml). However, no signal was obtained (data 
not shown). This could, in part, have been due to loss of some protein during the 
stripping and reprobing procedure.   
  
To determine the affinity of the POD-conjugated secondary antibody for the β–actin, 
Bip, FADD and GADD153 antibodies, a “dot blot” experiment was performed. It was 
found that the secondary antibody’s affinity for the GADD153 antibody was lower than 
for the other antibodies (data not shown). Therefore, it was decided to repeat the CHOP 
western blot analysis with increased POD-conjugated secondary antibody 
concentrations and increased subsequent washing steps (to minimize high background 
signal) (as described in section 2.3.3).     
 
A western blot assay with 10 and 50 µg protein (isolated from untreated and BFA (30 
µg/ml; 24 hrs) treated HL60 cells) was performed. The membrane was probed with 1 
µg/ml GADD153 antibody and detected with 80 mU/ml POD-conjugated secondary 
antibody. There was a slight improvement in band detection for 50 µg protein only, 
however, the background signal was somewhat high and there were non-specific bands 
present (data not shown).  
 
The experiment was repeated with the same protein and GADD153 antibody 
concentrations but using a higher POD-conjugated secondary antibody concentration 
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Fig. 24 shows that a signal for CHOP (29 kDa) was detected at 50 µg protein only 
(lanes 3-4) and the background signal had decreased significantly. However, there were 
still some non-specific bands present, which could not be improved upon. The 
requirements for detection of CHOP were therefore found to be: higher protein 
concentrations (greater or equal to 50 µg protein), an increased POD-conjugated 
secondary antibody concentration (160 mU/ml) (to increase its binding affinity to 
GADD153 antibody) and subsequent increased number of washing steps to minimize 
high background signal (section 2.3.3).  
 
3.1.2.5   Determination of optimal protein concentration required for detection   
 
Since the transfer apparatus used creates very strong fields during the transfer process, 
the amount of protein transferred onto the membrane may not always be quantitative. 
Therefore, the optimal protein concentration required for signal detection was 
determined. Since β-actin was used as a positive invariant control, it was expected to be 
present in both untreated and drug-treated samples, unlike the other genes (Bip, CHOP 
CHOP 29 kDa 
Non-specific bands 
Fig. 24. CHOP western blot analysis with 160 mU/ml POD-conjugated secondary antibody. 
Protein lysates (10-50 µg) from untreated and BFA treated (30 µg/ml BFA for 24 hrs) HL60 cells were 
separated via SDS-PAGE and transferred onto PVDF membrane. The membrane was probed with 1 
µg/ml GADD153 antibody and developed with 160 mU/ml POD-conjugated secondary antibody. Lane 
1: 10 µg of untreated HL60 cell protein. Lane 2: 10 µg of BFA treated HL60 cell protein. Lane 3: 50 
µg of untreated HL60 cell protein. Lane 4: 50 µg of BFA treated HL60 cell protein. 
 
   10 µg         50 µg      protein 
Non-specific bands 











and FADD), which could vary. It was therefore decided to use β-actin as reference for 
determining the optimal protein concentration required for detection. 
 
A western blot assay with protein (1 - 100 µg) extracted from untreated HL60 cells was 
performed (as described in section 2.3.4) (Fig. 25). 
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Fig. 25 shows that the intensity of the detected protein (β-actin, 45 kDa) does not 
significantly differ with increasing protein concentrations (lanes 2-5). Since there was 
no band detected for 1 µg protein (lane 1), it can be concluded that it was not sufficient 
for transfer. Therefore, less than 5 µg protein would not be recommended. Previous 
results (Fig. 20) indicated that 10 ug protein was sufficient for quantitative 
differentiation of Bip between untreated and BFA treated samples. Therefore, it was 
concluded that as little as 10 ug protein could be used for western blot analysis. 
However, since the membranes were to be stripped and reprobed in the final 
experiments to follow (section 3.2.2), it was decided to use 100 µg protein. This would 
ensure that enough protein was transferred and would remain on the membrane after 
successive stripping and reprobing steps. 
 
3.1.3   Caspase activity assays 
 
Increases in caspase activity were monitored using fluorometric caspase activity assays, 
which were optimised to determine optimal assay conditions (Köhler et al., 2002). Since 
β–actin 45 kDa 
Fig. 25. Determination of optimal protein concentration required for detection of β–actin 
protein. SDS-PAGE was performed on untreated HL60 cell protein extracts (1-100 µg) after 
which the protein was transferred onto PVDF membrane and probed with β-actin antibody 











a manufactured caspase activity assay kit was not used, it was necessary to confirm that 
the assay was working correctly and to optimise the parameters where necessary.   
 
3.1.3.1   Determination of minimal protein concentration required for caspase 
activity  
 
The minimal amount of protein that could be used to determine caspase activity was 
investigated using caspase-3 substrate (Anaspec, 2007). The assay was performed as 
described in section 2.4. The Relative Fluorescence Units (RFU) values obtained for the 




























Fig. 26 shows that the RFU values increased with higher protein concentrations, as well 
as higher drug concentrations, as expected. The BFA treated cells (30 µg/ml BFA for 24 
Fig. 26. Caspase-3 activity expressed as RFU for different protein concentrations. Different 
protein concentrations (1 - 10 µg) of BFA treated (0 µg/ml, 2.5 µg/ml and 30 µg/ml; 24 hrs) HL60 
cell lysates were used in a caspase activity assay with caspase-3 substrate (50 µM) to determine 
the optimal protein concentration required to produce a satisfactory fluorescence signal. The assay 
components were incubated for 60 min at 37°C before readings were taken. Readings were taken 
at Ex/Em= 354/442 nm with Ex/Em slit= 20/20nm and PMT Voltage= medium. An automatic 
blank setting was used. Samples were prepared and analysed in triplicate and RFU values reflect 











hrs, which induced approximately 20% apoptosis) showed much greater caspase-3 
activity compared to that of the 2.5 µg/ml BFA treated and untreated samples, as 
expected. The results indicated that the RFU values increased in proportion to the 
amount of protein added per caspase reaction. This can be seen in the linear increase in 
caspase activity from 5 - 10 µg protein and with increasing BFA concentration (Fig. 
26).  
 
The RFU values produced with 10 µg protein were the highest, although as little as 5 µg 
protein could be used at these assay conditions and fluorimeter settings (Fig. 26). The 
RFU values were, however, very low and therefore the caspase assay was optimised in 
terms of fluorimeter settings, incubation time and substrate concentration to try and 
increase the RFU signal and make the assay more robust. 
 
3.1.3.3   Optimisation of caspase assay reaction conditions 
  
3.1.3.2 A)   Determination of optimal incubation time 
 
Other studies have used a range of incubation times (60-120 min) to determine caspase 
activity (Juin et al., 1998; Cardier and Erickson-Miller, 2002; Nagase et al., 2002; 
Hosokawa et al., 2005; Karki et al., 2007).  
 
The optimal incubation time required for maximal RFU values and AMC release was 
determined as described in section 2.4.2.2. The results indicated that there was no 
significant difference between RFU values at extended incubation times. Furthermore, it 
was found that 60 min incubation time was sufficient for optimal caspase activity and 
AMC release (data not shown).   
 
3.1.3.2 B)   Optimal caspase substrate concentration 
 
The optimal caspase substrate concentration required to produce adequate RFU readings 
was determined as described in section 2.4.2.3. It was found that the RFU values 
increased in proportion to increased substrate concentrations. It was also found that 50 
µM of caspase-3 substrate was sufficient to produce adequate RFU signals that could be 











3.1.3.2 C)   Effect of protease inhibitors on caspase activity 
 
Some research groups performed caspase assays with protein lysates that contained a 
protease inhibitor cocktail (DiPietrantonio et al., 1999; Kim et al., 1999; Doyle et al., 
2002; Huang et al., 2004; Higuchi et al., 2006). Since caspases are proteases and 
caspase activity was being investigated, it was important to establish the effect of 
protease inhibitors on caspase activity. Therefore, cell lysates isolated with or without 
protease inhibitor cocktail (section 2.4.1) were analysed using caspase-3 substrate (50 
µM) (as described in sections 2.4.2 and 2.4.3). The RFU values obtained for these 
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It was found that the protease inhibitor cocktail did in fact significantly inhibit caspase-
3 activity, as indicated by Fig. 27. Both the untreated and drug-treated (30 µg/ml BFA) 
samples that did not contain protease inhibitor cocktail had higher caspase-3 activity 





Fig. 27. RFU plot showing the effect of protease inhibitor cocktail on caspase-3 activity. 
Untreated and BFA treated (30 µg/ml, 24 hrs) HL60 cell lysates (5 µg protein), which were isolated 
with or without protease inhibitor cocktail, were used in a caspase activity assay with caspase-3 
substrate (50 µM) to determine the effect of protease inhibitors on caspase activity. Samples were 
prepared and analysed in triplicate and RFU values (shown on graph) reflect averages with error 











cocktail. It was therefore decided not to include protease inhibitor cocktail when 
isolating protein for the caspase assays. 
 
3.1.3.3   Caspase assay controls    
 
Using the optimised conditions established (section 3.1.3.2), the following control 
assays were performed to determine if the caspase assay was working correctly and to 
understand the role of the various assay components in generating the fluorescent 
signal:   
1. Heat inactivation of lysates (15 min in rapidly boiling water)  
2. Cell lysates only (no caspase substrate) 
3. Caspase substrate (50 µM per sample) with reaction buffer only 
4. Caspase substrate (50 µM per sample) only 
5. Reaction buffer only  
6. Cell lysis buffer only 
 

















73.14 (± 26.8) 
18.60 (± 3.9) 
-164.9 (± 0.6) 
132.55 (± 7.0) 
36.62 (± 8.3) 



















Fig. 28. The effect of the heat inactivation on caspase activity and cell lysates on the assay 
reaction. Caspase reactions were performed with untreated and drug-treated (30 µg/ml BFA, 24hrs) 
HL60 cell lysates (5µg protein; without protease inhibitor cocktail). The effect of heat inactivation 
on caspase activity as well as the effect of the cell lysates (without caspase substrate) was 
determined. Samples were prepared and analysed in triplicate and the average RFU values are 
shown on the graph with the error bars representing the standard deviation. An automatic blank 











Fig. 28 indicates that the untreated cell lysates contained a low level of caspase-3 
activity, since approximately 5-10% of the cells were apoptotic (background level of 
apoptosis) (section 3.1.1.2), as expected. The BFA treated samples (approximately 20% 
early apoptosis) showed an increase in caspase-3 activity compared to the untreated 
samples, as expected. After heat inactivation (a basic means of inducing loss of 
enzymatic function through protein denaturation), the RFU values for both drug-treated 
and untreated samples significantly decreased. This indicated that the fluorescence 
signals were in fact due to enzyme (caspase) activity. Furthermore, the absence of a 
positive signal without addition of caspase-3 substrate (lysate only samples) indicated 

















Fig. 29 indicated that the caspase-3 substrate (on its own) auto-fluoresces, however, this 
effect was reduced after addition of reaction buffer, which contains DTT. Fig. 29 also 


























Fig. 29. The effects of the different assay components on the caspase assay reaction. Caspase 
assays were performed without any cell lysates and the effects of caspase-3 substrate, reaction buffer 
and cell lysis buffer were determined. Samples were prepared and analysed in triplicate and the 
average RFU values are shown on the graph with the error bars representing the standard deviation. 
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reaction, which contained all components (caspase substrate, reaction buffer and cell 
lysis buffer), had a greater RFU value than the cell lysis and reaction buffers on their 
own (Fig. 29 blue bars). Therefore, after the blank was subtracted, it resulted in large 
negative RFU values for both buffers (Fig. 29 yellow bars). In contrast, the caspase-3 
substrate (only) reaction had a greater RFU value than the blank reaction (Fig. 29 blue 
bars). Therefore, it produced a positive RFU value after the blank was subtracted (Fig. 
29 yellow bar).   
 
3.1.3.4   AMC standard curve 
 
Caspase activity was measured as an increase in fluorescence intensity, which occurred 
as a result of the cleavage of AMC molecules, and was expressed as RFU values. Since 
RFU values were not constant and can vary with each experiment, the sample RFU 
readings were converted to AMC release (µM) using the equation from a standard curve 
(Fig. 30). (The AMC standards were prepared as described in section 2.4.4 and Table 
3.) Fig. 30 shows an example of an AMC standard curve obtained from the RFU values 
of the AMC standards. 
 





















 c ce trati n (µ ) 
Fig. 30. Example of an AMC standard curve for caspase assays. AMC standards (3.13 µM - 0.0975 
µM) were prepared by serially diluting 10 mM AMC stock solution with dH2O. Sample RFU readings 
were converted to AMC release (µM) using the standard curve equation. The AMC standards were 
prepared and analysed in triplicate and the average RFU values are shown on the graph with the error 












3.1.3.5   Caspase assay for all caspase substrates    
 
After the optimisation experiments, the validity of the caspase assays for all caspase 
substrates (caspase-3, -4, -8 and -9) were confirmed using untreated and BFA treated 
(30 µg/ml BFA, 24 hrs) cell lysates. The aim was to see if the appropriate caspases 
would be activated after induction of the ER-stress induced apoptotic pathway (via BFA 
treatment).  
 
The caspase assays were performed as described in section 2.4 (according to the 

























0µg/ml BFA (heat inactivated)
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Fig. 31 shows that AMC release was reduced for all samples after heat inactivation, 
which indicated that enzyme activity was reduced. Any changes in AMC release were 
therefore due to changes in enzyme (caspase) activity. The untreated samples (0 µg/ml 
Fig. 31. AMC release for all caspase substrates using untreated and BFA lysates. BFA treated (30 
µg/ml, 24 hrs) (green) and untreated (blue) HL60 cell lysates (10 µg protein) were analysed for caspase 
activity and compared to heat inactivated controls (purple- untreated heat inactivated cell lysates and 
yellow- BFA treated heat inactivated cell lysates). Samples were prepared and analysed in triplicate 
and AMC release reflects averages with standard deviation as indicated by error bars. The average 
RFU for the blank readings were subtracted from the average sample RFU values before the AMC 
release was calculated. Readings were taken at Ex/Em= 354/442 nm with Ex/Em slit= 20/20nm and 












BFA, 24 hrs) indicated that all four caspases were activated in the apoptotic cell 
population (approximately 5-10% cell death; section 3.1.1.2), with caspase-4 and -8 
activity being greatest. As expected, there was an increase in caspase-3 and -4 activity 
for BFA treated cells (approximately 20% early apoptotic), since the ER-stress induced 
apoptotic pathway was activated. There was no increase in caspase-8 and -9 activity for 
BFA treated cells compared to their untreated values. The experiment therefore 
confirmed that the caspase assay could be performed for all four of the caspase 
substrates.    
 
3.1.3.6   Use of alternative protein extraction buffer for caspase assay 
 
Two different protein extraction buffers were used for the western blot analysis (RIPA 
buffer) and caspase assays (Cell lysis buffer). As a result, it was important to determine 
if one extraction buffer (RIPA), and therefore one protein sample, could be used for 
both assays (for the final experiments of section 3.2.3).  
 
The caspase assay was performed as described in section 2.4 (according to the 
optimised conditions determined), except protein was extracted with RIPA buffer 
(without protease inhibitors) instead. The AMC release for all samples is shown in Fig. 











































Fig. 32 shows a linear increase in caspase-3 activity with increasing protein 
concentrations. RIPA buffer could therefore be used to determine caspase activity, 
however, the AMC release (for 10 µg protein) was significantly lower (0.42 (±0.14) 
µM) compared to that of the Cell lysis buffer lysates in Fig. 31, which was 0.78 (±0.17) 
µM. Moreover, protease inhibitors, which would reduce caspase activity and the 
sensitivity of the assay, have to be included in the protein extraction buffer for the 
western blot experiments. Therefore, the same protein sample cannot be used for both 
experiments.   
 
3.1.4   Cytochrome c release immunohistochemistry assays 
 
Immunohistochemistry assays were performed on untreated and H2O2 treated HL60 
cells to investigate cytochrome c release from the mitochondria as described in section 





Fig. 32. AMC release for RIPA buffer extracted BFA treated HL60 cell lysates at different 
protein concentrations. HL60 cells were treated with BFA (30 µg/ml, 24 hrs) and protein was 
isolated with RIPA buffer. Caspase-3 activity (using 50 µM caspase-3 substrate per reaction) at 
different protein concentrations (10 - 20 µg) was determined at Ex/Em= 354/442 nm with Ex/Em 
slit= 20/20nm and PMT Voltage= High. Samples were prepared and analysed in triplicate and 
RFU values reflect averages with standard deviation. The average RFU for the blank readings 
were subtracted from the average sample RFU values. The RFU readings for the samples were 















































Initial cytochrome c immunohistochemistry assay 
To determine the optimal cytochrome c (6H2)-PE antibody concentration required and the 
optimal concentration of cells required per slide  
Cytochrome c immunohistochemistry assays with different cell permeabilization protocols  
To improve antibody labelling and visualization by using different methods of fixation and/or 
permeabilization 
 
Cleaved caspase-3 antibody immunohistochemistry assay  
Different antibody was used to see if the protocol was working or if the problem lied with the 
cytochrome c (6H2)-PE antibody 
 
Cytochrome c immunohistochemistry assay optimisation with higher antibody concentration 
To improve antibody labelling and visualization by using higher cytochrome c (6H2)-PE antibody 
concentrations 
Different immunohistochemistry assay protocol  
Performed by the Cardiovascular Research Unit  
   
Immunohistochemistry assays without cell permeabilization for cytochrome c (6H2)-PE 
and cleaved caspase-3-FITC antibodies 
To determine if detergent in permeabilization buffer could be interfering with antibody binding  
Immunohistochemistry assays to determine cell membrane permeability 
Control dye and antibody was used to determine if the cell membranes were permeable for 
antibody to enter (permeabilized vs. non- permeabilized cells) 
 
Cytochrome c (6H2)-PE antibody was placed on a slide and visualized under the microscope to 
see if the antibody could still fluoresce  
Fig. 33. Flow diagram that summarizes all the experiments conducted in this section. 
 
Verifying the results obtained by the Cardiovascular Research Unit by using their protocol to 













3.1.4.1   Initial cytochrome c immunohistochemistry assay 
 
Firstly, the optimal cytochrome c (6H2)-PE antibody concentration (required for 
visualization of cytochrome c release via fluorescent microscopy) and optimal 
concentration of cells required per slide was determined. The cells were treated as 
described in section 2.5.2. 
  
It was found that 105 cells per slide and 4 µg/ml cytochrome c (6H2)-PE antibody was 
required for fluorescence detection, since higher cell numbers caused the background 
fluorescence to increase (data not shown). However, it was very difficult to find the 
cells at lower exposure times (less than 2 s exposure) and increasingly difficult to 
maintain focus on the cells at these high exposure times. Therefore, it could not be 
clearly distinguished, even at higher magnification, whether the labelled cytochrome c 
molecules were inside the mitochondria or being released into the cytoplasm of the 
cells. 
 
3.1.4.2   Cytochrome c immunohistochemistry assays using different cell 
permeabilization protocols to improve antibody labelling 
 
Since the cells were difficult to visualize, it was decided to modify the 
immunohistochemistry protocol to see if cell labelling and visibility could improve. 
Different methods for fixation were performed, as well as including a cell membrane 
permeabilization step to ensure that the antibody was able to enter the cells and label 
cytochrome c molecules. A different blocking solution, instead of FBS, was also used 





























There was no significant difference found between the two fixation and 
permeabilization methods (Fig. 34). The unstained cells did not produce any 
fluorescence signal in the Cy3 (PE) channel (833 ms exposure), therefore indicating that 
the cells did not auto-fluoresce. However, the cytochrome c (6H2)-PE labelled cells (for 
both methods) did not fluoresce in the Cy3 (PE) channel (833 ms - 8 s exposure) either. 
Only the cells mounted with VECTASHIELD® could be visualized under the 
microscope in either the DAPI or DIA channels (833 ms exposure) (Fig. 34 A and B). 
At exposure times of 5 - 10 s the resolution on the microscope’s computer screen was 
considerably reduced and only static was visible without any cells.     
 
3.1.4.3  Cytochrome c immunohistochemistry assay optimisation with higher 
antibody concentration 
 
It was decided to repeat the assay using the methanol fixation and permeabilization 
method and a higher cytochrome c (6H2)-PE antibody concentration as described in 
section 2.5.4. An isotypic negative antibody was included as a control to check for non-
B: Fixation and permeabilization with 
IntraPrepTM kit 
A: Methanol fixation and 
permeabilization 
 
Fig. 34. Immunohistochemistry assay using different cell permeabilization protocols to improve 
cytochrome c labelling. Untreated HL60 cells (105 cells per slide) were either fixed and 
permeabilized using methanol and permeabilization buffer (A) or the IntraPrepTM kit (B) and labelled 
with cytochrome c (6H2)-PE labelled antibody (4 µg/ml). The cells were mounted with 
VECTASHIELD® mounting medium and visualized via a fluorescent microscope, using the DIA 












specific labelling. (Figures are not shown, since fluorescence was either too weak or 
there was no signal at all). 
  
The untreated, unstained cells did not fluoresce in any channel (at 833 ms or 4 s 
exposure) therefore the cells did not auto-fluoresce. However, the H2O2 treated, 
unstained cells showed some faint green fluorescence in the FITC channel (833ms 
exposure) but not in the Cy3 (PE) channel. This indicated that perhaps the drug 
treatment caused some auto-fluorescence in the FITC, but not Cy3 (PE), channel.  
 
There was no fluorescence signal detected for the untreated, 8 µg/ml or 20 µg/ml 
cytochrome c (6H2)-PE antibody labelled cells in the Cy3 (PE) channel, even at higher 
exposure times (4 s). The 20 µg/ml cytochrome c (6H2)-PE antibody labelled cells did, 
however, produce a non-specific green fluorescence signal in the FITC channel at 4 s 
exposure time. It therefore appeared that the untreated cells did not label with the 
cytochrome c (6H2)-PE antibody at both antibody concentrations. 
  
The H2O2 treated, 20 µg/ml cytochrome c (6H2)-PE antibody labelled cells had no 
fluorescence signal in the Cy3 (PE) channel (833 ms or 4 s exposure), thus indicating 
that the cells had not labelled with the antibody. The H2O2 treated, 8 µg/ml cytochrome 
c (6H2)-PE antibody labelled cells had some faint fluorescent signal in the Cy3 (PE) 
channel at 4 s exposure. However, the signal at 833 ms exposure was significantly 
reduced. Therefore, these cells did not label properly with the cytochrome c (6H2)-PE 
antibody either. At both cytochrome c (6H2)-PE antibody concentrations (8 µg/ml and 
20 µg/ml) the drug-treated cells did, however, fluoresce green in the FITC channel at 
833 ms exposure time. This indicated that the drug treatment possibly caused some 
auto-fluorescence and/or non-specific fluorescence in the FITC, but not Cy3 (PE), 
channel.  
 
The IgG-PE antibody labelled untreated cells (negative isotypic control) had no 
fluorescent signal in the Cy3 (PE) channel at 833 ms or 4 s exposure. This indicated that 
there was no non-specific labelling for the untreated cells. The IgG-PE antibody 
labelled drug-treated cells had a very faint fluorescent signal in the Cy3 (PE) channel at 











in the FITC channel at 833ms exposure, indicating again that H2O2 treatment may have 
caused some auto-fluorescence in the FITC channel.  
 
Since the IgG-PE antibody labelled cells (untreated and drug-treated) did not 
fluorescence in the FITC or Cy3 (PE) channels at 833 ms exposure, it was decided that 
this was sufficient to detect a true fluorescence signal. Higher exposure times caused 
non-specific fluorescence in the wrong channels, such as FITC.  
  
Given that the cells did not label with cytochrome c (6H2)-PE antibody, a drop of the 
antibody was placed on a slide and visualized under the microscope. The different 
channels were used to see if the antibody could still fluoresce. It was also compared to 
the fluorescence of a drop of the cleaved caspase-3-FITC antibody. It was found that 
both antibodies did fluoresce (data not shown). The cytochrome c (6H2)-PE antibody 
fluoresced bright orange-red in the DIA, FITC and Cy3 (PE) channels at 833 ms 
exposure and only in the DIA and Cy3 (PE) channels at 72 ms exposure. The cleaved 
caspase-3-FITC antibody fluoresced bright green in the FITC and DIA channels at 833 
ms exposure with no signal in the Cy3 (PE) channel. There was no signal for the 
cleaved caspase-3-FITC antibody at lower exposure times. It therefore appeared that 
high exposure times may have caused the cells to fluoresce in the wrong channels, and 
therefore did not reflect true fluorescence signals from antibody labelling. 
 
3.1.4.4  Immunohistochemistry assays to determine cell membrane permeability 
 
Given that the cells still did not have a fluorescence signal after cytochrome c (6H2)-PE 
antibody labelling, it was decided to determine their permeability status. Perhaps the 
cell membranes were not permeable to allow the antibody to enter and bind its target. 
Immunohistochemistry assays using CD45-FITC murine monoclonal antibody and 
propidium iodide (PI) as controls, to determine the cell permeability status, were 

















                   
 
 
           








The unstained controls for both untreated and H2O2 treated cells (permeabilized and 
non-permeabilized) showed no fluorescence in the Cy3 (PE) or FITC channels at 833 
ms exposure, indicating that the cells did not auto-fluoresce.  
 
All PI labelled cells (untreated and drug-treated, both permeabilized and non-
permeabilized) fluoresced in the Cy3 (PE) (red fluorescence for PI labelling) and DIA 
channels (Fig. 35). The DIA (triple) channel can detect and overlap the different colours 
from fluorescence signals in the FITC (green), Cy3 (PE) (red) and DAPI (blue) 
channels. The purple fluorescence seen in the DIA channel occurred as a result of the 
B: Untreated, non-permeabilized 
PI labelled cells (DIA channel) 
 
A: Untreated, non-permeabilized 
PI labelled cells (Cy3 (PE) channel) 
C: Untreated, permeabilized 
PI labelled cells (Cy3 (PE) channel) 
 
D: Untreated, permeabilized 
PI labelled cells (DIA channel) 
 
Fig. 35. Immunohistochemistry assay with PI labelling of non- permeabilized and permeabilized 
HL60 cells. Untreated HL60 cells (105 cells per slide) were fixated with methanol and either 
permeabilized with buffer (C, D) or not (A, B). The cells were labelled with PI, to determine if the 
permeabilization procedure worked, and mounted with VECTASHIELD® mounting medium. The 
cells were visualized via a fluorescent microscope using the Cy3 (PE) and DIA filters at 833ms 












overlap between the red fluorescence of the PI staining (in Cy3 (PE)) and the blue 
fluorescence of the DAPI stain (in the VECTASHIELD® mounting medium) (Figs. 35 
B and D).  
 
PI can only enter and stain the nuclei and DNA of permeabilized cells. Since all the 
cells (permeabilized and non-permeabilized) labelled with PI, it therefore indicated that 
all the cells were permeabilized. Therefore, the methanol fixation alone was sufficient to 
permeabilize the cell membranes to allow the cytochrome c (6H2)-PE antibody to enter 
and stain its target. The additional permeabilization step, with detergent buffer, would 
therefore not be necessary and the detergent could possibly hamper antibody-antigen 
binding.  
 
Cells were also labelled with CD45-FITC antibody, which served as a positive control 
for non-permeabilized cell membranes (Fig. 36). The CD45-FITC antibody binds to the 
CD45 family of cell-surface markers of intact haematopoietic cells, therefore no 












B: Untreated, non-permeabilized 
CD45-FITC labelled cells (DIA channel) 
 
A: Untreated, non-permeabilized 
 CD45-FITC labelled cells (FITC channel) 
Fig. 36. Immunohistochemistry assay with CD45-FITC antibody labelling of non- 
permeabilized and permeabilized HL60 cells. Untreated HL60 cells (105 cells per slide) were 
fixated with methanol without permeabilization. The cells were labelled with CD45-FITC murine 
monoclonal antibody, to determine if the cell membranes were still intact, and mounted with 
VECTASHIELD® mounting medium. The cells were visualized via a fluorescent microscope 
using the FITC (A) and DIA (B) filters at 833ms exposure time and 20x magnification. The white 












Fig. 36 shows the FITC (Fig. 36 A) and DIA channel (overlapping FITC and DAPI) 
(Fig. 36 B) for the untreated, non-permeabilized CD45-FITC labelled cells. Only the 
faint green outlines of some cells (indicated by the white arrows) were visible in both 
the DIA and FITC channels (833 ms exposure). This indicated that these cells’ 
membranes were still intact. However, the remaining cells that did not fluoresce in the 
FITC channel (Fig. 36 A) but only in the DIA channel (Fig. 36 B), did not label with 
CD45-FITC antibody. These cells therefore had permeabilized membranes. 
Furthermore, the drug-treated, permeabilized CD45-FITC labelled cells also showed 
some fluorescence in the FITC channel, although it was significantly weaker compared 
to the results in Fig. 36 (data not shown). In contrast, the untreated, permeabilized and 
drug-treated, non-permeabilized CD45-FITC labelled cells did not have any 
fluorescence signal in the FITC channel (833 ms exposure). This indicated that their cell 
membranes had been permeabilized (data not shown).  
 
It was therefore concluded that most cells (whether permeabilized with buffer or not) 
had permeablized membranes (due to the methanol fixation). This confirmed the 
previous results obtained from the PI labelled cells (Fig. 35). The protocol was therefore 
working, since the CD45-FITC antibody and PI could enter the cells and bind to their 
targets (whether the cells were incubated with permeabilization buffer or not). 
Furthermore, it indicated that the permeabilization buffer did not necessarily interfere 
with antibody-antigen binding properties, since the drug-treated, permeabilized (CD45-
FITC labelled) cells fluoresced in the FITC channel, albeit weakly.  
 
3.1.4.5   Cleaved caspase-3 (Asp175) antibody immunohistochemistry assay to 
determine viability of assay protocol 
 
The viability of the immunohistochemistry protocol (with the permeabilization step) 
was determined by repeating the experiment using another antibody as a positive 
control (as described in section 2.5.6). Cleaved caspase-3 (Asp175) polyclonal rabbit 
antibody (Alexa Fluor®488 conjugate), which binds to caspase-3 molecules in cells 
undergoing apoptosis, was used for this purpose (Fig. 37). By using another antibody, it 
could be determined if it was the protocol that was ineffective or if the antibody 






















The unstained controls (for both untreated and drug-treated cells) did not fluoresce in 
the Cy3 (PE) or FITC channels at 833 ms exposure, therefore indicating that the cells 
did not auto-fluoresce. There was also no fluorescence signal detected for the isotypic 
control (IgG1-FITC) antibody labelled cells, therefore indicating that the cells were not 
labelling non-specifically. Furthermore, the untreated, cleaved caspase-3-FITC antibody 
labelled cells did not fluoresce in the FITC channel at 833 ms exposure either. 
However, this could be due to low levels of apoptosis in untreated cells with insufficient 
levels of cleaved (activated) caspase-3 molecules present.  
  
The drug-treated (1.5 mM H2O2 for 24 hrs) cells successfully labelled with cleaved 
caspase-3-FITC antibody and produced a green fluorescence signal in the FITC and 
DIA channels at 833 ms exposure (Fig. 37).  It was concluded from Fig. 37 that the 
immunohistochemistry assay protocol worked, since the cleaved caspase-3-FITC 
antibody could bind to its target and produce a fluorescence signal. It therefore appeared 
that something was wrong with the cytochrome c (6H2)-PE antibody and its ability to 
bind successfully to its target molecule and to produce a fluorescent signal.  
B: 1.5 mM H2O2 
Cleaved caspase-3 antibody 
DIA channel 
A: 1.5 mM H2O2 
Cleaved caspase-3 antibody 
FITC channel 
Fig. 37. Immunohistochemistry assay with cleaved caspase-3-FITC antibody to determine 
viability of labelling protocol. H2O2 treated (1.5 mM H2O2 for 24 hrs) HL60 cells (105 cells per slide) 
were fixated with methanol and permeabilized. The cells were labelled with cleaved caspase-3-FITC 
antibody, to determine if the assay protocol works, and mounted with VECTASHIELD® mounting 
medium. The cells were visualized via a fluorescent microscope using the FITC (A) and DIA (B) 
filters at 833ms exposure time and 20x magnification. The white arrows indicate the green fluorescing 













3.1.4.6  Immunohistochemistry assays without cell permeabilization for 
cytochrome c (6H2)-PE and cleaved caspase-3-FITC antibodies 
 
Since the previous experiment was successful, it was decided to repeat the assay using 
the cytochrome c (6H2)-PE and cleaved caspase-3-FITC antibodies without the 
permeabilization step (as described in section 2.5.7). The aim was to determine if the 
buffer detergent could be interfering with the cytochrome c (6H2)-PE antibody’s ability 
to bind to its target antigen.  
 
There was no fluorescence signal detected in the Cy3 (PE) or FITC channels (833 ms 
exposure) for the unstained cells or isotypic controls (IgG1-PE and IgG1-FITC labelled 
cells). This indicated that the cells did not auto-fluoresce or label non-specifically.  
 
The untreated and drug-treated cells labelled with cytochrome c (6H2)-PE antibody did 
not fluoresce in the Cy3 (PE) channel (833 ms exposure). Furthermore, the untreated 
and drug-treated cells labelled with cleaved caspase-3-FITC antibody did not fluoresce 
in the FITC channel (833 ms exposure) either (data not shown). Therefore the 
experiment was unsuccessful, since both antibodies failed to label their target antigens. 
This again indicated that the permeabilization buffer did not appear to interfere with 
cytochrome c (6H2)-PE antibody binding affinity. Therefore, both the permeabilization 
and non-permeabilization protocols seemed to be ineffective for successful cytochrome 
c labelling.     
 
3.1.4.7  Different immunohistochemistry assay protocol for cytochrome c release     
 
Since the previous immunohistochemistry protocol was unsuccessful, it was decided to 
try another protocol. Untreated and H2O2 treated (1.5 mM H2O2 for 24 hrs) HL60 cells 
were fixed with methanol and the slides sent to the Cardiovascular Research Unit 
(MRC/UCT Cape Heart Centre) for labelling. The Cardiovascular Research Unit used 
their own method to label the cells with either cytochrome c (6H2)-PE (2 µg/ml) or 
cleaved caspase-3-FITC (1:10 dilution) antibodies. The cells were mounted with 














         








         







Fig. 38. Immunohistochemistry assay with cytochrome c (6H2)-PE antibody performed by 
the Cardiovascular Research Unit. Untreated HL60 cells (105 cells per slide) were fixated with 
methanol and labelled with cytochrome c (6H2)-PE antibody. The cells were mounted with 
VECTASHIELD® and visualized via a fluorescent microscope using the Cy3 (PE) (A) and DIA 
(B) filters at 1 s exposure time and 40x magnification.  
 
B: Untreated 




Cytochrome c (6H2)-PE antibody 
Cy3 (PE) channel 
 
A: 1.5 mM H2O2 
Cleaved caspase-3-FITC antibody 
FITC channel 
B: 1.5 mM H2O2 
Cleaved caspase-3-FITC antibody 
DIA channel 
Fig. 39. Immunohistochemistry assay with cleaved caspase-3-FITC antibody performed by 
the Cardiovascular Research Unit. H2O2 treated (1.5 mM H2O2 for 24 hrs) HL60 cells (105 cells 
per slide) were fixated with methanol and labelled with cleaved caspase-3-FITC antibody. The 
cells were mounted with VECTASHIELD® and visualized via a fluorescent microscope using the 












Their immunohistochemistry labelling protocol was successful, since both the 
cytochrome c (6H2)-PE and cleaved caspase-3-FITC antibodies labelled the target 
antigens and produced a fluorescence signal (Figs. 38 and 39). However, the 
fluorescence intensity of the cytochrome c (6H2)-PE labelled cells (Fig. 38), at such a 
high exposure time (1 s), was not as bright or intense compared to that of the cleaved 
caspase-3-FITC labelled cells at 583 ms exposure (Fig. 39). The cytochrome c (6H2)-
PE antibody therefore appeared to have some difficulty in labelling the cells.  
 
The Cardiovascular Research Unit did not perform experiments with unstained and 
isotypic controls, to check for auto-fluorescence and/or non-specific labelling. 
Furthermore, they did not check all three channels (Cy3 (PE), FITC and DIA), for each 
specimen, to determine if there was non-specific fluorescence. Therefore, it was decided 
to verify their results by using their protocol to label the cells with different cytochrome 
c (6H2)-PE antibody concentrations and to include all the relevant controls (as 
described in section 2.5.8).  
 






























    
 
 







The results seen in Fig. 40, for the untreated cells labelled with 2 µg/ml cytochrome c 
(6H2)-PE antibody, were similar for all the different controls used in the experiment. It 
was found that all the cells (untreated and drug-treated) and controls (unstained and 
isotypic IgG1-PE labelled) fluoresced in all three channels at 833 ms exposure. This 
indicated that the cells auto-fluoresced and were labelling non-specifically and therefore 
the assay was unsuccessful. The results obtained by the Cardiovascular Research Unit 
(Figs. 38-39) could therefore be due to non-specific fluorescence. This could not be 
verified, since all the controls were not included in their experiment. It was decided to 
abandon the cytochrome c release immunohistochemistry assay and to focus on changes 
in MTP (section 3.1.5), before and after drug treatment, using flow cytometry. 
B: Untreated 
Cytochrome c (6H2)-PE) antibody 
DIA channel 
A: Untreated 
Cytochrome c (6H2)-PE antibody 
Cy3 (PE) channel 
C: Untreated 
Cytochrome c (6H2)-PE) antibody 
FITC channel 
Fig. 40. Immunohistochemistry assay with new protocol using the cytochrome c (6H2)-PE 
antibody. Untreated HL60 cells (105 cells per slide) were labelled with cytochrome c (6H2)-PE labelled 
antibody (2 µg/ml), using the new immunohistochemistry protocol. The cells were mounted with 
VECTASHIELD® and visualized via a fluorescent microscope using the Cy3 (PE) (A), DIA (B) and 












3.1.5   Detection of changes in mitochondrial transmembrane potential (MTP) 
during apoptosis induction  
 
After drug treatment, the changes in MTP of the cells were determined with 
MitoCaptureTM labelling and flow cytometry as described in section 2.6. Fig. 41 shows 
the typical results obtained from drug-treated and untreated cells using the resultant 
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Fig. 41. Flow analysis of MitoCaptureTM labelled HL60 cells showing differences in MTP with 
increasing drug concentrations. HL60 cells were treated with 0.4 mM (B) and 1 mM (C) H2O2 for 24 






























Fig. 41 shows FL2-PE histograms, which represent cells with normal/unaltered MTPs 
(red fluorescence) and FL1-FITC histograms, which represent cells with disrupted MTP 
(green fluorescence).  
 
In the FL2-PE histogram, the “positive” peak represents normal functioning 
mitochondria with aggregated dye molecules, which fluoresce red in the FL2 channel. 
The “negative” peak represents dye molecules in the monomer state that have not been 
taken up by mitochondria (cells that do not fluoresce red).  
 
In the FL1-FITC histogram, the “positive” peak represents apoptotic cells with 
disrupted MTP. Therefore, an increased number of dye molecules, which could not be 
taken up by the mitochondria, exist in the monomer state and fluoresce green in the FL1 
channel. The “negative” peak represents cells that do not fluoresce green. 
 
The colour-coded density plots (FL2 Log vs. FL1 Log) in Fig. 41 indicate the changes 
in MTP of the cells. Depending on the status of MTP, the cells either fluoresce:  
1. Red – shown in area C1, representing cells that were non-apoptotic and had 
unaltered/normal MTP;  
2. Green – shown in area C4, representing apoptotic cells with disrupted MTP;  
3. Yellow-orange (both red and green) – shown in area C2, representing cells with 
both normal and disrupted MTP (intermediate MTP). 
 
Since the majority of the untreated cells (approximately 90% viable) were non-
apoptotic, most of the MitoCaptureTM dye was taken up by the mitochondria and 
therefore formed dye aggregates, which fluoresced red (Fig. 41 A, area C1). The 
untreated cells also had a greater percentage of red fluorescing cells in the FL2-PE 
histogram (“positive” peak) (Fig. 41 A) compared to that of the H2O2 treated cells (Figs. 
41 B and 42 C). 
 
After H2O2 treatment, the mitochondrial-mediated apoptotic pathway was initiated and 
resulted in disruption of MTP. Therefore, less dye molecules were taken up by the 
mitochondria, leaving it in the cytoplasm as monomers, which fluoresced green (Figs. 
41 B and C, area C4). The drug-treated cells (0.4 mM and 1 mM H2O2 for 24 hrs) (Figs. 











compared to the untreated cells (Fig. 41 A), as expected. Furthermore, the drug-treated 
cells also had a greater percentage of green fluorescing cells in the FL1-FITC 
histograms (“positive” peaks) (Figs. 41 B and C) compared to that of the untreated cells 
(Fig. 41 A). Fig. 41 B also shows that approximately 50% of the 0.4 mM H2O2 treated 
cells (approximately 7% apoptosis induced) were undergoing mitochondrial-mediated 
apoptosis (area C4). As the drug concentration was increased to 1 mM H2O2 
(approximately 20% apoptosis induced), this increased to 93% cells undergoing 
mitochondrial-mediated apoptosis (Fig. 41 C, area C4). 
 
Some cells (untreated and drug-treated) contained both normal functioning 
mitochondria, as well as mitochondria with disrupted MTP. These cells had 
intermediate MTP and had not completely committed to cell death. The cells contained 
dye aggregates (inside the mitochondria), as well as dye monomers (in the cytoplasm) 
resulting in a yellow-orange fluorescence (Fig. 41, area C2). The untreated cells had 
5.2% cells with intermediate MTP, whereas the 0.4 mM and 1 mM H2O2 treated cells 
had 8.2% and 6.1%, respectively (Fig. 41, area C2 of colour-coded density plots).   
 
The results of the flow analysis were confirmed by visualizing the MitoCaptureTM 
labelled cells using a fluorescent microscope (as described in section 2.6.3) (Fig. 42).  
 
 






A: Untreated cells B: 1 mM H2O2 treated cells 
Fig. 42. Fluorescent microscopy results of H2O2 treated HL60 cells after MitoCaptureTM 
labelling. HL60 cells were visualised at 40x magnification and 333 ms exposure time with a 
fluorescent microscope after labelling with MitoCaptureTM. Untreated (control) cells (A) and cells 












The fluorescent microscopy results showed that the untreated cells (Fig. 42 A) had a 
greater amount of red fluorescence (normal/unaltered MTP) in the DIA triple-band 
channel, compared to the drug-treated cells (Fig. 42 B). The majority of drug-treated 
cells had disrupted MTP, since they contained high amounts of green fluorescing 
MitoCaptureTM dye monomers in the cytoplasm (Fig. 42 B). The fluorescent 
microscopy results therefore validated the results obtained via flow cytometry (Fig. 41 
A and C).   
 
3.2   Final experiments to analyse all three apoptotic pathways 
 
The optimised conditions and techniques determined in section 3.1 were implemented 
in experiments to analyse all three apoptosis pathways. HL60 and Jurkat cells were 
treated with pathway-specific drugs as described in section 2.1.6. The cells were 
subsequently analysed for apoptotic response to drug treatment. The techniques 
included AV/PI labelling and flow cytometry, western blot analysis, caspase activity 
assays and detecting changes in MTP (MitoCaptureTM labelling and flow cytometry). 
These experiments were repeated for each drug (low and high dose) to compare results 
for each technique and determine if the results were reproducible and if the cell models 
are reliable.  
 
3.2.1   Analysis of apoptotic response for all three apoptosis pathways    
 
Cells were treated with pathway-specific drugs as described in section 2.1.6 and 
analysed as described in section 2.2. The experiments were performed twice for each 
drug and only one sample per drug concentration (untreated, low and high doses) was 
prepared per experiment (as shown in Table 7). The percentage of early apoptosis (% 
cells in area G4 of PI vs. AV colour-coded density plots) induced by all three drugs is 
shown in Tables 7 and 8. The values in Table 8 represent the average of the two 
experiments performed for each drug with the standard deviation. 
 
 
Table 7: The percentage of early apoptosis induced by all three drugs for each 
experiment (as determined by AV/PI labelling and flow analysis) 











concentration: (hrs): (Area G4) † : 
0 µg/ml BFA   7.00 
5 µg/ml BFA   12.98 
30 µg/ml BFA   17.88 
0 µg/ml BFA   2.10 
5 µg/ml BFA   8.80 
30 µg/ml BFA   22.60 
0 mM H2O2   3.60 
0.4 mM H2O2   10.20 
1 mM H2O2   20.70 
0 mM H2O2   5.00 
0.4 mM H2O2   14.40 
1 mM H2O2   28.30 
0 ng/ml FasL   4.90 
0.2 ng/ml FasL   13.50 
0.4 ng/ml FasL   38.0 
0 ng/ml FasL   4.60 
0.2 ng/ml FasL   24.60 





Table 7 shows the results obtained for all experiments (%G4 early apoptosis) and the 
variance of results between each experiment. Table 7 also shows that there was a greater 
variance in % early apoptosis of the untreated HL60 cells, compared to the Jurkat cells. 
However, this was also noted before in section 3.1.1.3 and is in accordance with the 
results obtained in section 3.1.1.2, which indicated that approximately 5-10% untreated 































† Values reflect the percentage of early apoptosis (%G4), obtained from each experiment, 







































Tables 7 and 8 show that the cells treated with H2O2 fell within the desired range of 
apoptosis, with approximately 8% (low) and 20% (high) early apoptosis induced above 
that of the untreated cells. These results were also similar to those obtained in section 
3.1.1.3 B.  
 
Tables 7 and 8 show that the FasL treated cells had a great variation in % early 
apoptosis (%G4) induced between experiments. The second FasL experiment had 
higher %G4, at both drug concentrations, than expected (Table 7). However, as 
indicated by Table 7, the high dose FasL (0.4 ng/ml) induced approximately 53% early 
apoptosis (above that of the untreated cells), which was close to the desired range (20-
50%). Values of the first FasL experiment fell within the desired range of apoptosis, 
with approximately 9% (low) and 33% (high) early apoptosis induced above that of the 
untreated cells (Table 7).  
 
Tables 7 and 8 show that the cells treated with 5 µg/ml BFA, of both experiments, fell 
within the desired range of apoptosis, with approximately 6% (low) early apoptosis 
induced above that of the untreated cells. The 30 µg/ml BFA treated cells of the second 
Values reflect the averages with standard deviation (n =2) 
‡ The average % of early apoptotic cells were obtained from area G4 of the respective PI vs. AV 
density plots 
†The average % of apoptosis of the untreated cells (for each time point) was subtracted from the 
average % of apoptosis obtained from the drug-treated cells   
 
      
 
Table 8: The average percentage of early apoptosis induced by all three drugs as 





Average % early apoptotic 
cells  (Area G4) ‡: 
Values corrected for 
background apoptosis †: 
0 µg/ml BFA  4.55 (±3.5) 0 
5 µg/ml BFA  10.89 (±3.0) 6.34 (±3.0) 
30 µg/ml BFA  20.24 (±3.3) 15.69 (±3.3) 
0 mM H2O2  4.3 (±1.0) 0 
0.4 mM H2O2  12.3 (±3.0) 8.0 (±3.0) 
1 mM H2O2  24.5 (±5.4) 20.2 (±5.4) 
0 ng/ml FasL  4.75 (±0.2) 0  
0.2 ng/ml FasL  19.05 (±7.9) 14.3 (±7.9) 















experiment also fell within the desired range of apoptosis, with approximately 20% 
(high) early apoptosis induced above that of the untreated cells (Table 7). These results 
were similar to those obtained in section 3.1.1.3 A for the low and high BFA 
concentrations. However, the 30 µg/ml BFA treated cells of the first BFA experiment, 
which were approximately 11% early apoptotic, had significantly less % early apoptosis 
induced than expected (20-50%) (Table 7). 
 
Since the % early apoptosis induced by the 30 µg/ml BFA treated cells of the first 
experiment were very low, it was decided to repeat the experiments. Previously (section 
3.1.1.3), only small volumes of cells (2-4 ml) (passage number 14-16) were treated to 
obtain the drug-response data. However, for these final experiments a larger number of 
cells were required for all the assays to be performed from one batch of cells per 
experimental condition (untreated and low and high drug doses). Therefore, larger 
volumes of cells were treated with drug. To determine if perhaps an increased 
volumetric error caused lower drug concentrations, thereby decreasing the percentage of 
apoptosis induced, the experiments were repeated in smaller volumes, as before (section 
3.1.1.3). However, after numerous repeats there was no significant increase in apoptosis 
induced (above 10%) (data not shown). The quality of BFA had not been compromised, 
since new BFA was used. Therefore, it was decided to repeat the drug treatment with 
new cells that were thawed (passage number 11-13) to see if the results could improve. 
However, the results obtained in Table 8 could not be improved upon.  
  
Figs. 43 - 45 show the representative PI vs. AV colour-coded density plots that were 
obtained for the low level (5-15%) and high level (20-50%) early apoptosis induced by 

































           A : Untreated                          B: 0.4 mM H2O2                      C: 1 mM H2O2 












  PI 
Fig. 44. PI vs. AV density plots of H2O2 treated HL60 cells. HL60 cells were treated for 24 hrs with 
(B) 0.4 mM H2O2 to induce 5-15% (low level) apoptosis and (C) 1 mM H2O2 to induce 20-50% (high 
level) apoptosis above that of the untreated cells (A). The cells were labelled with AV and PI and 
analysed via flow cytometry. 
 
Fig. 43. PI vs. AV density plots of BFA treated HL60 cells. HL60 cells were treated for 24 hrs with 
(B) 5 µg/ml BFA to induce 5-15% (low level) apoptosis and (C) 30 µg/ml BFA to induce 20-50% (high 
level) apoptosis above that of the untreated cells (A). The cells were labelled with AV and PI and 
analysed via flow cytometry. 
 
 
           A: Untreated                           B: 5 µg/ml BFA                      C: 30 µg/ml BFA 
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Fig. 45. PI vs. AV density plots of FasL treated Jurkat cells. Jurkat cells were treated for 4 hrs with 
(B) 0.2 ng/ml FLAG-tagged FasL (and 0.25 μg/ml ANTI-FLAG® antibody to induce 5-15% (low 
level) apoptosis and (C) 0.4 ng/ml FLAG-tagged FasL (and 0.25 μg/ml ANTI-FLAG® antibody to 
induce 20-50% (high level) apoptosis above that of the untreated cells (A). The cells were labelled with 











3.2.2   Western blot analysis for all three apoptotic pathways 
 
In the final western blot assays, all three apoptotic pathways were analysed for FADD, 
Bip and CHOP expression (with β–actin as the invariant positive control). The cells 
were treated as described in section 2.1.6 and analysed via western blotting as described 
in section 2.3. The western blot assays were performed twice for each drug (BFA, H2O2 
and FasL) using protein extracted from the two separate experiments for each drug as 
shown in Figs. 46 A and 47 A.  
 
For the benefit of visibility, since the figures appear lighter when printed (and protein 
samples were transferred onto the same horizontal membrane strip), darker images/blots 
were shown in Figs. 46 A and 47 A (as described in section 2.3.6). However, only bands 
that fell within the linear range of exposure, and were neither underexposed nor 
overexposed, were used to obtain densitometric data. The densitometric data, after 
normalization (specific gene/β–actin ratio), for each drug is represented in the bar 


















































β–actin 45 kDa  
Bip 78 kDa  
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Fig. 46. Western blot analysis of Bip, FADD and CHOP protein levels for all drugs (first experiment). 
(A) HL60 cells were treated with BFA (5 µg/ml or 30 µg/ml) or H2O2 (0.4 mM or 1 mM) for 24 hrs and 
Jurkat cells were treated with FLAG-tagged FasL (0.2 ng/ml or 0.4 ng/ml) for 4 hrs, in the presence of 0.25 
μg/ml ANTI-FLAG® M2 antibody. Protein (100 µg) isolated from untreated and drug-treated cells were 
separated via SDS-PAGE and transferred onto PVDF membrane. The membrane was probed with GADD153 
(CHOP), Bip, FADD and β-actin antibodies (section 3.2.4.4) and developed accordingly. Β-actin was used as 
an invariable control to confirm the equal loading of protein in each sample. Only bands that fell within the 
linear range of exposure, and were neither underexposed nor overexposed, were used to obtain densitometric 
data. After normalizing for the β-actin control, results from the densitometric analysis was used to measure 
changes in Bip and FADD protein levels between the different drugs, BFA (B), H2O2 (C) and FasL (D) and 
drug concentrations used.         
A 
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Fig. 47. Western blot analysis of Bip, FADD and CHOP protein levels for all drugs (second experiment). 
(A) HL60 cells were treated with BFA (5 µg/ml or 30 µg/ml) or H2O2 (0.4 mM or 1 mM) for 24 hrs and Jurkat 
cells were treated with FLAG-tagged FasL (0.2 ng/ml or 0.4 ng/ml) for 4 hrs, in the presence of 0.25 μg/ml 
ANTI-FLAG® M2 antibody. Protein (100 µg) isolated from untreated and drug-treated cells were separated 
via SDS-PAGE and transferred onto PVDF membrane. The membrane was probed with GADD153 (CHOP), 
Bip, FADD and β-actin antibodies (section 3.2.4.4) and developed accordingly. Β-actin was used as an 
invariable control to confirm the equal loading of protein in each sample. Only bands that fell within the linear 
range of exposure, and were neither underexposed nor overexposed, were used to obtain densitometric data. 
After normalizing for the β-actin control, results from the densitometric analysis was used to measure changes 
in Bip and FADD protein levels between the different drugs, BFA (B), H2O2 (C) and FasL (D) and drug 
concentrations used.        
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Figs. 46 A and 47 A show that the western blot analysis for β–actin, Bip and FADD 
were successful. However, non-specific bands, as well as a high background signal were 
detected with the CHOP western blot assays, as before (section 3.1.2.4), therefore 
densitometric data could not be acquired for CHOP protein. 
 
Figs. 46 B and 47 B show that Bip protein expression was upregulated after BFA 
treatment for both experiments. However, Bip protein levels were slightly higher for 5 
µg/ml BFA treated cells compared to 30 µg/ml BFA in Fig. 46 B. The increase in Bip 
protein expression indicated that the UPR was activated, and the HL60 cells were 
experiencing ER-stress after BFA treatment.  
 
Fig. 46 B shows that FADD protein levels were slightly decreased after BFA treatment, 
and were approximately equal at both BFA concentrations. However, the second BFA 
experiment (Fig. 47 B) shows that no FADD protein was detected in both untreated and 
BFA treated cells. Results of both experiments therefore indicated that there was no or 
limited death receptor pathway activity via FADD after BFA treatment of HL60 cells. 
 
Figs. 46 C and 47 C show that Bip protein expression was upregulated after H2O2 
treatment and Bip protein levels were higher for 1 mM H2O2 treated cells compared to 
0.4 mM H2O2. The increase in Bip protein expression indicated that the UPR was 
activated, and the HL60 cells were experiencing ER-stress after H2O2 treatment.  
 
Fig. 46 C shows that FADD protein levels were significantly decreased, after H2O2 
treatment. Moreover, the second H2O2 experiment (Fig. 47 C) shows that no FADD 
protein was detected in both untreated or H2O2 treated cells. Results of both 
experiments therefore indicated that there was no or limited death receptor pathway 
activity via FADD after H2O2 treatment of HL60 cells. 
 
Fig. 46 D shows that Bip protein levels were low in the untreated Jurkat cells and Bip 
protein expression was slightly downregulated after treatment with FLAG-tagged FasL 
and ANTI-FLAG® antibody. Furthermore, in the second FasL experiment, Bip protein 
levels were significantly low and remained unchanged after treatment with FLAG-











Figs. 46 D and 47 D show that the untreated Jurkat cells had significantly high levels of 
FADD protein. Fig. 46 D shows that there was no significant increase or decrease in 
FADD protein levels after treatment with FLAG-tagged FasL and ANTI-FLAG® 
antibody. Fig. 47 D shows that FADD protein levels were slightly lower after treatment 
with 0.2 ng/ml FasL, however, 0.4 ng/ml FasL treated cells showed a slight increase in 
FADD protein levels. Both FasL experiments therefore indicated that there was possible 
death receptor pathway activity via FADD after the Jurkat cells were treated with 
FLAG-tagged FasL and ANTI-FLAG® antibody. 
 
3.2.3   Caspase activity assays for all three apoptotic pathways 
 
The cells were treated as described in section 2.1.6 and the activity of caspase-3, -4, -8 
and -9, for each apoptotic pathway, was investigated (as described in section 2.4.5).  
 
3.2.3.1   Caspase activity assays for BFA treated HL60 cells 
 
The activity of caspase-3, -4, -8 and -9 as induced by 5 µg/ml and 30 µg/ml BFA (24 
hrs), for both BFA experiments, are shown in Figs. 48 and 49. The average values 
obtained for the blank and untreated (0 µg/ml BFA) samples were subtracted from the 
drug-treated sample readings. Therefore values on the graphs reflect AMC release, after 
























































  5 µg/ml BFA 
 
  30 µg/ml BFA 
Fig. 48. AMC release of BFA treated HL60 cells for all caspase substrates (first experiment). HL60 
cells were treated with 5 µg/ml BFA (blue) or 30 µg/ml BFA (yellow) for 24 hrs, after which protein was 
extracted. The HL60 cell lysates (10 µg protein) were analysed using caspase-3, -4, -8 and -9 substrates 
for caspase activity. BFA controls (30 µg/ml, 24 hrs) were included as a positive control for caspase-3 
activity. Samples were prepared and analysed in triplicate and AMC release reflects averages (RFU 
readings for samples were converted to AMC release using the equation of the AMC standard curve) 
with standard deviation. A t-Test was performed for data obtained from the low and high drug doses for 
each caspase assay and the p-values are shown on the graph (level of significance was 0.05). The average 
RFU for the blank and untreated (0 µg/ml BFA) control readings were subtracted from the average 
sample (drug-treated) RFU values before the AMC release was calculated. Readings were taken at 












































Figs. 48 and 49 show that BFA treatment, for both experiments, induced caspase-3 and 
caspase-4 activity but very little caspase-8 activity and no significant amount of 
caspase-9 activity. Fig. 48 shows negative values (graph) for the caspase-9 activity 
assay, since the blank and untreated values (AMC release) (which were higher) were 
subtracted from the drug-treated values (which were lower). Caspase-3 activity, in both 
experiments, was significantly higher for the 30 µg/ml BFA treated cells, compared to 5 
µg/ml BFA, as expected (p-values considerably less than 0.05). Caspase-4 activity, in 
both experiments, was also significantly higher for the 30 µg/ml BFA treated cells, 
compared to 5 µg/ml BFA, as expected (p-values considerably less than 0.05). BFA 
treatment therefore seemed to activate mainly caspase-4, which is involved in the ER-



























  5 µg/ml BFA 
 
  30 µg/ml BFA 
Fig. 49. AMC release of BFA treated HL60 cells for all caspase substrates (second experiment). 
HL60 cells were treated with 5 µg/ml BFA (blue) or 30 µg/ml BFA (yellow) for 24 hrs, after which 
protein was extracted. The HL60 cell lysates (10 µg protein) were analysed using caspase-3, -4, -8 and 
-9 substrates for caspase activity. BFA controls (30 µg/ml, 24 hrs) were included as a positive control 
for caspase-3 activity. Samples were prepared and analysed in triplicate and AMC release reflects 
averages (RFU readings for samples were converted to AMC release using the equation of the AMC 
standard curve) with standard deviation. A t-Test was performed for data obtained from the low and 
high drug doses for each caspase assay and the p-values are shown on the graph (level of significance 
was 0.05). The average RFU for the blank and untreated (0 µg/ml BFA) control readings were 
subtracted from the average sample (drug-treated) RFU values before the AMC release was calculated. 























apoptotic marker to all three pathways. The BFA controls (separate experiment in which 
approximately 19% apoptosis was induced) were positive for caspase-3 activity, 
therefore demonstrating that the caspase-3 substrate and caspase assay worked as 
expected.   
 
3.2.3.2   Caspase activity assays for FasL treated Jurkat cells 
 
The activity of caspase-3, -4, -8 and -9 as induced by 0.2 ng/ml and 0.4 ng/ml FLAG-
tagged FasL with 0.25 μg/ml ANTI-FLAG® M2 antibody (4 hrs), for both FasL 
experiments, are shown in Figs. 50 and 51. The average values obtained for the blank 
and untreated (0 µg/ml BFA) samples were subtracted from the drug-treated sample 
readings. Therefore values on the graphs reflect AMC release, after addition of caspase 



















Fig. 50. AMC release of FasL treated Jurkat cells for all caspase substrates (first experiment). 
Jurkat cells were treated with FLAG-tagged FasL (0.2 ng/ml (blue) or 0.4 ng/ml (yellow)) and 0.25 
μg/ml ANTI-FLAG® M2 antibody for 4 hrs, after which protein was extracted. The Jurkat cell lysates 
(10 µg protein) were analysed using caspase-3, -4, -8 and -9 substrates for caspase activity. BFA controls 
(30 µg/ml, 24 hrs) (green) were included as a positive control for caspase-3 activity. Samples were 
prepared and analysed in triplicate and AMC release reflects averages (RFU readings for samples were 
converted to AMC release using the equation of the AMC standard curve) with standard deviation. A t-
Test was performed for data obtained from the low and high drug doses for each caspase assay and the p-
values are shown on the graph. The average RFU for the blank and untreated control readings were 
subtracted from the average drug-treated sample RFU readings. Readings were taken at Ex/Em= 354/442 
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Figs. 50 and 51 show that FasL treatment, for both experiments, induced caspase-8 
activity, however, no significant amount of caspase-3 and -4 activity was detected. Low 
levels of caspase-9 activity were detected after treatment with 0.2 ng/ml FasL only (for 
both experiments). The negative values shown in Figs. 50 and 51 for caspase-3, -4 and -
9 activity was due to the blank and untreated sample readings (which were higher) being 
subtracted from the drug-treated sample readings. In both experiments caspase-8 
activity was significantly higher for 0.4 ng/ml FasL treated cells, compared to 0.2 ng/ml 
FasL, as expected (p-values considerably less than 0.05). Since there was no significant 
amount of caspase-3 activity detected, in both experiments, it could be deduced that 
very little cells were in the late stages of apoptosis, when the executioner caspases are 
activated. Treatment with FLAG-tagged FasL and ANTI-FLAG® antibody therefore 
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Fig. 51. AMC release of FasL treated Jurkat cells for all caspase substrates (second experiment). 
Jurkat cells were treated with FLAG-tagged FasL (0.2 ng/ml (blue) or 0.4 ng/ml (yellow)) and 0.25 
μg/ml ANTI-FLAG® M2 antibody for 4 hrs, after which protein was extracted. The Jurkat cell lysates 
(10 µg protein) were analysed using caspase-3, -4, -8 and -9 substrates for caspase activity. BFA 
controls (30 µg/ml, 24 hrs) (green) were included as a positive control for caspase-3 activity. Samples 
were prepared and analysed in triplicate and AMC release reflects averages (RFU readings for samples 
were converted to AMC release using the equation of the AMC standard curve) with standard 
deviation. A t-Test was performed for data obtained from the low and high drug doses for each caspase 
assay and the p-values are shown on the graph (level of significance was 0.05). The average RFU for 
the blank and untreated (0 ng/ml FasL) control readings were subtracted from the average sample 
(drug-treated) RFU values before the AMC release was calculated. Readings were taken at Ex/Em= 






































seemed to activate mainly caspase-8, which is specific to the death receptor apoptotic 
pathway. The BFA controls (approximately 19% apoptosis induced) were positive for 
caspase-3 activity, therefore demonstrating that the caspase-3 substrate and caspase 
assay worked as expected. 
 
3.2.3.3   Caspase activity assays for H2O2 treated HL60 cells 
 
The activity of caspase-3, -4, -8 and -9 as induced by 0.4 mM H2O2 and 1 mM H2O2 (24 
hrs), for both H2O2 experiments, are shown in Figs. 52 and 53. The average values 
obtained for the blank and untreated (0 mM H2O2) samples were subtracted from the 
drug-treated sample readings. Therefore values on the graphs reflect AMC release, after 
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Fig. 52. AMC release of H2O2 treated HL60 cells for all caspase substrates (first experiment). 
HL60 cells were treated with 0.4 mM H2O2 (blue) and 1 mM H2O2 (yellow) for 24 hrs, after which 
protein was extracted. The HL60 cell lysates (10 µg protein) were analysed using caspase-3, -4, -8 and 
-9 substrates for caspase activity. BFA controls (30 µg/ml, 24 hrs) (green) were included as a positive 
control for caspase-3 activity. Samples were prepared and analysed in triplicate and AMC release 
reflects averages (RFU readings for samples were converted to AMC release using the equation of the 
AMC standard curve) with standard deviation. A t-Test was performed for data obtained from the low 
and high drug doses for each caspase assay and the p-values are shown on the graph (level of 
significance was 0.05). The average RFU for the blank and untreated (0 mM H2O2) control readings 
were subtracted from the average sample (drug-treated) RFU values before the AMC release was 












































Figs. 52 and 53 show that treatment with H2O2, for both experiments, induced caspase-3 
and -9 activity but no activity was detected for caspase-4. Fig. 52 shows that caspase-8 
activity was detected after treatment with 0.4 mM H2O2, however, there was not a 
significant difference between the low and high drug doses since the p-value was 0.7. 
Furthermore, Fig. 53 shows that there was not a significant increase in caspase-8 
activity for both drug concentrations. Therefore, it could be concluded that after H2O2 
treatment there was not a significant increase in caspase-8 activity for both experiments. 
There was no significant difference in caspase-9 activity levels between the low and 
high H2O2 concentrations (of both experiments), since the p-values were significantly 
greater than 0.05. Fig. 53 also indicated that caspase-9 activity (for both drug 
concentrations) was lower compared to Fig. 52. Furthermore, there was no significant 
difference in caspase-3 activity between the low and high H2O2 concentrations (of both 
  0.4 mM H2O2 
 













Fig. 53. AMC release of H2O2 treated HL60 cells for all caspase substrates (second experiment). 
HL60 cells were treated with 0.4 mM H2O2 (blue) and 1 mM H2O2 (yellow) for 24 hrs, after which 
protein was extracted. The HL60 cell lysates (10 µg protein) were analysed using caspase-3, -4, -8 and 
-9 substrates for caspase activity. BFA controls (30 µg/ml, 24 hrs) (green) were included as a positive 
control for caspase-3 activity. Samples were prepared and analysed in triplicate and AMC release 
reflects averages (RFU readings for samples were converted to AMC release using the equation of the 
AMC standard curve) with standard deviation. A t-Test was performed for data obtained from the low 
and high drug doses for each caspase assay and the p-values are shown on the graph (level of 
significance was 0.05). The average RFU for the blank and untreated (0 mM H2O2) control readings 
were subtracted from the average sample (drug-treated) RFU values before the AMC release was 









































experiments), since the p-values were greater than 0.05. The levels of caspase activity of 
the H2O2 treated cells, of both experiments, were also lower than expected, even though 
the BFA controls demonstrated that the caspase-3 substrate and caspase assay worked 
as expected.   
 
Since caspase-9 activity was lower than expected for both experiments (Figs. 52-53) 
and caspase-3 activity was lower compared to the BFA treated HL60 cells (Figs. 48-49), 
it was decided to determine if any residual H2O2 in the cell lysates could inhibit caspase 
activity. Untreated HL60 cell lysates (20 µg protein) were analysed for caspase-3 
activity with or without the addition of 0.5 mM H2O2. Since the H2O2 treated cell lysates 
produced lower AMC release (caspase activity), compared to BFA and FasL treated 
cells, higher protein and substrate concentrations were used to try and increase the RFU 
signal obtained. As a basic means of measuring enzyme activity, a heat inactivated 

















Fig. 54. The effect of 0.5 mM H2O2 on caspase-3 activity. Untreated HL60 cell lysates (20 µg 
protein) were analysed using caspase-3 substrate (75 µM) for caspase-3 activity. 0.5 mM H2O2 was 
added to untreated cell lysate prior to analysis. Heat inactivated controls were included as a negative 
control for caspase-3 activity. Samples were prepared and analysed in triplicate and AMC release 
reflects averages (RFU readings for samples were converted to AMC release using the equation of the 
AMC standard curve) with standard deviation. Readings were taken at Ex/Em= 354/442 nm with 
Ex/Em slit= 20/20nm and PMT Voltage= High. 
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Fig. 54 shows that the addition of H2O2 significantly reduced caspase-3 activity, even at 
higher protein and substrate concentrations. The activity of caspases in the H2O2 treated 
cell lysates could therefore be inhibited or reduced if there was residual H2O2 left in the 
preparation. This could account for the lower caspase-3 and -9 activity detected for 
H2O2 treated cells in Figs. 52-53. 
 
3.2.4   Detection of changes in MTP during apoptosis induction for all three 
apoptotic pathways 
 
After drug treatment (section 2.1.6), the changes in MTP were determined with 
MitoCaptureTM labelling and flow cytometry as described in sections 2.6.1 and 2.6.2. 
The experiments were performed twice for each drug, although only one sample per 
drug concentration (untreated, low dose and high dose) was prepared per experiment for 
MitoCaptureTM labelling. The changes in MTP of the cells after drug treatment (for all 
drugs) are shown in Table 9. The values represent the average of the two experiments 
performed for each drug with the standard deviation. 
 
Table 9: The changes in MTP during apoptosis as determined by MitoCaptureTM 





% Cells Area C1 
(normal MTP): 
% Cells Area C2 
(intermediate 
MTP): 
% Cells Area C4 
(disrupted MTP): 
0 µg/ml BFA  80.15 (±11.2) 13.8 (±5.8) 5.95 (±5.4) 
5 µg/ml BFA  28.9 (±25.7) 21.5 (±12.7) 49.6 (±38.5) 
30 µg/ml BFA  19.6 (±21.07) 22.2 (±19.2) 58.25 (±40.23) 
0 mM H2O2  64.3 (±19.9) 22.3 (±17.5) 13.45 (±2.3) 
0.4 mM H2O2  30.15 (±9.9) 29.65 (±2.9) 40.25 (±12.7) 
1 mM H2O2  6.65 (±3.8) 18.25 (±9.4) 75.15 (±13.3) 
0 ng/ml FasL  85.15 (±3.6) 8.8 (±3.8)  6.05 (±0.2) 
0.2 ng/ml FasL  78.8 (±0) 9 (±0.1) 12.15 (±0.1) 




Values reflect the averages with standard deviation (n =2) 

















Table 9 shows that the majority of untreated cells (for all experiments) fluoresced red 
(normal MTP) in area C1. Approximately 10-20% of the untreated cells had an 
intermediate MTP (area C2) and approximately 5-15% fluoresced green (disrupted 
MTP) in area C4. The cells induced with BFA, H2O2 and FasL treatment (low and high 
doses) showed decreased fluorescence and cell density in area C1 and increased 
fluorescence and density in areas C2 and C4, compared to the untreated cells, as 
expected. Approximately 65-85% cells underwent mitochondrial membrane 
depolarisation (area C4) upon H2O2 treatment (high dose) compared to 30-87% for 30 
µg/ml BFA and 30% for 0.4 ng/ml FasL. 
 
The results for BFA treatment varied the most between the two experiments, with 5 
µg/ml BFA inducing 22% fluorescence in area C4 for the initial experiment and 76% 
for the second experiment (Table 9). For the initial high dose BFA experiment 
approximately 30% fluorescence was detected in area C4, compared to 87% for the last 
experiment. Therefore, the cells of the initial BFA experiment appeared to be dying via 
the ER-stress induced apoptotic pathway, with less mitochondrial activity (and changes 
in MTP) compared to the second experiment. In the second BFA experiment, the 
majority of cells seemed to be apoptosing via the mitochondrial-mediated apoptosis 
pathway.     
 
For both high and low doses of H2O2 treated cells, the majority fluoresced green (area 
C4), indicating that the cells were undergoing apoptosis via the mitochondrial-mediated 
apoptotic pathway (Table 9) (also seen in Fig. 56). Furthermore, the 1 mM H2O2 treated 
cells showed a significant decrease in fluorescence in area C2 compared to the 0.4 mM 
H2O2 treated cells. This would suggest that at 1 mM H2O2 there was a decrease in the 
number of cells with intermediate MTP and most cells were committed to 
mitochondrial-mediated apoptosis. 
 
The majority of cells treated with FasL (low and high dose) fluoresced red, with smaller 
increases in fluorescence in area C4, compared to the BFA and H2O2 treated cells (high 
and low doses) (Table 9). This indicated that most of the FasL treated cells did not 













Figs. 55-57 shows the representative colour-coded density plots for the MitoCaptureTM 
labelled cells after drug treatment.  
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Fig. 56.  Flow cytometry analysis of H2O2 treated HL60 cells after MitoCaptureTM labelling. 
HL60 cells were treated with 0.4 mM (B) and 1 mM (C) H2O2 for 24 hrs and labelled with 
MitoCaptureTM dye. The untreated (control) cells are shown in (A). 
Fig. 55.  Flow cytometry analysis of BFA treated HL60 cells after MitoCaptureTM labelling. 
HL60 cells were treated with 5 µg/ml (B) and 30 µg/ml (C) BFA for 24 hrs and labelled with 
MitoCaptureTM dye. The untreated (control) cells are shown in (A). 
Fig. 57. Flow cytometry analysis of FasL treated Jurkat cells after MitoCaptureTM labelling. 
Jurkat cells were treated with 0.2 ng/ml (B) and 0.4 ng/ml (C) FLAG-tagged FasL and 0.25 μg/ml 
ANTI-FLAG® antibody for 4 hrs and labelled with MitoCaptureTM dye. The untreated (control) 
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As the colour-coded density plots in Figs. 55-57 indicate, in untreated cells (Figs. 55-57 
A) most of the MitoCaptureTM dye was taken up by the mitochondria and fluoresced red 
(area C1). Therefore the majority of the untreated cells had unaltered or normal MTP. 
Initiation of the mitochondrial-mediated apoptotic pathway, via drug treatment, resulted 
in the disruption of MTP, therefore leaving the green fluorescing dye monomers in the 
cytoplasm (area C4) (Figs. 55-57 B and C). Some cells (untreated and drug-treated) had 
intermediate MTP and therefore fluoresced yellow-orange (both red and green) (area 










































4.1   Cell lines 
 
The myelodysplastic syndromes and other haematological disorders are associated with 
apoptotic defects in the progenitor cells (Hellström-Lindberg, 2005). Therefore, reliable 
models to study three caspase-dependent apoptotic pathways in defined cell populations 
were established and the assay techniques involved for each pathway were optimised. 
The promyelocytic HL60 and T lymphocyte Jurkat cell lines were used as leukaemic 
cell models to examine the specific apoptotic pathways after pathway-specific drug 
treatment.  
 
The Jurkat cell line is a continuous human T lymphocyte cell line, which was derived 
from the peripheral blood of a 14-year-old male with acute lymphoblastic T cell 
leukaemia (Schneider et al., 1977). The Jurkat cell line also grows in suspension culture 
and maintains continued proliferation without the addition of exogenous inducers. Cell 
growth is entirely dependent on the presence of foetal bovine serum in the culture 
medium (ATCC: Cell Biology Collection, 2007).   
 
The HL60 cell line is a continuous malignant human myeloid cell line, which was 
derived from the peripheral blood leukocytes of a patient diagnosed with acute 
myeloblastic leukaemia with maturation (Dalton et al., 1988). The ultrastructure of 
HL60 cells reveals many similarities to that of early promyelocytes. The HL60 cell line 
grows in suspension and cell growth remains completely dependent on the presence of 
foetal bovine serum in the culture medium. The cells are capable of sustaining 
proliferation in the absence of an added source of conditioned medium and can continue 
to replicate and differentiate along myeloid lines. The predominant cell type in cultures 
is a neutrophilic promyelocyte. Up to 10% of cells in culture differentiate spontaneously 
beyond the promyelocyte stage into more mature cells of the monocytic and 











HL60 cells are capable of adapting to different culture mediums and the cells’ 
morphology and sensitivity to chemical induction of differentiation remains unchanged 
through at least 85 passages (Gallagher et al., 1979). Leglise et al. (1988) have, 
however, found that HL60 cells have a wide variety of phenotypes and display an 
unstable phenotype when maintained in culture for a long period of time. When cultured 
in continuous/prolonged log phase (by subculturing twice a week) for 3-18 months, the 
cells underwent phenotypic drift. The cells developed drug resistance, oncogene 
amplification, loss of granulocyte and monocyte lineage markers and changes in cell 
growth parameters. The cells were found to develop from granulated promyelocytes to 
undifferentiated agranular blast-type cells. The loss of promyelocytic phenotype 
occurred within less than one month of culturing, after which the cells maintained a 
stable phenotype for a variable period. They suggested that the phenotypic drift resulted 
because the cells had lost their response to regulatory signals, which affected the cells’ 
gene expression.  
 
The cells in this study were subcultured twice or three times a week (for 1-3 months), 
however, the increase in passage number was not taken into account. Therefore, the 
HL60 cells were analysed and/or treated with drugs at different passage numbers. This 
could therefore have caused some inconsistency in the results obtained between 
experiments, since cells with different passage numbers would have different 
characteristics and/or gene expression. According to Leglise et al. (1988) the cells with 
higher passage number would also exhibit an unstable phenotype and drug resistance 
could occur, as discussed in section 4.3.1.  
 
The three central apoptotic pathways studied in this investigation, were the death 
receptor pathway, the ER-stress induced apoptotic pathway and the mitochondrial-
mediated apoptosis pathway. Each pathway was induced with a different drug known to 
be more specific to induce that particular pathway. The HL60 cell line was used to study 
the ER-stress induced and mitochondrial-mediated apoptosis pathways. The Jurkat cell 
line was used to investigate the death receptor pathway, since HL60 was found to be 
less responsive to apoptosis induction via FasL in this study. The assays used to detect 
the characteristic markers of each specific pathway, were optimised and tested for 












4.2   Development and optimisation of assays to monitor apoptosis pathways  
  
 
4.2.1   Analysis of the general apoptotic response to drug treatment 
 
 
4.2.1.1   AV/PI labelling and flow cytometry analysis 
 
The general apoptotic response of the two cell lines to drug treatment was determined 
via AV and PI labelling and flow cytometry. AV and PI are fluorescent dyes used for 
flow cytometry, since they bind to different components of the cell and allow for the 
monitoring of different characteristics of apoptotic cells. AV binds to 
phosphatidylserine molecules, which are exposed on the surface of cells during the early 
phase of apoptosis. Phosphatidylserine is a negatively charged phospholipid molecule 
that is exposed at the cell surface when the cell membrane is still intact but loses the 
asymmetry of its membrane phospholipids. PI intercalates DNA molecules, but can only 
do so when the cell membrane has become permeable. PI therefore labels cells that are 
in the advanced stages of apoptosis and have already lost their membrane integrity. PI 
can also label any cellular debris and/or apoptotic bodies that contain DNA fragments. 
However, PI cannot distinguish between apoptosis or other forms of cell death, such as 
necrosis (Mattes, 2007). Since this investigation was focussed on apoptosis, it was 
important to differentiate between necrosis and apoptosis. Cells that labelled with high 
PI, areas G2 and G1 of the PI vs. AV colour-coded density plots (section 3.1.1.1), were 
not necessarily apoptotic, since necrotic cells could directly label with PI. Therefore, 
only the percentage of cells that fluoresced in area G4 was analysed after drug 
treatment, since it represented early apoptotic cells that labelled with high AV and low 
PI (section 3.1.1.1).  
 
The flow cytometry results also provided information on the morphology of the cells 
analysed. During apoptosis, cells shrink and therefore decrease in size (FS), as well as 
increase in granularity (SS) due to chromatin condensation and proteolytic breakdown 
of all cellular components (Kerr et al., 1972). These changes could be seen in the FS vs. 
SS plots (section 3.1.1.2, Figs. 12 and 13) as the cells moved from population H to I 
(with increased apoptosis induction) due to decreased size (FS) and increased 
granularity (SS). This indicated that the FS vs. SS plots could be used as a quick basic 











situated in population H (Fig. 13). An apoptotic population of approximately 5-10% 
cells were noted in the untreated cells (section 3.1.1.2). Therefore, care was taken to 
only analyse cells (HL60 and Jurkat), which were not more than 10% apoptotic prior to 
drug treatment. 
 
4.2.1.3   Apoptotic response of cells to drug treatment  
 
In the first part of this investigation, the appropriate drug concentrations and exposure 
times required to induce each pathway were established. One of the aims was to detect 
and examine apoptotic markers for each pathway during the initial (Bip and FADD), 
intermediate (changes in mitochondrial transmembrane potential) and later stages of 
apoptosis (CHOP, cytochrome c release and caspase activation). Therefore, it was not 
required to induce an overall high percentage of apoptosis. For these investigations it 
was necessary to have cells that were still intact, albeit apoptotic. Cells that label with 
AV (high AV, low PI), have lost their membrane asymmetry and have exposed 
phosphatidylserine molecules on the membrane surface, however, the cell membrane is 
still intact. Therefore, drug concentrations and exposure times required to induce 
approximately 20-50% and a lower level of approximately 5-15% early apoptosis was 
decided on. The low and high drug concentrations served to determine if there were any 
differences in detecting the apoptotic markers at lower and/or higher levels of apoptosis 
induced. The colour-coded density plots played an important role in determining the 
stage of apoptosis of the drug-treated cells with increasing drug concentrations (section 
3.1.1.1). 
 
4.2.1.2 A) Induction of the ER-stress induced apoptotic pathway by BFA treatment  
 
HL60 cells were treated with Brefeldin A (BFA) to initiate the ER-stress induced 
apoptotic pathway. BFA blocks protein transport from the ER to the Golgi, therefore 
causing an accumulation of unprocessed proteins within the ER lumen. This leads to 
activation of the UPR, whereby ER chaperones like Bip, are employed to counteract 
protein aggregation, reduce protein translation and induce proteasome-mediated protein 
degradation of misfolded proteins (Guillemain and Exton, 1997; Li et al., 2006).  
ER chaperone proteins have an extended half-life, therefore a longer period of exposure 











have found that at least 24 hrs exposure to inducers is needed to overcome the UPR and 
induce apoptosis through the ER-stress induced apoptotic pathway (Rao et al., 2002 b). 
Similarly, in this present study, it was also found that 24 hrs exposure to BFA was 
optimal, since it produced a linear increase in apoptotic response with increasing BFA 
concentrations (Fig. 14). In contrast, another study achieved greater apoptosis induction 
in HL60 cells with less BFA (0.56 μg/ml) over a shorter exposure time (15 hrs) (Shao et 
al., 1996). Comparatively, the HL60 cells used in this study (section 3.1.1.3 A) 
appeared to be less sensitive to induction of apoptosis by BFA. However, since very 
little research on apoptosis (and the ER-stress induced apoptotic pathway) induced by 
BFA in HL60 cells has been done to date, it was difficult to compare results obtained.      
 
4.2.1.2 B)   Induction of the mitochondrial-mediated apoptotic pathway by H2O2 
treatment  
 
H2O2 was used to induce the mitochondrial-mediated apoptotic pathway in HL60 cells. 
H2O2 generates reactive oxygen species, which oxidizes the cell’s lipids, proteins and 
nucleic acids and augments the disruption of mitochondrial transmembrane potential. 
Mitochondrial functions are subsequently disrupted and the death signal is amplified, 
thereby reinforcing the cell’s fate towards apoptosis (Skommer et al., 2007).  
 
Hosokawa et al. (2005) exposed HL60 cells to 0.05 mM and 0.5 mM H2O2 for 4 min, 
after which the cells were washed and re-incubated in growth medium for 24 hrs. After 
the re-incubation, the percentage of apoptosis was determined via Trypan blue staining. 
They found that approximately 10% apoptosis was induced with 0.05 mM H2O2 and 
approximately 50% apoptosis with 0.5 mM H2O2. DiPietrantonio et al. (1999) found 
that 3 hrs incubation with 50 μM H2O2 induced approximately 25% apoptosis, whereas 
100 μM H2O2 induced approximately 80% apoptosis, as determined by Trypan blue 
staining. Since Trypan blue stains cells that have ruptured membranes, much like PI, it 
is not clear whether these cells were apoptotic or necrotic. However, in both studies, the 
cells were more susceptible to much lower H2O2 concentrations (and exposure times) 
than those that were established in this study (Fig. 16). Therefore, it appeared that the 
HL60 cells used in this study were less sensitive to induction of apoptosis by H2O2 
(section 3.1.1.3 B), compared to the other two studies. This was also observed for the 











4.2.1.2 C)  FasL treatment of cells to induce the death receptor pathway 
 
FLAG-tagged FasL binds to the Fas/CD95 receptor on the cell’s surface, while the 
ANTI-FLAG® M2 antibody binds to the FLAG-tag, to induce trimerization and 
activation of the receptor. The activated trimeric death receptor recruits the adaptor 
protein FADD, thereby forming the death-inducing signalling complex. The death-
inducing signalling complex recruits procaspase-8 molecules through FADD, resulting 
in autoproteolytic cleavage and cross-activation of caspase-8 molecules in close 
proximity. This generates a downstream caspase cascade leading to the activation of 
executioner caspases and ending in apoptosis (Lavrik et al., 2008).   
 
FLAG-tagged FasL and ANTI-FLAG® M2 antibody treatment had very little affect on 
the HL60 cells (section 3.1.1.3 C). Li, W. et al. (2006) used FasL concentrations of 1.5 
µg/ml - 50 µg/ml for 12 hrs (without anti-FLAG antibody) and found that 
approximately 6 µg/ml FasL was required to induce 50% apoptosis. Such high FasL 
concentrations were, however, not financially feasible in this study. Since the HL60 cell 
line appeared to be less sensitive to apoptosis induction, it was therefore decided to use 
the Jurkat cell line, which required lower concentrations of FasL to attain the required 
levels of apoptosis.  
 
The Jurkat cells were found to be significantly more susceptible to apoptosis induced by 
FLAG-tagged FasL and ANTI-FLAG® M2 antibody (section 3.1.1.3 D), compared to 
the HL60 cells. Schneider et al. (1998) induced apoptosis in Jurkat cells with treatment 
of FLAG-tagged recombinant FasL and anti-FLAG monoclonal antibody over 16 hrs. 
They determined cell viability via chromium release and established that approximately 
100 ng/ml FLAG-tagged FasL (with 1 μg/ml anti-FLAG antibody) induced almost 
100% cell death. Huang et al. (1999) found that Jurkat cells had completely apoptosed 
after 24 hrs incubation with 100 ng/ml FLAG-tagged FasL (with 1 μg/ml anti-FLAG 
antibody), as determined via AV and PI labelling. However, in this present study, it was 
found that 5 ng/ml FLAG-tagged FasL (with 0.25 μg/ml ANTI-FLAG® antibody) 
induced approximately 80% early apoptosis after 4 hrs incubation only (section 3.1.1.3 
D, Fig. 18). Therefore, the Jurkat cells used in this study required lower concentrations 
of FasL (and anti-FLAG antibody) and a shorter exposure time, compared to the other 











4.2.2   Western blot analysis    
 
The western blot assays for Bip, FADD and CHOP were optimised to determine the 
optimal experimental conditions for immunodetection of the proteins, as described in 
section 3.1.2. Since the transfer apparatus used created very strong currents during the 
transfer process, the amount of protein transferred would not always be quantitative. 
Therefore, the β-actin antibody was used as an invariant positive control to normalize 
the results obtained for Bip, FADD and CHOP in the final experiments of section 3.2.2.  
 
From the western blot analysis for Bip (section 3.1.2.2) it was found that the inclusion 
of protease inhibitors in the protein extraction buffer was essential to prevent any 
protein degradation. Higher antibody concentrations were also necessary for the 
detection of Bip and FADD (section 3.1.2.3).  
 
Different protein and antibody concentrations were used to optimise the CHOP western 
blot assay, to ensure that there was sufficient protein and primary antibody for 
detection. However, it was difficult to detect a signal for CHOP since a high 
background signal was present, or in some experiments no signal at all. To determine if 
the primary and secondary antibodies were compatible, the affinity of the POD-
conjugated secondary antibody for the GADD153 antibody was determined with a “dot 
blot” experiment. Since it was found that the secondary antibody’s affinity for the 
GADD153 antibody was lower compared to the other antibodies, an increased 
secondary antibody concentration was required for detection of CHOP (section 3.1.2.4). 
The number of subsequent washing steps was also increased to minimise background 
signal due to the higher concentration of secondary antibody used (section 2.3.3). 
However, some non-specific bands were detected and could not be removed nor could 
these results be improved upon. A way of differentiating between specific and non-
specific bands is the use of blocking peptides to block the specific bands, which 
















4.2.3   Caspase activity assays 
 
The caspase activity assays for caspases-3, -4, -8 and -9 were optimised with respect to 
the protein concentration, optimal incubation time, machine settings and optimal 
caspase substrate concentrations required.  
 
4.2.3.1   Minimal protein concentration required for caspase activity 
 
Other studies have used different protein concentrations for their caspase activity 
assays. Sommer et al. (2005) used 1 µg protein per caspase activity assay, whereas Liu 
et al. (2000) used 100 µg protein. For this study, it was found that as little as 5 µg 
protein could be used, although 10 µg protein was preferred since it obtained higher 
RFU values (section 3.1.3.1).  
  
RFU also increased with increasing concentrations of protein. Since high amounts of 
substrate could cause substrate saturation and slow down enzyme activity, an increase in 
enzyme (caspase) concentration would counteract this. Higher protein concentrations, 
which would include more caspase molecules, would therefore result in increased RFU, 
since caspase activity would be greater. Therefore, with higher protein concentrations, 
more caspases were available to proteolytically cleave substrate, thus resulting in 
increased RFU values (Berg et al., 2002). 
 
4.2.3.2   Effect of protease inhibitors on caspase activity 
 
It was also determined whether protease inhibitors should be added to the protein 
extraction (cell lysis) buffer or not. Some research groups performed caspase activity 
assays using protease inhibitors in their protein lysates (DiPietrantonio et al., 1999; Kim 
et al., 1999; Doyle et al., 2002; Huang et al., 2004; Higuchi et al., 2006). Since caspases 
are proteases, it was important to establish if protease inhibitors would in fact inhibit 
caspase activity. In this present study it was found that the protease inhibitors 
significantly reduced caspase-3 activity (section 3.1.3.2 C).  
 
The caspase assay cell lysis buffer contains EDTA, which removes metal ions that are 











(Ebbing, 1996). Therefore, additional protease inhibitors are not required and only 
decreases caspase activity. It was therefore concluded that protease inhibitors should not 
be added to the cell lysis buffer when isolating protein for caspase assays.  
 
4.2.3.3  Optimal fluorimeter settings 
 
The fluorimeter settings were adjusted so as to acquire maximal fluorescence readings 
from the samples analysed. It was important to generate RFU values that were clearly 
distinguishable from any background fluorescence. Initially an automatic blank setting, 
which automatically subtracted the blank reading from all the sample readings, was 
used. However, this was found to be unreliable and instead the blank samples were 
analysed in triplicate, with the samples (also prepared and analysed in triplicate). The 
average blank RFU value calculated was manually subtracted from the average sample 
RFU values.  
 
4.2.3.4   Determination of optimal incubation time 
 
Some studies used different incubation times, to allow for caspase activity and 
proteolytic cleavage of the caspase substrate. Nagase et al. (2002) and Doyle et al. 
(2002) both incubated their caspase assay samples with substrate for 1 hr at 37°C, 
whereas Liu et al. (2000) incubated their assay samples for 2 hrs at 37°C. In this study, 
no significant difference between RFU values at extended incubation times was found 
(section 3.1.3.2 A). It was therefore decided that 60 min incubation time was sufficient 
for caspase activity and substrate cleavage (and AMC release).  
 
4.2.3.5   Optimal caspase substrate concentration 
 
Other research groups have used various caspase substrate concentrations for their 
caspase activity assays. Karki et al. (2002) used 10-500 µM substrate (AMC 
conjugated) concentration to measure caspase-2, -3/7, -6, -8, -9, and -4 activity. Sommer 
et al. (2005) measured cysteine protease activity using 15 µM of n-carbobenzoxyl-
arginyl-arginyl-7-amido-4-methylcoumarin (Z-RR-AMC) as substrate. Liu et al. (2000) 
used 20 µM of caspase-3/7 (Ac-DEVD-AMC) substrate, whereas Juin et al. (1998) 











Nagase et al. (2002) determined caspase-3, -8 and -9 activity using 100 µM AMC 
conjugated caspase substrates and Doyle et al. (2002) measured caspase-3 and -9 
activity using 20 mM of AMC conjugated caspase substrates. In this study it was found 
that 50 µM AMC conjugated caspase substrate was sufficient to obtain adequate RFU 
readings (section 3.1.3.2 B). It was also found that RFU increased as substrate 
concentration was increased. This could be due to increased caspase activity, since more 
substrate is available for proteolytic cleavage, and also because the substrate on its own 
fluoresced (section 3.1.3.3). 
 
4.2.3.6   Caspase assay controls    
 
To understand the roles of the various assay components in generating RFU, controls 
that consisted of heat inactivated lysates, lysates only (no caspase substrate), caspase 
substrate with reaction buffer only, caspase substrate only, reaction buffer only and cell 
lysis buffer only were performed.  
 
Cell lysates were heat inactivated to denature proteins and induce loss of enzymatic 
function. Although the heat inactivation was not specific for caspase inhibition, it was 
only a basic method to determine enzyme activity. Heat inactivated controls could 
therefore verify whether the RFU values obtained for non-heat inactivated samples were 
due to enzyme (caspase) activity or some non-specific fluorescence signal. Since the 
heat inactivated samples had significantly lower RFU values, compared to the non-heat 
inactivated samples, it indicated that the RFU values obtained were in fact due to 
enzyme (caspase) activity (section 3.1.3.3).  
 
It was found that the caspase-3 substrate (only) auto-fluoresced (section 3.1.3.3). This 
fluorescence signal was, however, reduced by the addition of reaction buffer, which 
contained dithiothreitol (DTT). The cell lysis buffer and reaction buffer did not auto-
fluoresce. The reaction buffer consisted mainly of PIPES (1,4-
piperazinediethanesulfonic acid) and the cell lysis buffer mainly of HEPES (N-(2-
hydroxyethyl)piperazine-N’-(2- ethanesulfonic acid)), both of which contain sulphur 
groups. DTT maintains sulfhydryl (-SH) groups in the reduced state and reduces 











maintained a reduced environment, which quenched the caspase substrates and thus 
minimised auto-fluorescence.  
 
AMC alone produced a significant fluorescence signal in the presence of reaction buffer 
and DTT (AMC standards in section 3.1.3.4). However, the caspase substrates, which 
are short peptide sequences covalently bonded to AMC, did not fluoresce to such an 
extent in the presence of reaction buffer and DTT (fluorescence was quenched). The 
caspase substrates therefore only produced a significant fluorescence signal (in the 
presence of reaction buffer and DTT) once AMC was cleaved from the AMC-peptide 
bond by an active caspase. Therefore, the increase in fluorescence intensity, which was 
measured in RFU, occurred as a result of the cleavage of AMC molecules due to 
caspase activity. AMC was therefore the reporter molecule for caspase activity 
(Anaspec, 2007).  
 
4.2.3.7   Caspase assay for all caspase substrates    
 
The reliability of the caspase assays for all caspase substrates were confirmed with BFA 
treated cell lysates, to determine if the appropriate caspases were activated upon 
induction of the ER-stress induced apoptotic pathway (section 3.1.3.5). It was found 
that BFA treatment induced an increase in caspase-3 and -4 activity only. This indicated 
that the ER-stress induced apoptosis pathway was activated after BFA treatment, since 
caspase-4 is specific to that pathway. Caspase-3 is an executioner caspase that is 
common to all three pathways, during the late stages of apoptosis. The experiment 
therefore established that the caspase assay could be performed, using all four caspase 
substrates, for all three apoptosis pathways after pathway-specific drug treatment. 
 
4.2.3.8   Use of alternative protein extraction buffer for caspase assay 
 
Caspase assays using RIPA buffer for protein extraction, instead of cell lysis buffer, 
were performed to determine if one extraction buffer (RIPA), and therefore one protein 
sample, could be used for both western blot analysis and caspase assays. Zapata et al. 
(1998) successfully used RIPA buffer lysates for their caspase assays, therefore it was 












A linear increase in caspase activity, with increasing protein concentrations, was also 
obtained for the RIPA buffer lysates (section 3.1.3.6). However, the RIPA buffer lysates 
produced lower amounts of AMC release (caspase activity) compared to the cell lysis 
buffer lysates. Since it was also necessary to include protease inhibitors in the extraction 
buffer for the western blot analysis, it was therefore not practical to use RIPA buffer for 
the caspase assays.  
 
4.2.4   Cytochrome c release immunohistochemistry assays 
 
Cytochrome c release is a key event in the transmission of the death signal via the 
mitochondrial-mediated apoptotic pathway (as discussed in section 1.5.3). The aims of 
the cytochrome c immunohistochemistry assays were to visualize cytochrome c release 
via fluorescent microscopy, after intracellular labelling with cytochrome c (6H2)–PE 
antibody.  
 
A great deal of difficulty was experienced with the labelling protocols in terms of 
detecting a fluorescence signal for the cytochrome c (6H2)–PE labelled cells. 
Furthermore, the fluorescent microscope did not reach a higher magnification than 40x 
and often at higher exposure times (greater than 1 s) the picture resolution was poor and 
it was difficult to visualize the cells. At lower exposure times (less than 833 ms) it was 
often difficult to see the labelled cells and it was increasingly difficult to maintain focus 
on the cells at higher exposure times. Due to these constraints, the finer detail, such as 
the individually labelled mitochondria (with cytochrome c (6H2)–PE antibody) and 
cytochrome c release into the cytoplasm, could not be visualized. It could not be clearly 
distinguished (even at 40x magnification) whether the labelled cytochrome c molecules 
were inside the mitochondria (punctated staining pattern) or released into the cytoplasm 
(diffuse staining pattern), since the entire cell would fluoresce red (PE).  
 
To improve visibility and to assist in locating the cells, the samples were mounted with 
VECTASHIELD® mounting medium containing DAPI, which stained the cells’ nuclei 
blue. In addition, different methods for fixation, as well as cell membrane 
permeabilization, were also performed, however, no significant difference was found 
between the two methods or permeabilized and non-permeabilized cells (sections 











Various other studies have successfully established cytochrome c release using fixation 
and permeabilization methods to label their cells. Goebel et al. (2001) fixed and 
permeabilized HL60 cells before labelling with mouse anti–cytochrome c monoclonal 
antibody. Their specimen was labelled with secondary Cy3-conjugated F(ab’)2 
fragments donkey anti-mouse IgG antibody to visualize cytochrome c release. 
Tehranchi et al. (2003) fixed and permeabilized hematopoietic stem cells before 
labelling the cells, first with anti–cytochrome c antibody and then with secondary 
FITC–conjugated goat anti–mouse antibody. Dror (2003) fixed and permeabilized 
marrow cells and lymphoblasts before labeling with monoclonal anti-cytochrome c 
antibody sheep anti-human antibody. A secondary FITC-conjugated rabbit-anti-sheep 
IgG antibody was also used to visualize cytochrome c release. However, Hirpara et al. 
(2000) used methanol and acetone fixation only, without permeabilization, to label their 
M14 melanoma cells with monoclonal anti-cytochrome c antibody. They also labelled 
their samples with secondary anti-mouse FITC-conjugated IgG antibody to analyse 
cytochrome c release.  
 
These studies successfully labelled cytochrome c molecules and were able to visualise 
cytochrome c release. Cytochrome c that was released into the cytoplasm was seen as 
diffuse staining, whereas cytochrome c contained within the mitochondria produced a 
punctated staining pattern. These studies used unconjugated cytochrome c antibody and 
incubated with secondary Cy3 or FITC–conjugated antibody to obtain a fluorescence 
signal for cytochrome c molecules. In contrast, the cytochrome c antibody used in this 
study was already conjugated with PE (section 2.5.2). Perhaps the fluorescence signal 
would have been enhanced and/or visualisation of cytochrome c molecules better if an 
unconjugated antibody for cytochrome c was used together with a fluorochrome-
conjugated secondary antibody. 
 
Since the different immunohistochemistry assay protocol (used by the Cardiovascular 
Research Unit, section 3.1.4.7) could not be reproduced successfully, it was decided to 
abandon the cytochrome c release immunohistochemistry assay. Instead, it was decided 
to focus on changes in mitochondrial transmembrane potential, before and after drug 












4.2.5   Detection of changes in mitochondrial transmembrane potential (MTP) 
during apoptosis induction 
 
The changes in MTP of cells, upon induction of apoptosis, play an important role in the 
initiation of cytochrome c release (as discussed in section 1.5.2). These changes were 
examined using MitoCaptureTM labelling and flow cytometry analysis (section 3.1.5). 
 
It was found that the majority of untreated cells fluoresced red, thus indicating that most 
of the MitoCaptureTM dye was taken up by the mitochondria and existed in its 
aggregated state. Therefore, the majority of untreated cells had mitochondria with 
unaltered/normal transmembrane potential. In comparison, the majority of drug-treated 
cells fluoresced green, indicating that most of the MitoCaptureTM dye was present in the 
cytoplasm, in its monomer form. The majority of drug-treated cells therefore had 
mitochondria with disrupted transmembrane potential. Other studies also found that 
cells with normal/unaltered MTP fluoresced red, whereas disruption of MTP (e.g. after 
induction of apoptosis) resulted in green fluorescence (Piccoli et al., 2004; Lugli et al., 
2005; Chaoui et al., 2006).  
 
It was also observed that a certain percentage of cells, untreated and drug-treated, 
fluoresced orange-yellow. This indicated that these cells contained some mitochondria 
with normal/unaltered MTP, as well as mitochondria with disrupted MTP. As a result, a 
transitional (intermediate) fluorescent signal between red and green was generated. 
These cells therefore presented with an intermediated MTP. Lugli et al. (2005) also 
found this phenomenon in HL60 cells. They found that the cells with an intermediate 
MTP were positive for AV labelling, however, most did not label with PI and were 
therefore considered to be early apoptotic. Since ATP is required for the formation of 
the apoptosome, it was proposed that these cells continued to produce ATP for caspase-
9 activation, given that most of their mitochondrial membranes were still intact. Given 
the differences in MTP (normal and/or disrupted) of the mitochondria in these 
intermediate cells, it also indicated that different cells (untreated and drug-treated) were 
in different stages of apoptosis. The MitoCaptureTM results therefore gave an idea of the 
apoptotic status (non-apoptosing, intermediate or apoptosing) of the cells. These results 
can also be compared and used in conjunction with the AV/PI results to determine the 











4.3  Final experiments to analyse all three apoptotic pathways 
 
Large volumes of cells were treated with drug (either BFA, H2O2 or FasL) at the low 
and high doses to induce approximately 5-15% (low) and 20-50% (high) early 
apoptosis, as determined in section 3.1.1.3. From each batch of cells (untreated, low and 
high drug doses), cells were taken for AV/PI and MitoCaptureTM labelling and flow 
analysis, as well as protein extraction. The cells were subsequently analysed for 
apoptotic response to drug treatment (AV/PI labelling), changes in MTP 
(MitoCaptureTM labelling), activation of pathway-specific caspases and changes in Bip, 
CHOP and FADD expression via western blot analysis. These experiments were 
repeated for each drug (low and high dose) to compare results for each technique and 
determine if the results were sensitive and reproducible and if the cell models were 
reliable.  
 
It was also important to determine which markers were activated (for each pathway) at 
the untreated, low and high drug doses. This would establish the apoptotic status of the 
cells and determine how the markers are regulated and/or activated under different 
levels of apoptosis induction. In addition, it was important to determine if each marker 
was specific to its pathway or if there was cross talk between the pathways.   
 
4.3.1   BFA treatment experiments and ER-stress induced apoptosis pathway 
 
The % early apoptosis induced by the 30 µg/ml BFA treated cells (passage number 11-
13) of the first experiment was very low, compared to previous results obtained from 
cells with passage number 14-16 (section 3.1.1.3 A). The experiments were repeated, 
however, after numerous repeats (with cells at passage number 11-29) there was no 
significant increase in apoptosis induced (section 3.2.1). Leglise et al. (1988) have 
found that HL60 cells that were maintained in culture for a long time (3-18 months) 
underwent phenotypic drift and developed drug resistance. The cells in this study were 
maintained in culture for approximately 1-3 months. Therefore, the cells could have 
developed drug resistance, since Leglise et al. (1988) also found that the cells lost the 












The HL60 cells of this study were classified via May-Grünwald-Giemsa staining and 
identified as being a single population of predominantly undifferentiated promyelocytes 
(section 3.1.1.2). However, these cells were freshly thawed and at passage number 8 
(without culturing) when they were classified. Therefore, the cells maintained in culture 
could have undergone changes in phenotype, which could have contributed to drug 
resistance. The passage number of the cells in the second BFA experiment (passage 16-
19). and the drug-optimisation experiments (section 3.1.1.3 A) were similar. However, 
the passage number of the cells treated with BFA in the first experiment was lower by 
comparison. Therefore, it is not clear whether these cells did in fact undergo phenotypic 
changes during culturing, however, the results suggested that the cells had become more 
resistant to apoptose after BFA treatment.  
 
Results of both BFA experiments (section 3.2.1) indicated that a large population of 
BFA treated cells (low and high doses), which did not label with high AV (low PI) (% 
cells in area G4) did, however, have disrupted MTP. Since the majority of untreated 
(control) cells fluoresced red (normal/unaltered MTP), it indicated that the 
MitoCaptureTM assay was indeed reflecting changes in MTP after drug treatment 
(section 3.2.4). It can therefore be assumed that some BFA (low and high dose) treated 
cells had disrupted MTP but were negative for AV/PI labelling. This indicated that 
these cells did not have phosphatidylserine exposure (AV positive) and/or cell 
membrane lysis (PI positive) yet. It therefore appears that MTP disruption is an earlier 
event in the apoptosis pathway than phosphatidylserine exposure (positive AV 
labelling). This was also observed by Chaoui et al. (2006). They found that the average 
level of apoptotic cells were higher when measured via JC-1 (similar to MitoCaptureTM) 
than with AV/PI labelling. They proposed that this was due to the fact that changes in 
MTP (measured via JC-1 labelling) precede phosphatidylserine exposure (detected via 
AV labelling).  
 
The BFA treated cells of the first experiment had a higher percentage of cells with 
intermediate MTP, compared to the second experiment. Since there was no significant 
amount of caspase-9 activity detected for both BFA experiments (section 3.2.3.1), it 
appears that these cells (with intermediate MTP) were not required for ATP production 











However, these cells could be in different stages of apoptosis, containing varying 
amounts of mitochondria with both normal and disrupted MTP  (Lugli et al., 2005).  
 
The MitoCaptureTM results indicated that there was interaction between the ER-stress 
induced and mitochondrial-mediated apoptosis pathways (and both can function 
simultaneously) at the level of the mitochondria, since BFA treatment induced changes 
in MTP. This is in accordance with other researchers’ findings, which showed that 
activation of pro-apoptotic proteins, Bax and Bak, results in the transmission of the 
apoptotic signal from the ER to the mitochondria, where the death signal is amplified 
(Hacki et al., 2000; Zong et al., 2003). 
 
Wlodkowic et al. (2007) also found that BFA-
induced cell death in the HF1A3, HF4.9 and HF28RA human follicular lymphoma cell 
lines was associated with ER stress, mitochondrial rupture and subsequent activation of 
the caspase cascade.  
Disruption of MTP can lead to eventual rupture of the mitochondria and the subsequent 
release of pro-apoptotic molecules (such as cytochrome c) into the cytoplasm. 
Cytochrome c release results in caspase-9 activation via the apoptosome 
 
(Acehan et al., 
2002). However, since no significant amount of caspase-9 activity was detected for both 
BFA experiments (at low and high concentrations), it could be assumed that the 
apoptosome pathway was not activated in this instance. Furthermore, the lack of 
caspase-9 activity also indicated that the BFA treated cells did not follow the entire 
mitochondrial-mediated apoptosis pathway to its end point of caspase-9 activation.  
BFA treatment (both concentrations) induced mainly caspase-3 and -4 activity. The 5 
µg/ml BFA treated cells of both experiments had lower caspase-4 and -3 activity 
compared to the 30 µg/ml BFA treated cells. This indicated that the cells treated with 
the lower drug dose, were still in the earlier stages of the apoptosis pathway with lower 
caspase activity, preceding the activation of the caspase cascade. Since caspase-3 and -4 
activity was higher for the 30 µg/ml BFA treated cells (of both experiments), it 
indicated that the caspase cascade was activated via the ER-stress induced apoptosis 
pathway (caspase-4 activation). The high levels of caspase-3 activity also indicated that 
these cells were in the late stages of apoptosis with subsequent activation of executioner 











in human cells during periods of severe or prolonged ER stress, followed by activation 
of downstream caspases, like caspase-3. However, the group of caspases linked or 
activated upon ER stress-induced apoptosis has not yet been fully elucidated (Rao et al., 
2002 a).  
 
Very low levels of caspase-8 activity were detected for the BFA treated cells (of both 
experiments) (section 3.2.3.1). This was in contrast to the findings of Hu et al. (2006). 
They found that caspase-8 also mediates ER-stress induced apoptosis, since inhibition 
of caspase-8 activity was found to significantly decrease or prevent apoptosis induced 
by the ER stress inducers, thapsigargin and tunicamycin. They also found that inhibition 
of caspase-4 activity did not, however, prevent caspase-8 activity (and apoptosis 
induced by thapsigargin and tunicamycin). Hu et al. (2006) therefore proposed that 
caspase-4 and -8 are involved in separate apoptotic signalling pathways in response to 
ER stress. However, since no significant increase in caspase-8 activity was observed 
after BFA treatment (ER stress) in this present study, it could indicate that the caspase-4 
mediated apoptotic pathway was induced rather than the caspase-8 mediated pathway. 
Furthermore, FADD protein levels (section 3.2.2) were also significantly low or not 
present at all after BFA treatment (both high and low concentrations). The lack of 
FADD protein expression and caspase-8 activity therefore indicated that there was no or 
limited death receptor pathway activity after BFA treatment. 
 
Bip protein expression was upregulated after BFA treatment, at both high and low 
concentrations. The increase in Bip protein expression indicated that the UPR was 
activated and the cells were experiencing ER-stress after BFA treatment. Other studies 
have also found that Bip expression increases upon ER stress to prevent accumulation 
of misfolded proteins, since it acts as a chaperone by binding unfolded or misfolded 
proteins (Kozutsumi et al., 1988; Dorner et al., 1989; Flynn et al., 1991). 
 
4.3.2 H2O2 treatment experiments and mitochondrial-mediated apoptosis pathway 
 
For both H2O2 experiments (high and low H2O2 concentrations), the percentage of cells 
with disrupted MTP was higher than the percentage of cells positive for AV/PI labelling 
(% early apoptosis induced). Since the majority of untreated (control) cells fluoresced 











reflected changes in MTP after H2O2 treatment (section 3.2.4). Therefore the cell 
population, which had disrupted MTP but were negative for AV/PI labelling, did not 
have phosphatidylserine exposure yet. Disruption of MTP therefore preceded 
phosphatidylserine exposure (positive AV labelling) (Chaoui et al., 2006). This was 
also found for the BFA treated cells (section 4.3.1).  
 
Since the caspase activity was lower than expected for the H2O2 treated cells (of both 
experiments), it was determined if any residual H2O2 in the cell lysates could inhibit 
caspase activity. It was found that the addition of H2O2 significantly reduced caspase-3 
activity (section 3.2.3.3). This could therefore account for the lower and varied 
(increased standard deviation) caspase activity obtained for the H2O2 experiments, 
compared to the BFA controls and experiments.  
 
Both H2O2 experiments indicated that caspase-3 and -9 activity increased after H2O2 
treatment (low and high concentrations). Furthermore, it was found that caspase-3 and -
9 activity was higher for the 1 mM H2O2 treated cells, compared to the 0.4 mM H2O2 
treated cells (of both H2O2 experiments). This indicated that the cells treated with 1 mM 
H2O2 were in the late stages of apoptosis with resultant activation of the caspase cascade 
and executioner caspases, like caspase-3. These results were in accordance with 
DiPietrantonio et al. (1999), who also found that caspase-3 was activated in HL60 cells 
after treatment with H2O2. Since caspase-9 was activated for all H2O2 treated cells, it 
indicated that the cells were undergoing apoptosis via the mitochondrial-mediated 
apoptotic pathway. Other studies have also found that caspase-9 is activated upon 
induction of the mitochondrial-mediated apoptosis pathway, after activation of the 
apoptosome pathway (Li, P et al., 1997; Zou et al., 1997; Cain et al., 1999). 
  
There was no significant increase in caspase-8 activity observed for both H2O2 
experiments (at low and high concentrations). Similarly, Dumont et al. (1999) found 
that H2O2 treatment of T-cells induced caspase-3 activation, however, it did not induce 
activation of caspase-8. In the same experiments they also found that H2O2 treatment 
induced changes in MTP, which lead to the release of cytochrome c. Moreover, FADD 
protein levels (section 3.2.2) were also significantly low or not present at all after H2O2 
treatment (both low and high concentrations). This, and since no significant amount of 











activated after treatment with H2O2. Similarly, Dumont et al. (1999) found that the 
CD95 (Fas) death receptor pathway was not required for H2O2-induced apoptosis. They 
also found that caspase-8 was only activated by CD95/Fas ligation (and formation of the 
death-inducing signalling complex, as described in section 1.3) and not by H2O2 
treatment.     
 
The results of the two H2O2 experiments, in particular the MitoCaptureTM and caspase 
assays, indicated that mainly the mitochondrial-mediated apoptosis pathway was 
activated after treatment with H2O2. However, the western blot analysis showed that Bip 
protein expression was upregulated after treatment with H2O2 (at both low and high 
doses) (section 3.2.2). This indicated that the UPR, and possibly the ER-stress induced 
apoptosis pathway, was activated and H2O2 treatment caused some extent of ER-stress 
in HL60 cells. However, caspase-4 activity did not increase after H2O2 treatment 
demonstrating that the 
 
ER-stress induced apoptosis pathway was not activated to the 
extent of ER-caspase activation.   
4.3.3 FasL treatment experiments and death receptor apoptosis pathway  
 
The percentage of cells with disrupted MTP was lower than the percentage of cells 
positive for AV/PI labelling (% early apoptosis induced) for both FasL experiments 
(low and high FasL concentrations). Since the majority of untreated (control) cells 
fluoresced red (normal MTP), it indicated that the MitoCaptureTM assays reflected 
accurate changes in MTP after FasL treatment. Therefore, the FasL treated cells had 
phosphatidylserine exposure and loss of cell membrane asymmetry, without 
corresponding changes in MTP. Only some of the cells that had phosphatidylserine 
exposure (early apoptotic) also had disrupted MTP. Furthermore, the majority of cells 
treated with FasL (low and high dose of both experiments) fluoresced red (normal 
MTP), indicating that most of these cells did not undergo apoptosis via the 
mitochondrial-mediated apoptotic pathway. These cells may have bypassed the 
mitochondrial pathway and perhaps directly induced cell death via DISC formation, 
caspase-8 activation and subsequent activation of the caspase cascade. However, Jurkat 
cells are Type II cells and therefore rely on amplification of the death signal by the 











activation of the death receptor and mitochondrial-mediated apoptotic pathways in FasL 
treated Jurkat cells.  
 
FasL treatment, for both experiments, induced caspase-8 activity, indicating that the 
death receptor apoptotic pathway was activated. Moreover, caspase-8 activity was 
significantly higher for 0.4 ng/ml FasL treated cells, compared to 0.2 ng/ml FasL, 
indicating that these cells were in the later stages of apoptosis. However, no significant 
amount of caspase-3 activity was detected after FasL treatment for both experiments. 
Therefore, it appeared that these cells were not in the advanced stages of apoptosis, with 
subsequent activation of executioner caspases, like caspase-3. Since Jurkat cells are 
Type II cells, the activation of the caspase cascade is significantly delayed because the 
cells rely on amplification of the apoptotic signal by the mitochondria (Scaffidi et al., 
1998). Therefore, the shorter exposure time to FasL (4 hrs), compared to the longer 
exposure time of the other drugs (24 hrs), could have been insufficient to allow for 
caspase-3 activity, either directly or via the mitochondrial-mediated apoptosis pathway 
(Type II cells).  
 
Low levels of caspase-9 activity were detected after treatment with 0.2 ng/ml FasL only 
(for both experiments), indicating that the mitochondrial-mediated apoptosis pathway 
was activated to some extent. However, no significant amount of caspase-9 activity was 
observed for the 0.4 ng/ml FasL treated cells of both experiments. Furthermore, no 
caspase-4 was detected for all FasL treated cells (both experiments), indicating that the 
ER-stress induced apoptosis pathway was not activated to the extent of caspase 
activation. This was in accordance with the western blot analysis, which showed that 
Bip protein levels were significantly low after FasL treatment (low and high 
concentrations) in both experiments, compared to the other drugs.  
 
The western blot analysis also showed that the untreated Jurkat cells had significantly 
high levels of FADD protein, compared to the HL60 cells. Furthermore, FADD protein 
levels remained more or less unchanged after treatment with FasL (low and high 
concentrations) in both experiments. This could indicate that the death receptor pathway 
was activated, since FADD protein was present (in high levels) and recruited, upon 
induction of apoptosis, rather than upregulated. Hennio et al. (2000) found that high 











also found that FADD and procaspase-8 were not significantly upregulated after 
induction of death receptor-mediated apoptosis. Since the untreated HL60 cells 
contained significantly lower (or no) levels of FADD (compared to the untreated Jurkat 
cells), it could perhaps explain why the HL60 cells also had reduced sensitivity to 
apoptose after treatment with FasL (section 3.1.1.3 C). 
 
4.4    Comparison of apoptotic markers between pathways  
 
The MitoCaptureTM assays indicated that all drugs (BFA, H2O2 and FasL) induced 
changes in the MTP of the treated cells. This demonstrated that the mitochondrial-
mediated apoptotic pathway was involved, to some extent, in all three apoptosis 
pathways. The changes in MTP were greatest for cells treated with BFA and H2O2, 
compared to the FasL treated cells, since the majority of BFA and H2O2 treated cells had 
disrupted MTP. Since HL60 and Jurkat cells are both Type II cells, it can be concluded 
that the mitochondria play important roles in relaying and amplifying the apoptotic 
signal, for all three pathways (Scaffidi et al., 1998).     
 
The results of the caspase activity assays indicated that the caspases were specifically 
activated for each pathway and caspase activity was higher for cells treated with the 
higher drug concentrations, for all three pathways.  
 
The western blot analysis for β-actin, Bip and FADD were successful. However, non-
specific bands, as well as a high background signal were detected with the CHOP 
western blot analysis and therefore densitometric data could not be acquired for CHOP. 
Guérardel et al. (2005) performed a western blot analysis on untreated and tunicamycin 
treated RIN-1027-B2 cells and also detected a multiple band pattern for CHOP. To 
determine which band was CHOP, they compared untreated cells with tunicamycin 
treated cells, which enhanced CHOP expression. They found that a 27 kDa band 
increased in intensity after tunicamycin treatment and concluded that this was CHOP. 
The bands obtained for the CHOP western blot analysis in this present investigation 
(section 3.2.2) were, however, indistinct and amidst a high background signal. 
Therefore, a clear increase or decrease in band intensity, after BFA treatment, could not 
be determined. The CHOP western blot analysis could therefore not be used to 











Bip protein expression was upregulated after treatment with BFA and H2O2, at both 
high and low drug concentrations. This indicated that there was some interaction 
between the ER-stress induced and mitochondrial-mediated apoptosis pathways. 
Furthermore, H2O2 can possibly induce ER stress, which results in the apoptotic signal 
being transmitted to the mitochondria, in addition to acting directly to induce the 
mitochondrial-mediated apoptosis pathway. CHOP, JNK and the Bcl-2 family of 
proteins regulate both the ER-stress induced- and mitochondrial-mediated apoptosis 
pathways. Therefore, the apoptotic signal can be passed on from the ER to the 
mitochondria 
 
(Hacki et al., 2000; Boya et al., 2002). There was no significant increase 
in Bip protein expression for the FasL treated cells. In addition, FADD protein levels 
were significantly lower (or absent) in BFA and H2O2 treated cells, compared to FasL 
treated cells. However, this could be due to the lower FADD levels observed in the 
untreated HL60 cells, compared to the Jurkat cells (untreated and FasL-treated). Since 
FADD protein levels were significantly higher in the Jurkat cells, it appears that these 
cells contained the necessary levels of FADD protein required for apoptosis via the 
death receptor pathway. It therefore appears that FADD is recruited rather than 
upregulated, since FADD protein levels remained relatively unchanged after treatment 
with FasL, after induction of the death receptor pathway. 
4.5   Conclusions and future investigations 
 
BFA treatment mainly activated the ER-stress induced apoptosis pathway with 
subsequent activation of caspase-4 and upregulation of Bip. Treatment with H2O2 
mainly induced the mitochondrial-mediated apoptosis pathway with subsequent 
activation of caspase-9 and induction of changes in MTP, as well as upregulation of 
Bip. FasL treatment mainly activated the death receptor pathway with subsequent 
activation of caspase-8.  
 
The results indicated that the flow cytometry assays were reproducible and sensitive to 
detect changes within the cells after induction of apoptosis with drug treatment. The 
apoptotic status of the cells could be determined using both AV/PI and MitoCaptureTM 
assays. The MitoCaptureTM results demonstrated that the mitochondria play important 











interacted with the mitochondrial-mediated apoptosis pathway, as demonstrated by the 
MitoCaptureTM results, therefore indicating that it was not pathway specific.  
 
The western blot assays were not quantitatively reproducible for each experiment and 
not as sensitive as preferred, since a large amount of protein was required. Furthermore, 
Bip protein expression was increased after treatment with BFA and H2O2, therefore 
indicating that it was not a pathway-specific marker. Since FADD protein levels 
remained relatively unchanged after FasL treatment, it would not be suitable as a marker 
to indicate induction of the death receptor pathway. 
 
The caspase activity assays were sensitive, reproducible and pathway specific. Caspase 
activity could therefore be used to determine pathway-specific induction, with different 
caspases to differentiate which pathways were activated. H2O2 treatment, however, 
appeared to inhibit some caspase activity and was therefore not ideal. Perhaps another 
inducer/drug could be used to induce the mitochondrial-mediated apoptosis pathway, in 
future studies. 
 
This work provides a useful insight into the apoptosis pathways in the two cell lines 
studied. Future studies could include monitoring the three apoptosis pathways in CD34+ 
progenitors and establishing which pathway-specific markers are best suited for analysis 
in these cells. Eventually, apoptosis induction in individual cell types of bone marrow 
stroma (both normal and MDS) could be analysed to determine which apoptosis 
pathways are affected in MDS. This knowledge would assist in the diagnosis and 
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